CN1609616A - 糖尿病的特异性标记 - Google Patents
糖尿病的特异性标记 Download PDFInfo
- Publication number
- CN1609616A CN1609616A CNA2004100849804A CN200410084980A CN1609616A CN 1609616 A CN1609616 A CN 1609616A CN A2004100849804 A CNA2004100849804 A CN A2004100849804A CN 200410084980 A CN200410084980 A CN 200410084980A CN 1609616 A CN1609616 A CN 1609616A
- Authority
- CN
- China
- Prior art keywords
- gly
- leu
- ser
- ala
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Abstract
提供与前驱糖尿病,糖尿病或糖尿病易感性有关的多肽,其可用作前驱糖尿病,糖尿病或发展糖尿病的易感性或素因的诊断标记。还提供通过获得生物样品和检测和/或测量一种或多种本说明书公开的多肽的增加来诊断前驱糖尿病,糖尿病和/或糖尿病易感性的方法。提供涉及本说明书公开的特异性多肽的激动剂和拮抗剂的筛选方法。还可以针对这些多肽标记产生抗体以用于检测和/或治疗糖尿病。蛋白质,蛋白质片段或肽可用于治疗糖尿病或前驱糖尿病。
Description
本发明一般涉及诊断前驱糖尿病,糖尿病或对发展糖尿病敏感的患者的标记。另外,本发明一般涉及诊断前驱糖尿病,糖尿病和/或糖尿病易感性的体外方法,其包含以下步骤:a)获得生物样品;和b)检测和/或测量本说明书公开的特异性标记的增加或减少。此外,提供涉及本说明书公开的特异性标记的活化剂,激动剂或拮抗剂的筛选方法。另外,本发明提供使用在血液中的基因表达图谱(profiles)或它们的产物来分类参加临床研究的个体,用于鉴定在糖尿病治疗中治疗有效性。
糖尿病,更具体地II型糖尿病和糖尿病有关的并发症的发展在数年或数十年的时期内发生。在该期间,形成一个依赖于遗传和环境作用的过程并最终导致糖尿病和/或糖尿病有关的并发症如CVD,肾病,神经病,视网膜病等的发展。鉴定具有增加的发展这些病症的风险的个体的能力可以提供在药理学上干涉或改变该个体生活方式的机会,以便预防这些医学病症的发作。
按照本发明的一个方面,提供一种诊断前驱糖尿病,糖尿病或糖尿病易感性的方法,其包含获得生物样品;和检测或测量多肽标记的水平,所述多肽标记包含至少一种选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的多肽的多肽。
还提供一种诊断前驱糖尿病,糖尿病或糖尿病易感性的方法,其包含检测或测量生物样品中多肽标记的水平,所述多肽标记包含至少一种选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的多肽的多肽。
按照本发明的另一方面,提供一种诊断前驱糖尿病,糖尿病或糖尿病易感性的方法,其包含获得生物样品;和检测或测量标记的水平,该核酸标记包含至少一种选自SEQ ID No.1,3,5,7,9,11,13,15,17,19,21,23,25,27,29,31和33的核酸分子的核酸分子。
提供一种诊断前驱糖尿病,糖尿病或糖尿病易感性的方法,其包含检测或测量生物样品中标记的水平,该核酸标记包含至少一种选自SEQ IDNo.1,3,5,7,9,11,13,15,17,19,21,23,25,27,29,31和33的核酸分子的核酸分子。
按照本发明的另一方面,提供鉴定与在糖尿病中表达受调节的多肽相互作用的化合物的筛选方法,所述多肽选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的多肽,该方法包含将所述多肽与一种化合物或多种化合物在允许该化合物与该多肽相互作用的条件下接触;和检测该化合物或多种化合物与所述多肽之间的相互作用。
按照本发明还有的另一方面,提供鉴定化合物的筛选方法,所述化合物是在糖尿病中表达受调节的多肽的激动剂或拮抗剂,所述多肽选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的多肽,该方法包含将所述多肽与化合物在允许该化合物与该多肽相互作用的条件下接触;测定该多肽的第一活性水平;测定在未与所述化合物接触的宿主中表达的该多肽的第二活性水平;和使第一活性水平与第二活性水平定量关联,其中当第一活性水平低于第二活性水平时,将该化合物鉴定为所述多肽的激动剂或拮抗剂。
按照本发明还有的另一方面,提供鉴定化合物的筛选方法,所述化合物是在糖尿病中表达上调的多肽的表达的抑制剂,所述多肽选自具有SEQID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的多肽,该方法包含将表达所述多肽的宿主与化合物接触;测定该多肽的第一表达水平或活性;测定在未与所述化合物接触的宿主中该多肽的第二表达水平或活性;和使第一表达水平或活性与第二表达水平或活性定量关联,其中当第一表达水平或活性低于第二表达水平或活性时,将该化合物鉴定为所述多肽的表达的抑制剂。
按照本发明的另一方面,提供针对所述蛋白质的抗体,或其抗原-结合片段,以用于诊断前驱糖尿病,糖尿病或糖尿病易感性的体外方法,所述蛋白质选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的蛋白质。
按照本发明还有的另一方面,提供将哺乳动物中的蛋白质水平与前驱糖尿病,糖尿病或发展糖尿病的易感性的诊断相关联的方法,该方法包含选择一种或多种选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的蛋白质的蛋白质;测定所述哺乳动物中一种或多种蛋白质的水平;和产生指数,Y,其表示糖尿病或对其易感性的存在。
优选地,上述方法包含将指数Y与已知的糖尿病患者和非糖尿病患者的指数比较。在另一优选实施方案中,所述方法包含随时间监视所述指数Y以测定糖尿病或对其易感性的阶段。
按照本发明的另一方面,提供筛选化合物的试剂盒,所述化合物活化或抑制多肽或刺激或抑制任何一种多肽的表达,所述多肽选自具有SEQ IDNo.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的多肽。
按照本发明还有的另一方面,提供监视一种或多种蛋白质血清水平以检测前驱糖尿病病状,糖尿病病状或发展糖尿病病状的易感性的方法,该方法包含产生一种或多种蛋白质的抗体;检测该蛋白质的血清水平;和将该血清水平与已知糖尿病患者和已知非糖尿病患者的血清水平比较。
按照本发明的另一方面,提供一种治疗糖尿病和前驱糖尿病的方法,其包含向需要其的患者施用治疗有效量的至少一种抗体或其抗原结合片段,所述至少一种抗体针对至少一种蛋白质,该蛋白质选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的蛋白质。
按照本发明的另一方面,提供一种治疗糖尿病和前驱糖尿病的方法,其包含向需要其的患者施用治疗有效量的至少一种蛋白质,蛋白质片段或肽,其选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的蛋白质。
本发明的上述及其它目的,特征和优势将从结合附图的下面说明书的阅读中变得明显。
图1至17是对于在II型糖尿病患者的内脏和皮下脂肪组织中通过Affymetrix分析测量的各种脂肪的RNA水平,比例强度vs.胰岛素抗性的对数的图表。
鉴定适合作为用于早期诊断疾病的糖尿病标记的基因和多肽和对该标记的长期需要和渴望的问题被本发明克服。当比较正常,IGT(受损葡糖耐量)或糖尿病个体时,意外地发现在皮下和内脏脂肪组织中分泌的一特定组基因。差异表达的基因,和它们编码的多肽,连同它们的登记号在表1中列出。
表1:在T2D中脂肪分泌的蛋白质
名称 | 缩写 | 别名 | GenBank | 基因座连接(LocusLink) | MRNA | 蛋白质 |
血管内皮生长因子B | VEGF-B | VRG,VEGFL | BC008818 | 7423 | NM003377SEQ ID 1 | NP003368SEQ ID 2 |
载脂蛋白D | APOD | J02611 | 347 | NM001647SEQ ID 3 | NP001638SEQ ID 4 | |
胺氧化酶,含铜3 | AOC3 | VAP1,VAP-1:血管粘着蛋白I;HPAO | U39447 | 8639 | NM003734SEQ ID5 | NP003725SEQ ID 6 |
二肽酰肽酶IV | DPPIV,DPP4 | CD26,ADCP2,TP103,ADABP:腺苷脱氨酶复合蛋白质2,T-细胞活化抗原CD26 | S79876 | 1803 | NM001935SEQ ID7 | NP001926SEQ ID 8 |
成纤维细胞生长因子2(碱性) | FGF2,BFGF | Prostatropin,HBGH-2:肝素结合生长因子2前体 | J04513 | 2247 | NM002006SEQ ID9 | NP001997SEQ ID10 |
血小板反应蛋白2 | THBS2,TSP2 | L12350 | 7058 | NM003247SEQ ID11 | NP003238SEQ ID12 | |
Fibulin1* | FBLN1 | X53743 | 2192 | NM001996SEQ ID13 | NP001987SEQ ID14 | |
膜联蛋白XI | ANXA11 | CAP50:钙周期蛋白相关的膜联蛋白50自身抗原,56-kD | AJ278463 | 311 | NM001157SEQ ID15 | NP001148SEQ ID16 |
蛋白质S(α) | PROS1,PSA | M15036 | 5627 | NM000313SEQ ID17 | NP000304SEQ ID18 | |
H因子1(补体) | HF1 | CFH,HUS | Y00716 | 3075 | NM000186SEQ ID19 | NP000177SEQ ID20 |
超氧化物歧化酶3 | SOD-3 | 胞外超氧化物歧化酶 | U10116 | 6649 | NM003102SEQ ID21 | NP003093SEQID22 |
Neuronatin | NNAT | Peg5 | U31767 | 4826 | NM005386SEQ ID23 | NP005377SEQ ID24 |
滤泡素抑制素-样蛋白3(Follistatin-like 3) | FSTL3 | 分泌的糖蛋白FLRG,FSRP:滤泡素抑制素相关蛋白 | U76702 | 10272 | NM005860SEQ ID25 | NP005851SEQ ID26 |
蛋白酶,丝氨酸23 | SPUVE | ZSIG13,MGC5107,PRSS23-pending,脐内皮 | AF015287 | 11098 | NM007173SEQ ID27 | NP009104SEQ ID28 |
膜联蛋白A2 | ANXA2 | ANX2,LIP2,LPC2,CAL1H,LPC2D,ANX2L4 | D00017 | 302 | NM004039SEQ ID29 | NP004030SEQ ID30 |
赖氨酰氧化酶 | LOX | 蛋白质-赖氨酸6-氧化酶 | AF039290 | 4015 | NM002317SEQ ID31 | NP002308SEQ ID32 |
ECGF1 | ECGF1 | 内皮细胞生长因子1(血小板来源) | M58602,M63193 | 1890 | NM001953SEQ ID33 | NP001944SEQ ID34 |
基于表1所列多肽,本发明提供用于诊断糖尿病或早期糖尿病(前驱糖尿病)的标记,其包含至少一种选自表1所列多肽(Seq ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34)的多肽。因此,本说明书所用的术语“标记”是指一种或多种在内脏或皮下脂肪组织中受调节和可以用于诊断糖尿病,前驱糖尿病或糖尿病易感性的多肽,其为单独的或作为多种已知在脂肪组织中,或在糖尿病其它组织中受调节的多肽的组合。
本说明书所用的术语“多肽”是指氨基酸的聚合物,不是指特定长度。因此,多肽的定义包括肽,寡肽和蛋白质。
优选地,本发明的标记是包含至少一种选自表1所列多肽的多肽的标记。
随着糖尿病中受调节的多肽的鉴定,本发明提供诊断糖尿病,前驱糖尿病和/或糖尿病易感性的体外方法,其包含以下步骤:获得生物样品;和检测和/或测量上述标记的增加或减少。
按照本发明术语“差异表达”涉及相对于健康个体或未患糖尿病或无患糖尿病倾向的个体,在来源于糖尿病或前驱糖尿病个体/患者或糖尿病易感个体的组织和/或细胞中上调或下调的标记基因。
如附表2和后附实施例所示,上调的特异性标记基因包括但不限于二肽酰肽酶IV,成纤维细胞生长因子2(碱性),血小板反应蛋白2,fibulin1,蛋白质S(α),H因子1(补体),蛋白酶丝氨酸23,膜联蛋白A2,和赖氨酰氧化酶。
表2:在糖尿病中上调的基因
名称 | 缩写 | 别名 | GenBank | 基因座连接(LocusLink) | MRNA | 蛋白质 |
二肽酰肽酶IV | DPPIV,DPP4 | CD26,ADCP2,TP103,ADABP:腺苷脱氨酶复合蛋白质2,T-细胞活化抗原CD26 | S79876 | 1803 | NM001935SEQ ID7 | NP001926SEQID 8 |
成纤维细胞生长因子2(碱性) | FGF2,BFGF | Prostatropin,HBGH-2:肝素结合生长因子2前体 | J04513 | 2247 | NM002006SEQ ID9 | NP001997SEQID 10 |
血小板反应蛋白2 | THBS2,TSP2 | L12350 | 7058 | NM003247SEQ ID11 | NP003238SEQID 12 | |
Fibulin1* | FBLN1 | X53743 | 2192 | NM001996SEQ ID13 | NP001987SEQID 14 | |
蛋白质S(α) | PROS1,PSA | M15036 | 5627 | NM000313SEQ ID17 | NP000304SEQID 18 | |
H因子1(补体) | HF1 | CFH,HUS | Y00716 | 3075 | NM000186 | NP000177 |
SEQ ID19 | SEQID 20 | |||||
蛋白酶,丝氨酸23 | SPUVE | ZSIG13,MGC5107,PRSS23-pending,脐内皮 | AF015287 | 11098 | NM007173SEQ ID27 | NP009104SEQID 28 |
膜联蛋白A2 | ANXA2 | ANX2,LIP2,LPC2,CAL1H,LPC2D,ANX2L4 | D00017 | 302 | NM004039SEQ ID29 | NP004030SEQID 30 |
赖氨酰氧化酶 | LOX | 蛋白质-赖氨酸6-氧化酶 | AF039290 | 4015 | NM002317SEQ ID31 | NP002308SEQID 32 |
在糖尿病中下调的标记基因包括但不限于血管内皮生长因子,载脂蛋白D,胺氧化酶,含铜3,超氧化物歧化酶3和neuronatin,滤泡素抑制素-样蛋白3(Follistatin-like 3)。
表3:在糖尿病中下调的基因
名称 | 缩写 | 别名 | GenBank | 基因座连接(LocusLink) | MRNA | 蛋白质 |
血管内皮生长因子B | VEGF-B | VRG,VEGFL | BC008818 | 7423 | NM003377SEQID 1 | NP003368SEQID 2 |
载脂蛋白D | APOD | J02611 | 347 | NM001647SEQID3 | NP001638SEQID 4 | |
胺氧化酶,含铜3 | AOC3 | VAP1,VAP-1:血管粘着蛋白I;HPAO | U39447 | 8639 | NM003734SEQID 5 | NP003725SEQID 6 |
超氧化物歧化酶3 | SOD-3 | 胞外超氧化物歧化酶 | U10116 | 6649 | NM003102SEQID 21 | NP003093SEQID22 |
Neuronatin | NNAT | Peg5 | U31767 | 4826 | NM005386SEQID 23 | NP005377SEQID 24 |
滤泡素抑制素-样蛋白3 | FSTL3 | 分泌糖蛋白FLRG,FSRP:滤泡素抑制素相关蛋白 | U76702 | 10272 | NM005860SEQID 25 | NP005851SEQID 26 |
按照本发明,本说明书所用的术语“生物样品”意指包含材料的样品,所述材料中可以测量标记基因的差异表达并且可以获自个体。特别优选的样品包含体液,如血液,血清,血浆,尿,滑液,脊髓液,脑脊髓液,精液或淋巴,以及体组织,如内脏和皮下脂肪组织。
差异表达的标记基因的检测和/或测量可以包含检测特定核酸分子例如RNA或cDNA的增加,减少和/或缺乏,测量/检测表达的多肽/蛋白质以及测量/检测表达的蛋白质/多肽的(生物)活性(或其缺乏)。(生物)活性可包含酶活性,与信号途径事件例如抗原识别以及效应器事件相关的活性。
检测/测量RNA和/或cDNA水平的方法在本领域公知并包含在后附实施例中所述的方法。这些方法包括但不限于PCR-技术,RNA印迹,affymetrix芯片等。
本说明书所用的术语“检测”是指定量测定多肽的缺乏或存在。本说明书所用的术语“测量”是指定量测定在来自糖尿病患者的生物样品和来自健康个体的生物样品中多肽表达的差异。另外,术语“测量”还可以指定量测定在来自内脏脂肪组织和皮下脂肪组织的生物样品中多肽表达的差异。
检测和/或测量生物样品中多肽的方法在本领域公知并且包括但不限于蛋白质印迹法,ELISA或RIA,或各种蛋白质组学技术。为了检测多肽或其肽片段,例如通过用纯化的蛋白质免疫兔子,可以产生识别表1所列多肽或其肽片段的单克隆或多克隆抗体,或者,可以使用识别该多肽或肽片段的已知的抗体。例如,能够与变性蛋白质结合的抗体如多克隆抗体可以在蛋白质印迹中用于检测本发明的肽。测量标记的方法实例是ELISA。该类型的蛋白质定量是基于能够捕捉特定抗原的抗体,和能够检测捕捉的抗原的第二抗体。检测糖尿病诊断标记的另一方法是通过分析活检标本的本发明的标记的存在或缺乏。这些标记的检测方法在本领域是公知的,包括但不限于免疫组织化学或免疫荧光检测本发明标记多肽的存在或缺乏。制备和使用抗体的方法,及上述测定在Harlow,E.和Lane,D.Antibodies:ALaboratory Manual,(1988),Cold Spring Harbor Laboratory Press中描述。
尽管分析表1所列多肽之一可以准确诊断糖尿病或前驱糖尿病,糖尿病诊断的准确性可以通过分析多种表1所列多肽的组合而提高。因此,此前所述体外方法包含一种标记,其包含至少两种,优选至少三种,更优选至少四种,还更优选至少五种,和最优选至少六种表1所列多肽。
为了诊断糖尿病,需要待分析存在或缺乏标记的适当的生物样品。生物样品可以是血清,血浆,或各种组织,包括脂肪组织的细胞。通过任何已知方法如ERCP,肠促胰液素刺激,细针(fine-needle)抽吸,细胞刷(cytologic brushings)和大孔穿刺活检可以获得脂肪组织细胞。
还可以通过检测和/或测量编码上述标记的核酸分子诊断糖尿病。优选地,核酸分子是RNA或DNA。
在本发明的一个实施方案中,此前所述体外方法包含将怀疑患前驱糖尿病,糖尿病和/或糖尿病易感个体中至少一种编码所述多肽的核酸的表达水平与健康个体中相同核酸的表达水平比较。
在本发明另一实施方案中,此前所述体外方法包含将怀疑患前驱糖尿病,糖尿病和/或糖尿病易感个体中至少一种多肽的表达水平与健康个体中相同核酸的表达水平比较。
在本发明还有的另一实施方案中,此前所述的体外方法包含将怀疑患前驱糖尿病,糖尿病和/或糖尿病易感个体中多肽标记的表达水平与健康个体中相同标记的表达水平比较。在更优选的体外方法的实施方案中,标记表达水平的增加或减少是糖尿病或糖尿病易感性的征兆。
在本发明还有的另一实施方案中,此前所述的体外方法包含将怀疑患前驱糖尿病,糖尿病和/或糖尿病易感个体中核酸标记的表达水平与健康个体中相同标记的表达水平比较。在体外方法的更优选的实施方案中,标记表达水平的增加或减少是糖尿病或糖尿病易感性的征兆。
还有,在本发明另一实施方案中,本发明的体外方法包含一种方法,其中通过检测和/或测量由表1所列基因编码的蛋白质/多肽或其片段进行检测和/或测量步骤。同样,这些检测/测量步骤包含本领域已知的方法,尤其如蛋白质组学,免疫化学方法如蛋白质印迹,ELISA等。
优选地,在本发明的体外方法中,比较至少两个表1所列标记基因的表达水平。还优选在本发明的体外方法中,将至少一种表2所列标记基因的表达水平与至少一种表3所列标记基因比较。例如,设想本发明的方法包含测量/检测至少一种上调的和至少一种下调的标记基因或基因产物。
本发明还提供鉴定和/或获得与表1所列的在糖尿病中表达受调节的多肽相互作用的化合物的筛选方法,其包含以下步骤:该方法包含将所述多肽与一种化合物或多种化合物在允许该化合物与该多肽相互作用的条件下接触;和检测该化合物或多种化合物与所述多肽之间的相互作用。
对于与细胞表面上的细胞膜有关的多肽,或作为跨膜或整合膜多肽表达的多肽,可以用不同方法检测化合物与多肽的相互作用,所述方法包括但不限于,使用正常表达多肽或过量表达多肽的细胞的方法,例如通过检测标记的已知配体被待筛选的化合物所替换。备选地,膜制剂可以用于检测化合物与这样一种多肽的相互作用。
本说明书公开的方法中所用的相互作用测定可包含FRET-测定(荧光共振能量转移;如特别在Ng,Science 283(1999),2085-2089或Ubarretxena-Belandia,Biochem.38(1999),7398-7405中所述),TR-FRET和本说明书公开的生物化学测定。另外,可以使用商业测定如“AmplifiedLuminescent Proximity Homogenous Assay TM”(BioSignal Packard)。另外的方法在本领域公知,并且特别在Fernandez,Curr.Opin.Chem.Biol.2 (1998),547-603中所述
还可以通过特异性免疫学和/或生物化学测定进行“相互作用试验”,这些测定在本领域公知并且包含例如以下所述的均相和多相测定。使用读出(read-out)系统的相互作用测定在本领域公知,并且特别包含双杂交筛选(如特别在EP-0 963 376,WO 98/25947,WO 00/02911中所述;和如后附实施例所例举),GST-pull-down柱,细胞提取物的共沉淀测定,如特别在Kasus-Jacobi,Oncogene 19(2000),2052-2059中所述,“相互作用-诱捕”系统(如特别在US 6,004,746中所述)表达克隆(例如λgt11),噬菌体展示(如特别在US 5,541,109中所述),体外结合测定等。另外的相互作用测定方法和对应的读出系统特别在US 5,525,490,WO 99/51741,WO00/17221,WO 00/14271或WO 00/05410中描述。Vidal和Legrain(1999)在NucleicAcids Research 27,919-929中描述,综述和总结本领域已知的可以按照本发明使用的另外的相互作用测定。
均相(相互作用)测定包含其中结合配偶体(partner)保持在溶液中的测定和包含诸如凝集测定的测定。多相测定包含诸如特别是免疫测定的测定,例如酶联免疫吸附测定(ELISA),放射性免疫测定(RIA),免疫放射分析(IRMA),流动注射分析(FIA),流动活化细胞分选(FACS),化学发光免疫测定(CLIA)或电致化学发光(ECL)报告。
本发明另外提供鉴定和/或获得化合物的筛选方法,所述化合物是表1所列在糖尿病患者中表达受调节的多肽的激动剂或拮抗剂,该方法包含以下步骤:a)将所述多肽与通过上述筛选方法鉴定和/或获得的化合物在允许该化合物与该多肽相互作用的条件下接触;b)测定该多肽的活性;c)测定如(a)所定义的在未与所述化合物接触的宿主中表达的该多肽的活性;和d)使在(b)和(c)中测定的活性定量关联,其中在(b)中测定的与(c)相比减小的活性是激动剂或拮抗剂的征兆。该筛选测定可以作为体外测定或者作为基于宿主的测定进行。用于本发明筛选方法和包含和/或表达表1所列多肽的宿主可包含原核以及真核细胞。细胞可包含细菌细胞,酵母细胞,以及培养的(组织)细胞系,尤其是来源于哺乳动物的。另外动物也可以用作宿主,例如非人类转基因动物。因此,宿主(细胞)可以用包含核酸分子的载体转染或转化,所述核酸分子编码如本说明书所公开的在糖尿病中差异调节的多肽。宿主细胞或宿主因此可以用编码该多肽的核酸分子或包含该核酸分子的载体基因修饰。术语“基因修饰”是指宿主细胞或宿主除了其天然基因组以外包含编码表1所列多肽或至少其片段的核酸分子或载体。另外的遗传物质可以导入宿主(细胞)或其祖先/亲代之一。核酸分子或载体可以作为基因组外独立的分子,优选作为能够复制的分子存在于基因修饰的宿主细胞或宿主中,或者它可以稳定地整合到宿主细胞或宿主的基因组中。
如上所述,本发明的宿主细胞可以是任何原核或真核细胞。适当的原核细胞是通常用于克隆的那些,如大肠杆菌(E.coli)或枯草芽孢杆菌(Bacillus subtilis)。然而,这些原核宿主细胞也被视为在本说明书公开的筛选方法中。另外,真核细胞包含例如真菌或动物细胞。适当的真菌细胞的实例为酵母细胞,优选属于酵母属的那些,最优选属于酿酒酵母(Saccharomyces cerevisiae)种的那些。适当的动物细胞是例如昆虫细胞,脊椎动物细胞,优选哺乳动物细胞,如例如CHO,Hela,NIH3T3或MOLT-4。本领域已知的另外的适当细胞系可以获自细胞系保藏机构,如美国典型培养物保藏中心(ATCC)。
宿主还可以选自非人类哺乳动物,最优选小鼠,大鼠,羊,牛,狗,猴或猿。如本说明书所述,动物/哺乳动物还可以包含非人类转基因动物,其优选表达至少一种如本说明书所公开的在糖尿病中差异调节的多肽。优选地,多肽是一种在来源于糖尿病患者的组织中受调节的多肽。然而也设想产生不表达本说明书公开的标记基因或表达有限量的标记基因产物的非人类转基因动物。动物优选涉及在糖尿病中下调的多肽。包含和/或表达本发明的上调多肽或备选地包含沉默的或较低效率类型(version)的下调多肽的转基因非人类动物是研究糖尿病发展的有用模型,并为检验糖尿病治疗和/或预防的药物和疗法提供有用模型。
通过测定在化合物存在下的多肽活性鉴定与表1所列多肽相互作用和抑制或拮抗该多肽的化合物。
本说明书所用的术语“活性”涉及特定多肽的功能性质或性质。对于酶,术语“活性”涉及特定多肽的酶活性。对于粘附分子,术语“活性”涉及多肽的粘着性质并可以使用诸如不限于粘着测定、细胞扩散测定的测定,或粘着分子与已知配体的体外相互作用测定。对于细胞骨架蛋白,术语“活性”是指细胞骨架被这些多肽调节,或它们整合至细胞骨架中。作为非限制性的实例,使用体外肌动蛋白聚合分析可以测定凝溶胶蛋白调节肌动蛋白聚合的能力,或细丝蛋白A促进肌动蛋白细丝的垂直分支的能力。另外可以通过作为非限制性实例的细胞扩散测定,细胞迁移测定,细胞增殖测定,或免疫荧光检测,或通过用荧光标记的鬼笔毒环肽将肌动蛋白丝染色测定有关细胞骨架结构调节的活性。对于离子通道术语“活性”是指跨膜离子流(氯化物流)。对于转录因子,术语“活性”涉及它们调节基因转录的能力。使用常规使用的分析如报告基因分析可以测定基因的转录活性。对于生长因子和激素或它们的受体,术语“活性”分别涉及它们结合它们的受体或配体的能力,和诱导受体活化和随后信号级联放大的能力,和/或涉及因子或受体介导最终由生长因子或激素介导的受体活化导致的细胞功能或多种功能的能力。通过常规已知的配体结合分析可以测定生长因子或激素与受体的结合。通过检验受体自磷酸化,或通过分析下游信号介质对受体的修饰或募集(通过信号复合体的免疫沉淀和蛋白质印迹法)可以测定受体的活化。生长因子或激素和它们的受体调节的细胞功能可以是细胞增殖(例如通过使用胸腺嘧啶掺入或细胞计数测定),细胞迁移测定(例如通过使用改进的Boyden chamber测定),细胞存活或编程性细胞死亡测定(例如通过使用DAPJ染色测定),血管生成测定(例如测量内皮管成形的可商购的体外测定)。除了这些测定以外,还可以使用其它分析来测定这些和其它细胞功能。
通过本发明方法鉴定和/或获得的抑制剂,拮抗剂,活化剂或激动剂在治疗管理,预防和/或治疗糖尿病中特别有用。
当在筛选方法中,与化合物不存在相比,存在在化合物的存在下测定的降低的活性时,其是抑制剂或拮抗剂的征兆,则通过上述筛选方法可以鉴定表1所列多肽的抑制剂或拮抗剂。
因此,用本发明方法鉴定、筛选和/或获得的潜在的抑制剂或拮抗剂包括结合、干涉和/或占据表达的标记基因上的相关位点的分子,优选小分子,所述标记基因在源自糖尿病或前驱糖尿病患者或糖尿病易感个体的组织或细胞中上调。
还设想这些抑制剂干涉(功能性)上调的标记基因或基因产物的合成/生产,如例如反义构建体、核酶等。可以按照本发明方法筛选和获得的抑制剂和/或拮抗剂特别包括肽,蛋白质,核酸,其包括DNA,RNA,RNAi,PNA,核酶,抗体,小有机化合物,小分子,配体等。
因此,差异表达的标记基因的抑制剂和/或拮抗剂可以包含抗体。该抗体可以包含单克隆抗体以及多克隆抗体。另外,可以设想嵌合抗体,合成抗体以及抗体片段(如Fab,F(ab)2,Fv,scFV),或化学修饰的抗体衍生物。设想抗体与标记基因或其基因产物结合和/或干涉其活性。
另外,与本说明书定义的标记基因结合或干涉所述标记基因活性的寡核苷酸和/或适体(aptamer)被视为抑制剂和/或拮抗剂。按照本发明所用的术语“寡核苷酸”包含编码和非编码序列,其包含DNA和RNA和/或还包含任何可能的衍生物。术语“寡核苷酸”另外包含肽核酸(PNA),其包含具有酰胺主链键的DNA类似物(Nielson,Science 274(1991),1497-1500)。可抑制和/或拮抗标记基因活性并可以通过本发明方法鉴定和/或获得的寡核苷酸可以尤其是使用本领域公知和可商购的合成仪,如AB1394 DNA-RNA合成仪容易地化学合成。另外,~22nt合成的小的干涉dsRNA(siRNA)的应用可以用于抑制基因表达。
除了以上公开的筛选方法以外,本发明提供鉴定和/或获得化合物的筛选方法,所述化合物是在糖尿病中表达受调节的多肽表达的抑制剂,该方法以下步骤:(a)将表达所述多肽的宿主与化合物接触;(b)测定该多肽的表达水平和/或活性;(c)测定如(a)所定义的在未与所述化合物接触的宿主中表达的该多肽的表达水平和/或活性;和d)使在(b)和(c)中测定的表达水平定量关联,其中在(b)中测定的与(c)相比降低的表达水平是该多肽表达的抑制剂的征兆。
通过上述筛选方法鉴定表1所列多肽表达的抑制剂,当在筛选方法中与缺乏化合物相比,在化合物的存在下测定到减少的蛋白质表达时,其是多肽表达的抑制剂的征兆。
本说明书所用的术语“表达”涉及在糖尿病受调节的表1所列多肽的表达水平。优选地,在糖尿病脂肪组织细胞中的表达水平是健康脂肪组织细胞中的至少2倍,更优选至少3倍,还更优选至少4倍,最优选至少5倍。
另外,本发明提供通过上述筛选方法中的任何一种鉴定和/或获得的化合物。该化合物进一步包含在药物组合物中。可以使用任何常规载体材料。载体材料可以是适于eteral,经皮或肠胃外给药的有机或无机物。适当的载体包括水,明胶,阿拉伯胶,乳糖,淀粉,硬脂酸镁,滑石,植物油,聚亚烷基二醇,矿脂等。另外,药物制剂可以包含其它药物活性剂。按照药物配制的常例可以加入另外的添加剂如调味剂,稳定剂,乳化剂,缓冲液等。
化合物可以用于制备治疗或预防糖尿病的药物。另外,化合物还可以用于制备诊断糖尿病或糖尿病素因的诊断组合物。优选地,化合物包含抗体,抗体衍生物,抗体片段,肽或反义构建体。
在本发明的范围内,针对表1所列蛋白质的抗体,或其抗原结合片段可以用于诊断糖尿病的体外方法。
为了有效进行诊断筛选,本发明提供用于针对早期糖尿病(前驱糖尿病),糖尿病易感性,或糖尿病的试剂盒,其包含上述的一种或多种抗体,或其抗原结合片段。本发明提供的另一试剂盒是用于诊断前驱糖尿病,糖尿病易感性,或糖尿病的试剂盒,其包含一种或多种编码上述标记的核酸。而本发明提供的另一试剂盒是用于筛选化合物的试剂盒,该化合物激动或拮抗表1所列多肽中的任何一种,或抑制这些多肽中任何一种的表达。
如上所述,抑制剂和/或拮抗剂还可以包含小分子。然而通过本说明书公开的方法也可以鉴定小分子为活化剂或激动剂。术语“小分子”涉及,但不限于,小的肽,无机和/或有机物或肽样分子,如包含D-氨基酸的肽类似物。
另外,可以使用适当拮抗剂、抑制剂、激动剂或活化剂的肽模拟(peptidomimetics)和/或计算机辅助设计以便获得在本发明方法中检验的候选化合物。例如蛋白质和肽的计算机辅助设计的适当计算机系统在现有技术中,例如在Berry,Biochem.Soc.Trans.22(1994),1033-1036;Wodak,Ann.N.Y.Acad.Sci.501(1987),1-13;Pabo,Biochemistry 25(1986),5987-5991中描述。可以将上述计算机分析获得的结果与本发明的方法结合使用以例如优化已知化合物,物质或分子。通过连续化学修饰合成肽模拟物组合文库和例如按照本说明书所述方法检验获得的化合物,也可以鉴定适当的化合物。产生和使用肽模拟物组合文库的方法在现有技术中,例如在Ostresh,Methods in Enzymology 267(1996),220-234和Dorner,Bioorg.Med.Chem.4(1996),709-715中描述。另外,本发明标记或编码表达的标记的核酸分子的抑制剂活化剂、激动剂或活化剂的三维和/或晶体结构可以用于设计在本发明方法中检验的肽模拟物的抑制剂,拮抗剂,激动剂或活化剂(Rose,Biochemistry 35(1996),12933-12944;Rutenber,Bioorg.Med.Chem.4(1996),1545-1558)。
用本发明方法筛选的化合物不仅包含单独的分离的化合物。还设想用本发明的方法筛选化合物的混合物。还可以使用提取物,如特别是来自原核或真核细胞或生物的细胞提取物。
另外,通过本发明方法鉴定或精制的化合物可以用作先导化合物来实现改变的作用位点,活性谱(spectrum),器官特异性,和/或改善的效力,和/或减小的毒性(提高的治疗指数),和/或减小的副作用,和/或改进的治疗作用的起始,作用持续期间,和/或改进的药物动力学参数(再吸收,分布,代谢和排泄),和/或改进的生理化学参数(溶解度,吸湿性,颜色,味道,气味,稳定性,状态),和/或改善的总体特异性,器官/组织特异性,和/或优化的施用形式和途径可以通过以下改进:羧基的酯化,或羟基被碳氢酸酯化,或将羟基酯化成例如磷酸酯,焦磷酸酯或硫酸酯或半琥珀酸酯,或形成药用盐,或形成药用复合物,或合成药物活性聚合物,或引入亲水(hydrophylic)部分,或引入/交换aromates或侧链上的取代基,改变取代基模式,或通过引入等排或生物等排部分修饰,或合成同系物,或引入支化侧链,或将烷基取代基转化为环状类似物,或将羟基衍生为缩酮(ketale),缩醛(acetale),或N-乙酰化为酰胺,苯基氨基甲酸酯,或合成曼尼希碱,亚胺,或将酮或醛转化为席夫碱,肟,缩醛,缩酮,烯醇酯,噁唑烷,噻唑烷(thiozolidine)或其组合。
另外,本发明提供一种化合物或多种化合物在制备用于诊断前驱糖尿病,糖尿病或糖尿病素因的诊断组合物中的应用,所述化合物可以通过本说明书公开的方法获得。例如设想特异性检测或识别差异表达的本发明公开的标记基因产物的特异性抗体、其片段或其衍生物用于该诊断组合物。然而,可以检测和/或扩增本发明标记基因的特异性引物/引物对可以用于诊断组合物。
本发明提供治疗有效量的至少一种针对至少一种蛋白质的抗体或其抗原结合片段在制备用于治疗糖尿病和前驱糖尿病的药物中的应用,所述蛋白质选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的蛋白质。另外,本发明还提供治疗有效量的至少一种选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的蛋白质的蛋白质,蛋白质片段或肽在制备用于治疗糖尿病和前驱糖尿病的药物中的应用。
因此,用于药物以及诊断组合物中的化合物可以包含抗体,抗体衍生物,抗体片段,肽或核酸,如引物/引物对以及反义构建体,RNAi或核酶。
诊断组合物还可以包含本领域已知用于检测的适当装置。
通过参考下列生物实施例进一步描述本发明,所述实施例仅为举例说明性的并且不应被认为是限制范围。
特别参考下列实施例,还要求保护上述方法和试剂盒。
实施例:
按照制造商的方案使用UltraspecRNA(Biotecx,Houston,TX)提取RNA,并使用RNeasy Mini试剂盒(Qiagen,Valencia,CA)用DNA酶处理纯化。通过SuperScriptTM双链cDNA合成试剂盒(Life Technology,Rockville,MD)使用T7-T24引物从10ug总RNA合成双链cDNA。通过酚/氯仿/异戊醇提取,使用锁相凝胶(Eppendorf,Westbury,NY)纯化双链cDNA产物。使用体外转录(IVT)MEGAscriptTM T7试剂盒(Ambion,Austin,TX)将双链cDNA进一步转化为cRNA,并用生物素化的核苷酸标记。使用RNeasyMini试剂盒(Qiagen,Valencia,CA)纯化体外转录产物,并如所述片段化(Wodicka L,Dong H,Mittmann M,Ho MH,Lockhart DJ.Genome-wideexpression monitoring in Saccharomyces cerevisiae.Nat Biotechnol 1997;15:1359-67)。如制造商(Affymetrix,Santa Clara,CA)建议进行片段化的体外转录产物与人类基因组U95(HG-U95)Genechip阵列组的杂交。
统计学方法
通过Affymetrix的MAS算法(Affymetrix技术说明:监视Genechip探针阵列上基因表达的新的统计学算法(2001))对报告的信号强度进行所有的数值分析。将芯片各自对所有实验芯片的总平均值标准化。基因未分开标准化。
将数据分析构建成各因子的线性模型(Draper N.,Smith H.AppliedRegression Analysis,第二版John Wiley and Sons.New York,New York.(1966);Searle S.R.Linear Models John Wiley and Sons.New York,New York.(1971)),所述因子分别关于BMI,组织来源(皮下vs.内脏脂肪),胰岛素抗性(通过HOMA测量),禁食葡萄糖,禁食胰岛素和组织来源与禁食葡萄糖,禁食胰岛素,和胰岛素抗性之间的分别的相互作用。使用SAS 8.1版进行计算。模型的方程如下:
信号强度=BMI+组织+IR+葡萄糖+胰岛素+组织*IR+组织*葡萄糖+组织*胰岛素+误差
然后使用该模型进行9个统计学试验(对比)。1)内脏脂肪中的作用;2)皮下脂肪中的作用;3)内脏和皮下脂肪之间的差异作用。以三个相互作用项进行那些三次试验中的每一个,导致最后的9个试验。
然后筛选模型计算和统计学对比的结果而导致最终的目的基因。显著性定义为对于整个模型的小于0.001的p值和对于特定对比的小于0.01的p值。选择p-值截止以便控制假阳性,同时仍发现大多数真阳性(Sokal R.R.,Rohlf F.J.Biometry W.H.Freeman and Company.New York,New York.(1969))。
最后通过将Affymetrix提供的Genbank登记号与Unigene(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene)和LocusLink(http://www.ncbi.nlm.nih.gov/LocusLink/)对那些登记号的注释连接对基因作注解。
贯穿以上整个说明书讨论的所有参考文献通过对它们包含的主题的参考完整地结合于本说明书。
当然,应当理解,上述涉及本发明的优选实施方案,并且可以在不背离如后附权利要求所阐明的本发明精神和范围下进行改进。
序列表
<110> 霍夫曼-拉罗奇有限公司
<120> 糖尿病的特异性标记
<130> 21270
<160> 34
<170> PatentIn version 3.2
<210> 1
<211> 1172
<212> DNA
<213> Homo sapiens
<220>
<221> VEGF-B mRNA
<222> (1)..(1172)
<400> 1
gcgatgcggg cgcccccggc gggcggcccc ggcgggcacc atgagccctc tgctccgccg 60
cctgctgctc gccgcactcc tgcagctggc ccccgcccag gcccctgtct cccagcctga 120
tgcccctggc caccagagga aagtggtgtc atggatagat gtgtatactc gcgctacctg 180
ccagccccgg gaggtggtgg tgcccttgac tgtggagctc atgggcaccg tggccaaaca 240
gctggtgccc agctgcgtga ctgtgcagcg ctgtggtggc tgctgccctg acgatggcct 300
ggagtgtgtg cccactgggc agcaccaagt ccggatgcag atcctcatga tccggtaccc 360
gagcagtcag ctgggggaga tgtccctgga agaacacagc cagtgtgaat gcagacctaa 420
aaaaaaggac agtgctgtga agccagacag ggctgccact ccccaccacc gtccccagcc 480
ccgttctgtt ccgggctggg actctgcccc cggagcaccc tccccagctg acatcaccca 540
tcccactcca gccccaggcc cctctgccca cgctgcaccc agcaccacca gcgccctgac 600
ccccggacct gccgctgccg ctgccgacgc cgcagcttcc tccgttgcca agggcggggc 660
ttagagctca acccagacac ctgcaggtgc cggaagctgc gaaggtgaca catggctttt 720
cagactcagc agggtgactt gcctcagagg ctatatccca gtgggggaac aaagaggagc 780
ctggtaaaaa acagccaagc ccccaagacc tcagcccagg cagaagctgc tctaggacct 840
gggcctctca gagggctctt ctgccatccc ttgtctccct gaggccatca tcaaacagga 900
cagagttgga agaggagact gggaggcagc aagaggggtc acataccagc tcaggggaga 960
atggagtact gtctcagttt ctaaccactc tgtgcaagta agcatcttac aactggctct 1020
tcctcccctc actaagaaga cccaaacctc tgcataatgg gatttgggct ttggtacaag 1080
aactgtgacc cccaaccctg ataaaagaga tggaaggaaa aaaaaaaaaa aaaaaaaaaa 1140
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 1172
<210> 2
<211> 207
<212> PRT
<213> Homo sapiens
<220>
<221> VEGF-B多肽序列
<222> (1)..(207)
<400> 2
Met Ser Pro Leu Leu Arg Arg Leu Leu Leu Ala Ala Leu Leu Gln Leu
1 5 10 15
Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His Gln
20 25 30
Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys Gln
35 40 45
Pro Arg Glu Val Val Val Pro Leu Thr Val Glu Leu Met Gly Thr Val
50 55 60
Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly Gly
65 70 75 80
Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His Gln
85 90 95
Val Arg Met Gln Ile Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu Gly
100 105 110
Glu Met Ser Leu Glu Glu His Ser Gln Cys Glu Cys Arg Pro Lys Lys
115 120 125
Lys Asp Ser Ala Val Lys Pro Asp Arg Ala Ala Thr Pro His His Arg
130 135 140
Pro Gln Pro Arg Ser Val Pro Gly Trp Asp Ser Ala Pro Gly Ala Pro
145 150 155 160
Ser Pro Ala Asp Ile Thr His Pro Thr Pro Ala Pro Gly Pro Ser Ala
165 170 175
His Ala Ala Pro Ser Thr Thr Ser Ala Leu Thr Pro Gly Pro Ala Ala
180 185 190
Ala Ala Ala Asp Ala Ala Ala Ser Ser Val Ala Lys Gly Gly Ala
195 200 205
<210> 3
<211> 809
<212> DNA
<213> Homo sapiens
<220>
<221> 载脂蛋白D mRNA
<222> (1)..(809)
<400> 3
atgcctgtct tcatcttgaa agaaaagctc caggtccctt ctccagccac ccagccccaa 60
gatggtgatg ctgctgctgc tgctttccgc actggctggc ctcttcggtg cggcagaggg 120
acaagcattt catcttggga agtgccccaa tcctccggtg caggagaatt ttgacgtgaa 180
taagtatctc ggaagatggt acgaaattga gaagatccca acaacctttg agaatggacg 240
ctgcatccag gccaactact cactaatgga aaacggaaag atcaaagtgt taaaccagga 300
gttgagagct gatggaactg tgaatcaaat cgaaggtgaa gccaccccag ttaacctcac 360
agagcctgcc aagctggaag ttaagttttc ctggtttatg ccatcggcac cgtactggat 420
cctggccacc gactatgaga actatgccct cgtgtattcc tgtacctgca tcatccaact 480
ttttcacgtg gattttgctt ggatcttggc aagaaaccct aatctccctc cagaaacagt 540
ggactctcta aaaaatatcc tgacttctaa taacattgat gtcaagaaaa tgacggtcac 600
agaccaggtg aactgcccca agctctcgta accaggttct acagggaggc tgcacccact 660
ccatgttact tctgcttcgc tttcccctac cccacccccc cccataaaga caaaccaatc 720
aaccacgaca aaggaagttg acctaaacat gtaaccatgc cctaccctgt taccttgcta 780
gctgcaaaat aaacttgttg ctgacctgc 809
<210> 4
<211> 189
<212> PRT
<213> Homo sapiens
<220>
<221> 载脂蛋白D多肽序列
<222> (1)..(189)
<400> 4
Met Val Met Leu Leu Leu Leu Leu Ser Ala Leu Ala Gly Leu Phe Gly
1 5 10 15
Ala Ala Glu Gly Gln Ala Phe His Leu Gly Lys Cys Pro Asn Pro Pro
20 25 30
Val Gln Glu Asn Phe Asp Val Asn Lys Tyr Leu Gly Arg Trp Tyr Glu
35 40 45
Ile Glu Lys Ile Pro Thr Thr Phe Glu Asn Gly Arg Cys Ile Gln Ala
50 55 60
Asn Tyr Ser Leu Met Glu Asn Gly Lys Ile Lys Val Leu Asn Gln Glu
65 70 75 80
Leu Arg Ala Asp Gly Thr Val Asn Gln Ile Glu Gly Glu Ala Thr Pro
85 90 95
Val Asn Leu Thr Glu Pro Ala Lys Leu Glu Val Lys Phe Ser Trp Phe
100 105 110
Met Pro Ser Ala Pro Tyr Trp Ile Leu Ala Thr Asp Tyr Glu Asn Tyr
115 120 125
Ala Leu Val Tyr Ser Cys Thr Cys Ile Ile Gln Leu Phe His Val Asp
130 135 140
Phe Ala Trp Ile Leu Ala Arg Asn Pro Asn Leu Pro Pro Glu Thr Val
145 150 155 160
Asp Ser Leu Lys Asn Ile Leu Thr Ser Asn Asn Ile Asp Val Lys Lys
165 170 175
Met Thr Val Thr Asp Gln Val Asn Cys Pro Lys Leu Ser
180 185
<210> 5
<211> 4040
<212> DNA
<213> Homo sapiens
<220>
<221> 铜单胺氧化酶mRNA
<222> (1)..(4040)
<400> 5
gtccttccca cccttagtcc caggcatctg actaccggga acctcagcca gagtccggga 60
gccccccacc ccgtccagga gccaacagag cccccgtctt gctggcgtga gaatacattg 120
ctctcctttg gttgaatcag ctgtccctct tcgtgggaaa atgaaccaga agacaatcct 180
cgtgctcctc attctggccg tcatcaccat ctttgccttg gtttgtgtcc tgctggtggg 240
caggggtgga gatgggggtg aacccagcca gcttccccat tgcccctctg tatctcccag 300
tgcccagcct tggacacacc ctggccagag ccagctgttt gcagacctga gccgagagga 360
gctgacggct gtgatgcgct ttctgaccca gcggctgggg ccagggctgg tggatgcagc 420
ccaggcccgg ccctcggaca actgtgtctt ctcagtggag ttgcagctgc ctcccaaggc 480
tgcagccctg gctcacttgg acagggggag ccccccacct gcccgggagg cactggccat 540
cgtcttcttt ggcaggcaac cccagcccaa cgtgagtgag ctggtggtgg ggccactgcc 600
tcacccctcc tacatgcggg acgtgactgt ggagcgtcat ggaggccccc tgccctatca 660
ccgacgcccc gtgctgttcc aagagtacct ggacatagac cagatgatct tcaacagaga 720
gctgccccag gcttctgggc ttctccacca ctgttgcttc tacaagcacc ggggacggaa 780
cctggtgaca atgaccacgg ctccccgtgg tctgcaatca ggggaccggg ccacctggtt 840
tggcctctac tacaacatct cgggcgctgg gttcttcctg caccacgtgg gcttggagct 900
gctagtgaac cacaaggccc ttgaccctgc ccgctggact atccagaagg tgttctatca 960
aggccgctac tacgacagcc tggcccagct ggaggcccag tttgaggccg gcctggtgaa 1020
tgtggtgctg atcccagaca atggcacagg tgggtcctgg tccctgaagt cccctgtgcc 1080
cccgggtcca gctccccctc tacagttcta tccccaaggc ccccgcttca gtgtccaggg 1140
aagtcgagtg gcctcctcac tgtggacttt ctcctttggc ctcggagcat tcagtggccc 1200
aaggatcttt gacgttcgct tccaaggaga aagactagtt tatgagataa gcctccaaga 1260
ggccttggcc atctatggtg gaaattcccc agcagcaatg acgacccgct atgtggatgg 1320
aggctttggc atgggcaagt acaccacgcc cctgacccgt ggggtggact gcccctactt 1380
ggccacctac gtggactggc acttcctttt ggagtcccag gcccccaaga caatacgtga 1440
tgccttttgt gtgtttgaac agaaccaggg cctccccctg cggcgacacc actcagatct 1500
ctactcgcac tactttgggg gtcttgcgga aacggtgctg gtcgtcagat ctatgtccac 1560
cttgctcaac tatgactatg tgtgggatac ggtcttccac cccagtgggg ccatagaaat 1620
acgattctat gccacgggct acatcagctc ggcattcctc tttggtgcta ctgggaagta 1680
cgggaaccaa gtgtcagagc acaccctggg cacggtccac acccacagcg cccacttcaa 1740
ggtggatctg gatgtagcag gactggagaa ctgggtctgg gccgaggata tggtctttgt 1800
ccccatggct gtgccctgga gccctgagca ccagctgcag aggctgcagg tgacccggaa 1860
gctgctggag atggaggagc aggccgcctt cctcgtggga agcgccaccc ctcgctacct 1920
gtacctggcc agcaaccaca gcaacaagtg gggtcacccc cggggctacc gcatccagat 1980
gctcagcttt gctggagagc cgctgcccca aaacagctcc atggcgagag gcttcagctg 2040
ggagaggtac cagctggctg tgacccagcg gaaggaggag gagcccagta gcagcagcgt 2100
tttcaatcag aatgaccctt gggcccccac tgtggatttc agtgacttca tcaacaatga 2160
gaccattgct ggaaaggatt tggtggcctg ggtgacagct ggttttctgc atatcccaca 2220
tgcagaggac attcctaaca cagtgactgt ggggaacggc gtgggcttct tcctccgacc 2280
ctataacttc tttgacgaag acccctcctt ctactctgcc gactccatct acttccgagg 2340
ggaccaggat gctggggcct gcgaggtcaa ccccctagct tgcctgcccc aggctgctgc 2400
ctgtgccccc gacctccctg ccttctccca cgggggcttc tctcacaact aggcggtcct 2460
gggatggggc atgtggccaa gggctccagg gccagggtgt gagggatggg gagcagctgg 2520
gcactgggcc ggcagcctgg ttccctcttt cctgtgccag gactctcttt cttccactac 2580
cctccctcgc atccgcctct gagccaggag cctcctgacc ctgtgatgcc tgacacaggg 2640
gacactgaac cttgttgatg ccagctgtac tgagttctca tccacagagg ccaggcatgg 2700
cccagcctgg agccgtggcc gagggcttcc ctagatggtt ccctttgttg ctgtctggct 2760
ttcccgaatc tttttaggcc acctccaagg actctaaaag ggggctattc cctggagacc 2820
ccagagtagg gttgccagtc ctgcaagtcc atagctgagc tggaaaggat gcttctgctc 2880
acattccctc tcatccaggt cctttccttc tcgtcttcct ctctctcacc tacttcctcc 2940
tcctcctcct gttcctgcct tctcttctat cctgcaattt ctcccgaatc ctgaggggat 3000
atccctatgt cccagcccct ggtactcccc cagccctcag ttttcagtca agttccgtct 3060
cctctccagc cctatggaag tctcaaggtc acgggacccc taatcagagt ggccaatccc 3120
tgtgtgtcgt tcccttgtgt ctgttgctta ttgggagtag gagttgctcc tacccctgtc 3180
ctggggctgg gtgtgtttca ggacagctgc ttctgtgcat ttgtgtctgc ctgcctcatg 3240
ctctctatag aggaggatgg tcatcgtgac agcagcagct caagttagca tttcaagtga 3300
tttgggggtg caatgataat gaagaatggc cattttgtac cagggctctg tattctgcaa 3360
cagcctgttt gggaggctgg agtggaaaca aagggtgggc atcaaagatg agaagccaaa 3420
gcccctacaa ctccagccac ccagccagga ggggctgtcc aatcacattc aggcatgcga 3480
atgagctggg ccctgggtga ggtgggggtc tggcctagtg gggaggggcc tggcctgggt 3540
ggggcagggc ctggcctggt ccaggcttgg gctccattcc catcactgct gtccctcctg 3600
aggtctggat tggggatggg gacaaagaaa tagcaagaga tgagaaacaa cagaaacttt 3660
tttctctaaa ggactggtta aatcaattct gatacagcct tacaatacaa tagtatgcag 3720
ctaaaaaata attgtatgtc tttatatact aatatgtaat aatcttcagg tgaaaaaggc 3780
aagccacaga aatgtgtwta gcgcacttcc catttgtgtt tcagaaagga gtagaatata 3840
aacacataat tgcttatgta tgcctattca gaataaatgg gtaacactga ttacttttgg 3900
gaggggaacc agtaggttga ggacaggaga gggaagggtc ttaacactta cacccttttg 3960
tacattttga attttgaacc atgtgactgt attacctatt caaaataaac aataaatggg 4020
cccaaaaaaa aaaaaaaaaa 4040
<210> 6
<211> 763
<212> PRT
<213> Homo sapiens
<220>
<221> 铜单胺氧化酶多肽序列
<222> (1)..(763)
<400> 6
Met Asn Gln Lys Thr Ile Leu Val Leu Leu Ile Leu Ala Val Ile Thr
1 5 10 15
Ile Phe Ala Leu Val Cys Val Leu Leu Val Gly Arg Gly Gly Asp Gly
20 25 30
Gly Glu Pro Ser Gln Leu Pro His Cys Pro Ser Val Ser Pro Ser Ala
35 40 45
Gln Pro Trp Thr His Pro Gly Gln Ser Gln Leu Phe Ala Asp Leu Ser
50 55 60
Arg Glu Glu Leu Thr Ala Val Met Arg Phe Leu Thr Gln Arg Leu Gly
65 70 75 80
Pro Gly Leu Val Asp Ala Ala Gln Ala Arg Pro Ser Asp Asn Cys Val
85 90 95
Phe Ser Val Glu Leu Gln Leu Pro Pro Lys Ala Ala Ala Leu Ala His
100 105 110
Leu Asp Arg Gly Ser Pro Pro Pro Ala Arg Glu Ala Leu Ala Ile Val
115 120 125
Phe Phe Gly Arg Gln Pro Gln Pro Asn Val Ser Glu Leu Val Val Gly
130 135 140
Pro Leu Pro His Pro Ser Tyr Met Arg Asp Val Thr Val Glu Arg His
145 150 155 160
Gly Gly Pro Leu Pro Tyr His Arg Arg Pro Val Leu Phe Gln Glu Tyr
165 170 175
Leu Asp Ile Asp Gln Met Ile Phe Asn Arg Glu Leu Pro Gln Ala Ser
180 185 190
Gly Leu Leu His His Cys Cys Phe Tyr Lys His Arg Gly Arg Asn Leu
195 200 205
Val Thr Met Thr Thr Ala Pro Arg Gly Leu Gln Ser Gly Asp Arg Ala
210 215 220
Thr Trp Phe Gly Leu Tyr Tyr Asn Ile Ser Gly Ala Gly Phe Phe Leu
225 230 235 240
His His Val Gly Leu Glu Leu Leu Val Asn His Lys Ala Leu Asp Pro
245 250 255
Ala Arg Trp Thr Ile Gln Lys Val Phe Tyr Gln Gly Arg Tyr Tyr Asp
260 265 270
Ser Leu Ala Gln Leu Glu Ala Gln Phe Glu Ala Gly Leu Val Asn Val
275 280 285
Val Leu Ile Pro Asp Asn Gly Thr Gly Gly Ser Trp Ser Leu Lys Ser
290 295 300
Pro Val Pro Pro Gly Pro Ala Pro Pro Leu Gln Phe Tyr Pro Gln Gly
305 310 315 320
Pro Arg Phe Ser Val Gln Gly Ser Arg Val Ala Ser Ser Leu Trp Thr
325 330 335
Phe Ser Phe Gly Leu Gly Ala Phe Ser Gly Pro Arg Ile Phe Asp Val
340 345 350
Arg Phe Gln Gly Glu Arg Leu Val Tyr Glu Ile Ser Leu Gln Glu Ala
355 360 365
Leu Ala Ile Tyr Gly Gly Asn Ser Pro Ala Ala Met Thr Thr Arg Tyr
370 375 380
Val Asp Gly Gly Phe Gly Met Gly Lys Tyr Thr Thr Pro Leu Thr Arg
385 390 395 400
Gly Val Asp Cys Pro Tyr Leu Ala Thr Tyr Val Asp Trp His Phe Leu
405 410 415
Leu Glu Ser Gln Ala Pro Lys Thr Ile Arg Asp Ala Phe Cys Val Phe
420 425 430
Glu Gln Asn Gln Gly Leu Pro Leu Arg Arg His His Ser Asp Leu Tyr
435 440 445
Ser His Tyr Phe Gly Gly Leu Ala Glu Thr Val Leu Val Val Arg Ser
450 455 460
Met Ser Thr Leu Leu Asn Tyr Asp Tyr Val Trp Asp Thr Val Phe His
465 470 475 480
Pro Ser Gly Ala Ile Glu Ile Arg Phe Tyr Ala Thr Gly Tyr Ile Ser
485 490 495
Ser Ala Phe Leu Phe Gly Ala Thr Gly Lys Tyr Gly Asn Gln Val Ser
500 505 510
Glu His Thr Leu Gly Thr Val His Thr His Ser Ala His Phe Lys Val
515 520 525
Asp Leu Asp Val Ala Gly Leu Glu Asn Trp Val Trp Ala Glu Asp Met
530 535 540
Val Phe Val Pro Met Ala Val Pro Trp Ser Pro Glu His Gln Leu Gln
545 550 555 560
Arg Leu Gln Val Thr Arg Lys Leu Leu Glu Met Glu Glu Gln Ala Ala
565 570 575
Phe Leu Val Gly Ser Ala Thr Pro Arg Tyr Leu Tyr Leu Ala Ser Asn
580 585 590
His Ser Asn Lys Trp Gly His Pro Arg Gly Tyr Arg Ile Gln Met Leu
595 600 605
Ser Phe Ala Gly Glu Pro Leu Pro Gln Asn Ser Ser Met Ala Arg Gly
610 615 620
Phe Ser Trp Glu Arg Tyr Gln Leu Ala Val Thr Gln Arg Lys Glu Glu
625 630 635 640
Glu Pro Ser Ser Ser Ser Val Phe Asn Gln Asn Asp Pro Trp Ala Pro
645 650 655
Thr Val Asp Phe Ser Asp Phe Ile Asn Asn Glu Thr Ile Ala Gly Lys
660 665 670
Asp Leu Val Ala Trp Val Thr Ala Gly Phe Leu His Ile Pro His Ala
675 680 685
Glu Asp Ile Pro Asn Thr Val Thr Val Gly Asn Gly Val Gly Phe Phe
690 695 700
Leu Arg Pro Tyr Asn Phe Phe Asp Glu Asp Pro Ser Phe Tyr Ser Ala
705 710 715 720
Asp Ser Ile Tyr Phe Arg Gly Asp Gln Asp Ala Gly Ala Cys Glu Val
725 730 735
Asn Pro Leu Ala Cys Leu Pro Gln Ala Ala Ala Cys Ala Pro Asp Leu
740 745 750
Pro Ala Phe Ser His Gly Gly Phe Ser His Asn
755 760
<210> 7
<211> 3948
<212> DNA
<213> Homo sapiens
<220>
<221> 二肽酰肽酶IV mRNA
<222> (1)..(3948)
<400> 7
ctttcactgg caagagacgg agtcctgggt ttcagttcca gttgcctgcg gtgggctgtg 60
tgagtttgcc aaagtcccct gccctctctg ggtctcggtt ccctcgcctg tccacgtgag 120
gttggaggag ctgaacgccg acgtcatttt tagctaagag ggagcagggt ccccgagtcg 180
ccggcccagg gtctgcgcat ccgaggccgc gcgccctttc ccctccccca cggctcctcc 240
gggccccgca ctctgcgccc cggctgccgc ccagcgccct acaccgccct cagggggccc 300
tcgcgggctc cccccggccg ggatgccagt gccccgcgcc acgcgcgcct gctcccgcgc 360
cgcctgccct gcagcctgcc cgcggcgcct ttatacccag cgggctcggc gctcactaat 420
gtttaactcg gggccgaaac ttgccagcgg cgagtgactc caccgcccgg agcagcggtg 480
caggacgcgc gtctccgccg cccgcggtga cttctgcctg cgctccttct ctgaacgctc 540
acttccgagg agacgccgac gatgaagaca ccgtggaagg ttcttctggg actgctgggt 600
gctgctgcgc ttgtcaccat catcaccgtg cccgtggttc tgctgaacaa aggcacagat 660
gatgctacag ctgacagtcg caaaacttac actctaactg attacttaaa aaatacttat 720
agactgaagt tatactcctt aagatggatt tcagatcatg aatatctcta caaacaagaa 780
aataatatct tggtattcaa tgctgaatat ggaaacagct cagttttctt ggagaacagt 840
acatttgatg agtttggaca ttctatcaat gattattcaa tatctcctga tgggcagttt 900
attctcttag aatacaacta cgtgaagcaa tggaggcatt cctacacagc ttcatatgac 960
atttatgatt taaataaaag gcagctgatt acagaagaga ggattccaaa caacacacag 1020
tgggtcacat ggtcaccagt gggtcataaa ttggcatatg tttggaacaa tgacatttat 1080
gttaaaattg aaccaaattt accaagttac agaatcacat ggacggggaa agaagatata 1140
atatataatg gaataactga ctgggtttat gaagaggaag tcttcagtgc ctactctgct 1200
ctgtggtggt ctccaaacgg cactttttta gcatatgccc aatttaacga cacagaagtc 1260
ccacttattg aatactcctt ctactctgat gagtcactgc agtacccaaa gactgtacgg 1320
gttccatatc caaaggcagg agctgtgaat ccaactgtaa agttctttgt tgtaaataca 1380
gactctctca gctcagtcac caatgcaact tccatacaaa tcactgctcc tgcttctatg 1440
ttgatagggg atcactactt gtgtgatgtg acatgggcaa cacaagaaag aatttctttg 1500
cagtggctca ggaggattca gaactattcg gtcatggata tttgtgacta tgatgaatcc 1560
agtggaagat ggaactgctt agtggcacgg caacacattg aaatgagtac tactggctgg 1620
gttggaagat ttaggccttc agaacctcat tttacccttg atggtaatag cttctacaag 1680
atcatcagca atgaagaagg ttacagacac atttgctatt tccaaataga taaaaaagac 1740
tgcacattta ttacaaaagg cacctgggaa gtcatcggga tagaagctct aaccagtgat 1800
tatctatact acattagtaa tgaatataaa ggaatgccag gaggaaggaa tctttataaa 1860
atccaactta gtgactatac aaaagtgaca tgcctcagtt gtgagctgaa tccggaaagg 1920
tgtcagtact attctgtgtc attcagtaaa gaggcgaagt attatcagct gagatgttcc 1980
ggtcctggtc tgcccctcta tactctacac agcagcgtga atgataaagg gctgagagtc 2040
ctggaagaca attcagcttt ggataaaatg ctgcagaatg tccagatgcc ctccaaaaaa 2100
ctggacttca ttattttgaa tgaaacaaaa ttttggtatc agatgatctt gcctcctcat 2160
tttgataaat ccaagaaata tcctctacta ttagatgtgt atgcaggccc atgtagtcaa 2220
aaagcagaca ctgtcttcag actgaactgg gccacttacc ttgcaagcac agaaaacatt 2280
atagtagcta gctttgatgg cagaggaagt ggttaccaag gagataagat catgcatgca 2340
atcaacagaa gactgggaac atttgaagtt gaagatcaaa ttgaagcagc cagacaattt 2400
tcaaaaatgg gatttgtgga caacaaacga attgcaattt ggggctggtc atatggaggg 2460
tacgtaacct caatggtcct gggatcggga agtggcgtgt tcaagtgtgg aatagccgtg 2520
gcgcctgtat cccggtggga gtactatgac tcagtgtaca cagaacgtta catgggtctc 2580
ccaactccag aagacaacct tgaccattac agaaattcaa cagtcatgag cagagctgaa 2640
aattttaaac aagttgagta cctccttatt catggaacag cagatgataa cgttcacttt 2700
cagcagtcag ctcagatctc caaagccctg gtcgatgttg gagtggattt ccaggcaatg 2760
tggtatactg atgaagacca tggaatagct agcagcacag cacaccaaca tatatatacc 2820
cacatgagcc acttcataaa acaatgtttc tctttacctt agcacctcaa aataccatgc 2880
catttaaagc ttattaaaac tcatttttgt tttcattatc tcaaaactgc actgtcaaga 2940
tgatgatgat ctttaaaata cacactcaaa tcaagaaact taaggttacc tttgttccca 3000
aatttcatac ctatcatctt aagtagggac ttctgtcttc acaacagatt attaccttac 3060
agaagtttga attatccggt cgggttttat tgtttaaaat catttctgca tcagctgctg 3120
aaacaacaaa taggaattgt ttttatggag gctttgcata gattccctga gcaggatttt 3180
aatctttttc taactggact ggttcaaatg ttgttctctt ctttaaaggg atggcaagat 3240
gtgggcagtg atgtcactag ggcagggaca ggataagagg gattagggag agaagatagc 3300
agggcatggc tgggaaccca agtccaagca taccaacacg agcaggctac tgtcagctcc 3360
cctcggagaa gagctgttca cagccagact ggcacagttt tctgagaaag actattcaaa 3420
cagtctcagg aaatcaaata tgcaaagcac tgacttctaa gtaaaaccac agcagttgaa 3480
aagactccaa agaaatgtaa gggaaactgc cagcaacgca ggcccccagg tgccagttat 3540
ggctataggt gctacaaaaa cacagcaagg gtgatgggaa agcattgtaa atgtgctttt 3600
aaaaaaaaat actgatgttc ctagtgaaag aggcagcttg aaactgagat gtgaacacat 3660
cagcttgccc tgttaaaaga tgaaaatatt tgtatcacaa atcttaactt gaaggagtcc 3720
ttgcatcaat ttttcttatt tcatttcttt gagtgtctta attaaaagaa tattttaact 3780
tccttggact cattttaaaa aatggaacat aaaatacaat gttatgtatt attattccca 3840
ttctacatac tatggaattt ctcccagtca tttaataaat gtgccttcat tttttcagaa 3900
aaaaaaaaaa aaagtcagtg cttgcatact caaggagtct tatctaga 3948
<210> 8
<211> 766
<212> PRT
<213> Homo sapiens
<220>
<221> 二肽酰肽酶IV多肽序列
<222> (1)..(766)
<400> 8
Met Lys Thr Pro Trp Lys Val Leu Leu Gly Leu Leu Gly Ala Ala Ala
1 5 10 15
Leu Val Thr Ile Ile Thr Val Pro Val Val Leu Leu Asn Lys Gly Thr
20 25 30
Asp Asp Ala Thr Ala Asp Ser Arg Lys Thr Tyr Thr Leu Thr Asp Tyr
35 40 45
Leu Lys Asn Thr Tyr Arg Leu Lys Leu Tyr Ser Leu Arg Trp Ile Ser
50 55 60
Asp His Glu Tyr Leu Tyr Lys Gln Glu Asn Asn Ile Leu Val Phe Asn
65 70 75 80
Ala Glu Tyr Gly Asn Ser Ser Val Phe Leu Glu Asn Ser Thr Phe Asp
85 90 95
Glu Phe Gly His Ser Ile Asn Asp Tyr Ser Ile Ser Pro Asp Gly Gln
100 105 110
Phe Ile Leu Leu Glu Tyr Asn Tyr Val Lys Gln Trp Arg His Ser Tyr
115 120 125
Thr Ala Ser Tyr Asp Ile Tyr Asp Leu Asn Lys Arg Gln Leu Ile Thr
130 135 140
Glu Glu Arg Ile Pro Asn Asn Thr Gln Trp Val Thr Trp Ser Pro Val
145 150 155 160
Gly His Lys Leu Ala Tyr Val Trp Asn Asn Asp Ile Tyr Val Lys Ile
165 170 175
Glu Pro Asn Leu Pro Ser Tyr Arg Ile Thr Trp Thr Gly Lys Glu Asp
180 185 190
Ile Ile Tyr Asn Gly Ile Thr Asp Trp Val Tyr Glu Glu Glu Val Phe
195 200 205
Ser Ala Tyr Ser Ala Leu Trp Trp Ser Pro Asn Gly Thr Phe Leu Ala
210 215 220
Tyr Ala Gln Phe Asn Asp Thr Glu Val Pro Leu Ile Glu Tyr Ser Phe
225 230 235 240
Tyr Ser Asp Glu Ser Leu Gln Tyr Pro Lys Thr Val Arg Val Pro Tyr
245 250 255
Pro Lys Ala Gly Ala Val Asn Pro Thr Val Lys Phe Phe Val Val Asn
260 265 270
Thr Asp Ser Leu Ser Ser Val Thr Asn Ala Thr Ser Ile Gln Ile Thr
275 280 285
Ala Pro Ala Ser Met Leu Ile Gly Asp His Tyr Leu Cys Asp Val Thr
290 295 300
Trp Ala Thr Gln Glu Arg Ile Ser Leu Gln Trp Leu Arg Arg Ile Gln
305 310 315 320
Asn Tyr Ser Val Met Asp Ile Cys Asp Tyr Asp Glu Ser Ser Gly Arg
325 330 335
Trp Asn Cys Leu Val Ala Arg Gln His Ile Glu Met Ser Thr Thr Gly
340 345 350
Trp Val Gly Arg Phe Arg Pro Ser Glu Pro His Phe Thr Leu Asp Gly
355 360 365
Asn Ser Phe Tyr Lys Ile Ile Ser Asn Glu Glu Gly Tyr Arg His Ile
370 375 380
Cys Tyr Phe Gln Ile Asp Lys Lys Asp Cys Thr Phe Ile Thr Lys Gly
385 390 395 400
Thr Trp Glu Val Ile Gly Ile Glu Ala Leu Thr Ser Asp Tyr Leu Tyr
405 410 415
Tyr Ile Ser Asn Glu Tyr Lys Gly Met Pro Gly Gly Arg Asn Leu Tyr
420 425 430
Lys Ile Gln Leu Ser Asp Tyr Thr Lys Val Thr Cys Leu Ser Cys Glu
435 440 445
Leu Asn Pro Glu Arg Cys Gln Tyr Tyr Ser Val Ser Phe Ser Lys Glu
450 455 460
Ala Lys Tyr Tyr Gln Leu Arg Cys Ser Gly Pro Gly Leu Pro Leu Tyr
465 470 475 480
Thr Leu His Ser Ser Val Asn Asp Lys Gly Leu Arg Val Leu Glu Asp
485 490 495
Asn Ser Ala Leu Asp Lys Met Leu Gln Asn Val Gln Met Pro Ser Lys
500 505 510
Lys Leu Asp Phe Ile Ile Leu Asn Glu Thr Lys Phe Trp Tyr Gln Met
515 520 525
Ile Leu Pro Pro His Phe Asp Lys Ser Lys Lys Tyr Pro Leu Leu Leu
530 535 540
Asp Val Tyr Ala Gly Pro Cys Ser Gln Lys Ala Asp Thr Val Phe Arg
545 550 555 560
Leu Asn Trp Ala Thr Tyr Leu Ala Ser Thr Glu Asn Ile Ile Val Ala
565 570 575
Ser Phe Asp Gly Arg Gly Ser Gly Tyr Gln Gly Asp Lys Ile Met His
580 585 590
Ala Ile Asn Arg Arg Leu Gly Thr Phe Glu Val Glu Asp Gln Ile Glu
595 600 605
Ala Ala Arg Gln Phe Ser Lys Met Gly Phe Val Asp Asn Lys Arg Ile
610 615 620
Ala Ile Trp Gly Trp Ser Tyr Gly Gly Tyr Val Thr Ser Met Val Leu
625 630 635 640
Gly Ser Gly Ser Gly Val Phe Lys Cys Gly Ile Ala Val Ala Pro Val
645 650 655
Ser Arg Trp Glu Tyr Tyr Asp Ser Val Tyr Thr Glu Arg Tyr Met Gly
660 665 670
Leu Pro Thr Pro Glu Asp Asn Leu Asp His Tyr Arg Asn Ser Thr Val
675 680 685
Met Ser Arg Ala Glu Asn Phe Lys Gln Val Glu Tyr Leu Leu Ile His
690 695 700
Gly Thr Ala Asp Asp Asn Val His Phe Gln Gln Ser Ala Gln Ile Ser
705 710 715 720
Lys Ala Leu Val Asp Val Gly Val Asp Phe Gln Ala Met Trp Tyr Thr
725 730 735
Asp Glu Asp His Gly Ile Ala Ser Ser Thr Ala His Gln His Ile Tyr
740 745 750
Thr His Met Ser His Phe Ile Lys Gln Cys Phe Ser Leu Pro
755 760 765
<210> 9
<211> 6803
<212> DNA
<213> Homo sapiens
<220>
<221> 成纤维细胞生长因子2 mRNA
<222> (1)..(6803)
<400> 9
cggccccaga aaacccgagc gagtaggggg cggcgcgcag gagggaggag aactgggggc 60
gcgggaggct ggtgggtgtc gggggtggag atgtagaaga tgtgacgccg cggcccggcg 120
ggtgccagat tagcggacgc gctgcccgcg gttgcaacgg gatcccgggc gctgcagctt 180
gggaggcggc tctccccagg cggcgtccgc ggagacaccc atccgtgaac cccaggtccc 240
gggccgccgg ctcgccgcgc accaggggcc ggcggacaga agagcggccg agcggctcga 300
ggctggggga ccgcgggcgc ggccgcgcgc tgccgggcgg gaggctgggg ggccggggcc 360
ggggccgtgc cccggagcgg gtcggaggcc ggggccgggg ccgggggacg gcggctcccc 420
gcgcggctcc agcggctcgg ggatcccggc cgggccccgc agggaccatg gcagccggga 480
gcatcaccac gctgcccgcc ttgcccgagg atggcggcag cggcgccttc ccgcccggcc 540
acttcaagga ccccaagcgg ctgtactgca aaaacggggg cttcttcctg cgcatccacc 600
ccgacggccg agttgacggg gtccgggaga agagcgaccc tcacatcaag ctacaacttc 660
aagcagaaga gagaggagtt gtgtctatca aaggagtgtg tgctaaccgt tacctggcta 720
tgaaggaaga tggaagatta ctggcttcta aatgtgttac ggatgagtgt ttcttttttg 780
aacgattgga atctaataac tacaatactt accggtcaag gaaatacacc agttggtatg 840
tggcactgaa acgaactggg cagtataaac ttggatccaa aacaggacct gggcagaaag 900
ctatactttt tcttccaatg tctgctaaga gctgatttta atggccacat ctaatctcat 960
ttcacatgaa agaagaagta tattttagaa atttgttaat gagagtaaaa gaaaataaat 1020
gtgtatagct cagtttggat aattggtcaa acaatttttt atccagtagt aaaatatgta 1080
accattgtcc cagtaaagaa aaataacaaa agttgtaaaa tgtatattct cccttttata 1140
ttgcatctgc tgttacccag tgaagcttac ctagagcaat gatctttttc acgcatttgc 1200
tttattcgaa aagaggcttt taaaatgtgc atgtttagaa acaaaatttc ttcatggaaa 1260
tcatatacat tagaaaatca cagtcagatg tttaatcaat ccaaaatgtc cactatttct 1320
tatgtcattc gttagtctac atgtttctaa acatataaat gtgaatttaa tcaattcctt 1380
tcatagtttt ataattctct ggcagttcct tatgatagag tttataaaac agtcctgtgt 1440
aaactgctgg aagttcttcc acagtcaggt caattttgtc aaacccttct ctgtacccat 1500
acagcagcag cctagcaact ctgctggtga tgggagttgt attttcagtc ttcgccaggt 1560
cattgagatc catccactca catcttaagc attcttcctg gcaaaaattt atggtgaatg 1620
aatatggctt taggcggcag atgatataca tatctgactt cccaaaagct ccaggatttg 1680
tgtgctgttg ccgaatactc aggacggacc tgaattctga ttttatacca gtctcttcaa 1740
aaacttctcg aaccgctgtg tctcctacgt aaaaaaagag atgtacaaat caataataat 1800
tacactttta gaaactgtat catcaaagat tttcagttaa agtagcatta tgtaaaggct 1860
caaaacatta ccctaacaaa gtaaagtttt caatacaaat tctttgcctt gtggatatca 1920
agaaatccca aaatattttc ttaccactgt aaattcaaga agcttttgaa atgctgaata 1980
tttctttggc tgctacttgg aggcttatct acctgtacat ttttggggtc agctcttttt 2040
aacttcttgc tgctcttttt cccaaaaggt aaaaatatag attgaaaagt taaaacattt 2100
tgcatggctg cagttccttt gtttcttgag ataagattcc aaagaactta gattcatttc 2160
ttcaacaccg aaatgctgga ggtgtttgat cagttttcaa gaaacttgga atataaataa 2220
ttttataatt caacaaaggt tttcacattt tataaggttg atttttcaat taaatgcaaa 2280
tttgtgtggc aggattttta ttgccattaa catatttttg tggctgcttt ttctacacat 2340
ccagatggtc cctctaactg ggctttctct aattttgtga tgttctgtca ttgtctccca 2400
aagtatttag gagaagccct ttaaaaagct gccttcctct accactttgc tggaaagctt 2460
cacaattgtc acagacaaag atttttgttc caatactcgt tttgcctcta tttttcttgt 2520
ttgtcaaata gtaaatgata tttgcccttg cagtaattct actggtgaaa aacatgcaaa 2580
gaagaggaag tcacagaaac atgtctcaat tcccatgtgc tgtgactgta gactgtctta 2640
ceatagactg tcttacccat cccctggata tgctcttgtt ttttccctct aatagctatg 2700
gaaagatgca tagaaagagt ataatgtttt aaaacataag gcattcatct gccatttttc 2760
aattacatgc tgacttccct tacaattgag atttgcccat aggttaaaca tggttagaaa 2820
caactgaaag cataaaagaa aaatctaggc cgggtgcagt ggctcatgcc tatattccct 2880
gcactttggg aggccaaagc aggaggatcg cttgagccca ggagttcaag accaacctgg 2940
tgaaaccccg tctctacaaa aaaacacaaa aaatagccag gcatggtggc gtgtacatgt 3000
ggtctcagat acttgggagg ctgaggtggg agggttgatc acttgaggct gagaggtcaa 3060
ggttgcagtg agccataatc gtgccactgc agtccagcct aggcaacaga gtgagacttt 3120
gtctcaaaaa aagagaaatt ttccttaata agaaaagtaa tttttactct gatgtgcaat 3180
acatttgtta ttaaatttat tatttaagat ggtagcacta gtcttaaatt gtataaaata 3240
tcccctaaca tgtttaaatg tccattttta ttcattatgc tttgaaaaat aattatgggg 3300
aaatacatgt ttgttattaa atttattatt aaagatagta gcactagtct taaatttgat 3360
ataacatctc ctaacttgtt taaatgtcca tttttattct ttatgcttga aaataaatta 3420
tggggatcct atttagctct tagtaccact aatcaaaagt tcggcatgta gctcatgatc 3480
tatgctgttt ctatgtcgtg gaagcaccgg atgggggtag tgagcaaatc tgccctgctc 3540
agcagtcacc atagcagctg actgaaaatc agcactgcct gagtagtttt gatcagttta 3600
acttgaatca ctaactgact gaaaattgaa tgggcaaata agtgcttttg tctccagagt 3660
atgcgggaga cccttccacc tcaagatgga tatttcttcc ccaaggattt caagatgaat 3720
tgaaattttt aatcaagata gtgtgcttta ttctgttgta ttttttatta ttttaatata 3780
ctgtaagcca aactgaaata acatttgctg ttttataggt ttgaagaaca taggaaaaac 3840
taagaggttt tgtttttatt tttgctgatg aagagatatg tttaaatatg ttgtattgtt 3900
ttgtttagtt acaggacaat aatgaaatgg agtttatatt tgttatttct attttgttat 3960
atttaataat agaattagat tgaaataaaa tataatggga aataatctgc agaatgtggg 4020
tttcctggtg tttcctctga ctctagtgca ctgatgatct ctgataaggc tcagctgctt 4080
tatagttctc tggctaatgc agcagatact cttcctgcca gtggtaatac gattttttaa 4140
gaaggcagtt tgtcaatttt aatcttgtgg atacctttat actcttaggg tattatttta 4200
tacaaaagcc ttgaggattg cattctattt tctatatgac cctcttgata tttaaaaaac 4260
actatggata acaattcttc atttacctag tattatgaaa gaatgaagga gttcaaacaa 4320
atgtgtttcc cagttaacta gggtttactg tttgagccaa tataaatgtt taactgtttg 4380
tgatggcagt attcctaaag tacattgcat gttttcctaa atacagagtt taaataattt 4440
cagtaattct tagatgattc agcttcatca ttaagaatat cttttgtttt atgttgagtt 4500
agaaatgcct tcatatagac atagtctttc agacctctac tgtcagtttt catttctagc 4560
tgctttcagg gttttatgaa ttttcaggca aagctttaat ttatactaag cttaggaagt 4620
atggctaatg ccaacggcag tttttttctt cttaattcca catgactgag gcatatatga 4680
tctctgggta ggtgagttgt tgtgacaacc acaagcactt tttttttttt taaagaaaaa 4740
aaggtagtga atttttaatc atctggactt taagaaggat tctggagtat acttaggcct 4800
gaaattatat atatttggct tggaaatgtg tttttcttca attacatcta caagtaagta 4860
cagctgaaat tcagaggacc cataagagtt cacatgaaaa aaatcaattc atttgaaaag 4920
gcaagatgca ggagagagga agccttgcaa acctgcagac tgctttttgc ccaatataga 4980
ttgggtaagg ctgcaaaaca taagcttaat tagctcacat gctctgctct cacgtggcac 5040
cagtggatag tgtgagagaa ttaggctgta gaacaaatgg ccttctcttt cagcattcac 5100
accactacaa aatcatcttt tatatcaaca gaagaataag cataaactaa gcaaaaggtc 5160
aataagtacc tgaaaccaag attggctaga gatatatctt aatgcaatcc attttctgat 5220
ggattgttac gagttggcta tataatgtat gtatggtatt ttgatttgtg taaaagtttt 5280
aaaaatcaag ctttaagtac atggacattt ttaaataaaa tatttaaaga caatttagaa 5340
aattgcctta atatcattgt tggctaaata gaatagggga catgcatatt aaggaaaagg 5400
tcatggagaa ataatattgg tatcaaacaa atacattgat ttgtcatgat acacattgaa 5460
tttgatccaa tagtttaagg aataggtagg aaaatttggt ttctattttt cgatttcctg 5520
taaatcagtg acataaataa ttcttagctt attttatatt tccttgtctt aaatactgag 5580
ctcagtaagt tgtgttaggg gattatttct cagttgagac tttcttatat gacattttac 5640
tatgttttga cttcctgact attaaaaata aatagtagaa acaattttca taaagtgaag 5700
aattatataa tcactgcttt ataactgact ttattatatt tatttcaaag ttcatttaaa 5760
ggctactatt catcctctgt gatggaatgg tcaggaattt gttttctcat agtttaattc 5820
caacaacaat attagtcgta tccaaaataa cctttaatgc taaactttac tgatgtatat 5880
ccaaagcttc tccttttcag acagattaat ccagaagcag tcataaacag aagaataggt 5940
ggtatgttcc taatgatatt atttctacta atggaataaa ctgtaatatt agaaattatg 6000
ctgctaatta tatcagctct gaggtaattt ctgaaatgtt cagactcagt cggaacaaat 6060
tggaaaattt aaatttttat tcttagctat aaagcaagaa agtaaacaca ttaatttcct 6120
caacattttt aagccaatta aaaatataaa agatacacac caatatcttc ttcaggctct 6180
gacaggcctc ctggaaactt ccacatattt ttcaactgca gtataaagtc agaaaataaa 6240
gttaacataa ctttcactaa cacacacata tgtagatttc acaaaatcca cctataattg 6300
gtcaaagtgg ttgagaatat attttttagt aattgcatgc aaaatttttc tagcttccat 6360
cctttctccc tcgtttcttc tttttttggg ggagctggta actgatgaaa tcttttccca 6420
ccttttctct tcaggaaata taagtggttt tgtttggtta acgtgataca ttctgtatga 6480
atgaaacatt ggagggaaac atctactgaa tttctgtaat ttaaaatatt ttgctgctag 6540
ttaactatga acagatagaa gaatcttaca gatgctgcta taaataagta gaaaatataa 6600
atttcatcac taaaatatgc tattttaaaa tctatttcct atattgtatt tctaatcaga 6660
tgtattactc ttattatttc tattgtatgt gttaatgatt ttatgtaaaa atgtaattgc 6720
ttttcatgag tagtatgaat aaaattgatt agtttgtgtt ttcttgtctc ccgaaaaaaa 6780
aaaaaaaaaa aaaaaaaaaa aaa 6803
<210> 10
<211> 288
<212> PRT
<213> Homo sapiens
<220>
<221> 成纤维细胞生长因子2多肽序列
<222> (1)..(288)
<400> 10
Met Val Gly Val Gly Gly Gly Asp Val Glu Asp Val Thr Pro Arg Pro
1 5 10 15
Gly Gly Cys Gln Ile Ser Gly Arg Ala Ala Arg Gly Cys Asn Gly Ile
20 25 30
Pro Gly Ala Ala Ala Trp Glu Ala Ala Leu Pro Arg Arg Arg Pro Arg
35 40 45
Arg His Pro Ser Val Asn Pro Arg Ser Arg Ala Ala Gly Ser Pro Arg
50 55 60
Thr Arg Gly Arg Arg Thr Glu Glu Arg Pro Ser Gly Ser Arg Leu Gly
65 70 75 80
Asp Arg Gly Arg Gly Arg Ala Leu Pro Gly Gly Arg Leu Gly Gly Arg
85 90 95
Gly Arg Gly Arg Ala Pro Glu Arg Val Gly Gly Arg Gly Arg Gly Arg
100 105 110
Gly Thr Ala Ala Pro Arg Ala Ala Pro Ala Ala Arg Gly Ser Arg Pro
115 120 125
Gly Pro Ala Gly Thr Met Ala Ala Gly Ser Ile Thr Thr Leu Pro Ala
130 135 140
Leu Pro Glu Asp Gly Gly Ser Gly Ala Phe Pro Pro Gly His Phe Lys
145 150 155 160
Asp Pro Lys Arg Leu Tyr Cys Lys Asn Gly Gly Phe Phe Leu Arg Ile
165 170 175
His Pro Asp Gly Arg Val Asp Gly Val Arg Glu Lys Ser Asp Pro His
180 185 190
Ile Lys Leu Gln Leu Gln Ala Glu Glu Arg Gly Val Val Ser Ile Lys
195 200 205
Gly Val Cys Ala Asn Arg Tyr Leu Ala Met Lys Glu Asp Gly Arg Leu
210 215 220
Leu Ala Ser Lys Cys Val Thr Asp Glu Cys Phe Phe Phe Glu Arg Leu
225 230 235 240
Glu Ser Asn Asn Tyr Asn Thr Tyr Arg Ser Arg Lys Tyr Thr Ser Trp
245 250 255
Tyr Val Ala Leu Lys Arg Thr Gly Gln Tyr Lys Leu Gly Ser Lys Thr
260 265 270
Gly Pro Gly Gln Lys Ala Ile Leu Phe Leu Pro Met Ser Ala Lys Ser
275 280 285
<210> 11
<211> 5826
<212> DNA
<213> Homo sapiens
<220>
<221> 血小板反应蛋白2 mRNA
<222> (1)..(5826)
<400> 11
gaggaggaga cggcatccag tacagagggg ctggacttgg acccctgcag cagccctgca 60
caggagaagc ggcatataaa gccgcgctgc ccgggagccg ctcggccacg tccaccggag 120
catcctgcac tgcagggccg gtctctcgct ccagcagagc ctgcgccttt ctgactcggt 180
ccggaacact gaaaccagtc atcactgcat ctttttggca aaccaggagc tcagctgcag 240
gaggcaggat ggtctggagg ctggtcctgc tggctctgtg ggtgtggccc agcacgcaag 300
ctggtcacca ggacaaagac acgaccttcg accttttcag tatcagcaac atcaaccgca 360
agaccattgg cgccaagcag ttccgcgggc ccgaccccgg cgtgccggct taccgcttcg 420
tgcgctttga ctacatccca ccggtgaacg cagatgacct cagcaagatc accaagatca 480
tgcggcagaa ggagggcttc ttcctcacgg cccagctcaa gcaggacggc aagtccaggg 540
gcacgctgtt ggctctggag ggccccggtc tctcccagag gcagttcgag atcgtctcca 600
acggccccgc ggacacgctg gatctcacct actggattga cggcacccgg catgtggtct 660
ccctggagga cgtcggcctg gctgactcgc agtggaagaa cgtcaccgtg caggtggctg 720
gcgagaccta cagcttgcac gtgggctgcg acctcataga cagcttcgct ctggacgagc 780
ccttctacga gcacctgcag gcggaaaaga gccggatgta cgtggccaaa ggctctgcca 840
gagagagtca cttcaggggt ttgcttcaga acgtccacct agtgtttgaa aactctgtgg 900
aagatattct aagcaagaag ggttgccagc aaggccaggg agctgagatc aacgccatca 960
gtgagaacac agagacgctg cgcctgggtc cgcatgtcac caccgagtac gtgggcccca 1020
gctcggagag gaggcccgag gtgtgcgaac gctcgtgcga ggagctggga aacatggtcc 1080
aggagctctc ggggctccac gtcctcgtga accagctcag cgagaacctc aagagagtgt 1140
cgaatgataa ccagtttctc tgggagctca ttggtggccc tcctaagaca aggaacatgt 1200
cagcttgctg gcaggatggc cggttctttg cggaaaatga aacgtgggtg gtggacagct 1260
gcaccacgtg tacctgcaag aaatttaaaa ccatttgcca ccaaatcacc tgcccgcctg 1320
caacctgcgc cagtccatcc tttgtggaag gcgaatgctg cccttcctgc ctccactcgg 1380
tggacggtga ggagggctgg tctccgtggg cagagtggac ccagtgctcc gtgacgtgtg 1440
gctctgggac ccagcagaga ggccggtcct gtgacgtcac cagcaacacc tgcttggggc 1500
cctccatcca gacacgggct tgcagtctga gcaagtgtga cacccgcatc cggcaggacg 1560
gcggctggag ccactggtca ccttggtctt catgctctgt gacctgtgga gttggcaata 1620
tcacacgcat ccgtctctgc aactccccag tgccccagat ggggggcaag aattgcaaag 1680
ggagtggccg ggagaccaaa gcctgccagg gcgccccatg cccaatcgat ggccgctgga 1740
gcccctggtc cccgtggtcg gcctgcactg tcacctgtgc cggtgggatc cgggagcgca 1800
cccgggtctg caacagccct gagcctcagt acggagggaa ggcctgcgtg ggggatgtgc 1860
aggagcgtca gatgtgcaac aagaggagct gccccgtgga tggctgttta tccaacccct 1920
gcttcccggg agcccagtgc agcagcttcc ccgatgggtc ctggtcatgc ggctcctgcc 1980
ctgtgggctt cttgggcaat ggcacccact gtgaggacct ggacgagtgt gccctggtcc 2040
ccgacatctg cttctccacc agcaaggtgc ctcgctgtgt caacactcag cctggcttcc 2100
actgcctgcc ctgcccgccc cgatacagag ggaaccagcc cgtcggggtc ggcctggaag 2160
cagccaagac ggaaaagcaa gtgtgtgagc ccgaaaaccc atgcaaggac aagacacaca 2220
actgccacaa gcacgcggag tgcatctacc tgggccactt cagcgacccc atgtacaagt 2280
gcgagtgcca gacaggctac gcgggcgacg ggctcatctg cggggaggac tcggacctgg 2340
acggctggcc caacctcaat ctggtctgcg ccaccaacgc cacctaccac tgcatcaagg 2400
ataactgccc ccatctgcca aattctgggc aggaagactt tgacaaggac gggattggcg 2460
atgcctgtga tgatgacgat gacaatgacg gtgtgaccga tgagaaggac aactgccagc 2520
tcctcttcaa tccccgccag gctgactatg acaaggatga ggttggggac cgctgtgaca 2580
actgccctta cgtgcacaac cctgcccaga tcgacacaga caacaatgga gagggtgacg 2640
cctgctccgt ggacattgat ggggacgatg tcttcaatga acgagacaat tgtccctacg 2700
tctacaacac tgaccagagg gacacggatg gtgacggtgt gggggatcac tgtgacaact 2760
gccccctggt gcacaaccct gaccagaccg acgtggacaa tgaccttgtt ggggaccagt 2820
gtgacaacaa cgaggacata gatgacgacg gccaccagaa caaccaggac aactgcccct 2880
acatctccaa cgccaaccag gctgaccatg acagagacgg ccagggcgac gcctgtgacc 2940
ctgatgatga caacgatggc gtccccgatg acagggacaa ctgccggctt gtgttcaacc 3000
cagaccagga ggacttggac ggtgatggac ggggtgatat ttgtaaagat gattttgaca 3060
atgacaacat cccagatatt gatgatgtgt gtcctgaaaa caatgccatc agtgagacag 3120
acttcaggaa cttccagatg gtccccttgg atcccaaagg gaccacccaa attgatccca 3180
actgggtcat tcgccatcaa ggcaaggagc tggttcagac agccaactcg gaccccggca 3240
tcgctgtagg ttttgacgag tttgggtctg tggacttcag tggcacattc tacgtaaaca 3300
ctgaccggga cgacgactat gccggcttcg tctttggtta ccagtcaagc agccgcttct 3360
atgtggtgat gtggaagcag gtgacgcaga cctactggga ggaccagccc acgcgggcct 3420
atggctactc cggcgtgtcc ctcaaggtgg tgaactccac cacggggacg ggcgagcacc 3480
tgaggaacgc gctgtggcac acggggaaca cgccggggca ggtgcgaacc ttatggcacg 3540
accccaggaa cattggctgg aaggactaca cggcctatag gtggcacctg actcacaggc 3600
ccaagactgg ctacatcaga gtcttagtgc atgaaggaaa acaggtcatg gcagactcag 3660
gacctatcta tgaccaaacc tacgctggcg ggcggctggg tctatttgtc ttctctcaag 3720
aaatggtcta tttctcagac ctcaagtacg aatgcagaga tatttaaaca agatttgctg 3780
catttccggc aatgccctgt gcatgccatg gtccctagac acctcagttc attgtggtcc 3840
ttgtggcttc tctctctagc agcacctcct gtcccttgac cttaactctg atggttcttc 3900
acctcctgcc agcaacccca aacccaagtg ccttcagagg ataaatatca atggaactca 3960
gagatgaaca tctaacccac tagaggaaac cagtttggtg atatatgaga ctttatgtgg 4020
agtgaaaatt gggcatgcca ttacattgct ttttcttgtt tgtttaaaaa gaatgacgtt 4080
tacatataaa atgtaattac ttattgtatt tatgtgtata tggagttgaa gggaatactg 4140
tgcataagcc attatgataa attaagcatg aaaaatattg ctgaactact tttggtgctt 4200
aaagttgtca ctattcttga attagagttg ctctacaatg acacacaaat cccattaaat 4260
aaattataaa caagggtcaa ttcaaatttg aagtaatgtt ttagtaagga gagattagaa 4320
gacaacaggc atagcaaatg acataagcta ccgattaact aatcggaaca tgtaaaacag 4380
ttacaaaaat aaacgaactc tcctcttgtc ctacaatgaa agccctcatg tgcagtagag 4440
atgcagtttc atcaaagaac aaacatcctt gcaaatgggt gtgacgcggt tccagatgtg 4500
gatttggcaa aacctcattt aagtaaaagg ttagcagagc aaagtgcggt gctttagctg 4560
ctgcttgtgc cgctgtggcg tcggggaggc tcctgcctga gcttccttcc ccagctttgc 4620
tgcctgagag gaaccagagc agacgcacag gccggaaaag gcgcatctaa cgcgtatcta 4680
ggctttggta actgcggaca agttgctttt acctgatttg atgatacatt tcattaaggt 4740
tccagttata aatattttgt taatatttat taagtgacta tagaatgcaa ctccatttac 4800
cagtaactta ttttaaatat gcctagtaac acatatgtag tataatttct agaaacaaac 4860
atctaataag tatataatcc tgtgaaaata tgaggcttga taatattagg ttgtcacgat 4920
gaagcatgct agaagctgta acagaataca tagagaataa tgaggagttt atgatggaac 4980
cttaaatata taatgttgcc agcgatttta gttcaatatt tgttactgtt atctatctgc 5040
tgtatatgga attcttttaa ttcaaacgct gaaaagaatc agcatttagt cttgccaggc 5100
acacccaata atcagtcatg tgtaatatgc acaagtttgt ttttgttttt gttttttttg 5160
ttggttggtt tgtttttttg ctttaagttg catgatcttt ctgcaggaaa tagtcactca 5220
tcccactcca cataaggggt ttagtaagag aagtctgtct gtctgatgat ggataggggg 5280
caaatctttt tcccctttct gttaatagtc atcacatttc tatgccaaac aggaacaatc 5340
cataacttta gtcttaatgt acacattgca ttttgataaa attaattttg ttgtttcctt 5400
tgaggttgat cgttgtgttg ttgttttgct gcacttttta cttttttgcg tgtggagctg 5460
tattcccgag accaacgaag cgttgggata cttcattaaa tgtagcgact gtcaacagcg 5520
tgcaggtttt ctgtttctgt gttgtggggt caaccgtaca atggtgtggg agtgacgatg 5580
atgtgaatat ttagaatgta ccatattttt tgtaaattat ttatgttttt ctaaacaaat 5640
ttatcgtata ggttgatgaa acgtcatgtg ttttgccaaa gactgtaaat atttatttat 5700
gtgttcacat ggtcaaaatt tcaccactga aaccctgcac ttagctagaa cctcattttt 5760
aaagattaac aacaggaaat aaattgtaaa aaaggttttc tatacatgaa aaaaaaaaaa 5820
aaaaaa 5826
<210> 12
<211> 1172
<212> PRT
<213> Homo sapiens
<220>
<221> 血小板反应蛋白2多肽序列
<222> (1)..(1172)
<400> 12
Met Val Trp Arg Leu Val Leu Leu Ala Leu Trp Val Trp Pro Ser Thr
1 5 10 15
Gln Ala Gly His Gln Asp Lys Asp Thr Thr Phe Asp Leu Phe Ser Ile
20 25 30
Ser Asn Ile Asn Arg Lys Thr Ile Gly Ala Lys Gln Phe Arg Gly Pro
35 40 45
Asp Pro Gly Val Pro Ala Tyr Arg Phe Val Arg Phe Asp Tyr Ile Pro
50 55 60
Pro Val Asn Ala Asp Asp Leu Ser Lys Ile Thr Lys Ile Met Arg Gln
65 70 75 80
Lys Glu Gly Phe Phe Leu Thr Ala Gln Leu Lys Gln Asp Gly Lys Ser
85 90 95
Arg Gly Thr Leu Leu Ala Leu Glu Gly Pro Gly Leu Ser Gln Arg Gln
100 105 110
Phe Glu Ile Val Ser Asn Gly Pro Ala Asp Thr Leu Asp Leu Thr Tyr
115 120 125
Trp Ile Asp Gly Thr Arg His Val Val Ser Leu Glu Asp Val Gly Leu
130 135 140
Ala Asp Ser Gln Trp Lys Asn Val Thr Val Gln Val Ala Gly Glu Thr
145 150 155 160
Tyr Ser Leu His Val Gly Cys Asp Leu Ile Asp Ser Phe Ala Leu Asp
165 170 175
Glu Pro Phe Tyr Glu His Leu Gln Ala Glu Lys Ser Arg Met Tyr Val
180 185 190
Ala Lys Gly Ser Ala Arg Glu Ser His Phe Arg Gly Leu Leu Gln Asn
195 200 205
Val His Leu Val Phe Glu Asn Ser Val Glu Asp Ile Leu Ser Lys Lys
210 215 220
Gly Cys Gln Gln Gly Gln Gly Ala Glu Ile Asn Ala Ile Ser Glu Asn
225 230 235 240
Thr Glu Thr Leu Arg Leu Gly Pro His Val Thr Thr Glu Tyr Val Gly
245 250 255
Pro Ser Ser Glu Arg Arg Pro Glu Val Cys Glu Arg Ser Cys Glu Glu
260 265 270
Leu Gly Asn Met Val Gln Glu Leu Ser Gly Leu His Val Leu Val Asn
275 280 285
Gln Leu Ser Glu Asn Leu Lys Arg Val Ser Asn Asp Asn Gln Phe Leu
290 295 300
Trp Glu Leu Ile Gly Gly Pro Pro Lys Thr Arg Asn Met Ser Ala Cys
305 310 315 320
Trp Gln Asp Gly Arg Phe Phe Ala Glu Asn Glu Thr Trp Val Val Asp
325 330 335
Ser Cys Thr Thr Cys Thr Cys Lys Lys Phe Lys Thr Ile Cys His Gln
340 345 350
Ile Thr Cys Pro Pro Ala Thr Cys Ala Ser Pro Ser Phe Val Glu Gly
355 360 365
Glu Cys Cys Pro Ser Cys Leu His Ser Val Asp Gly Glu Glu Gly Trp
370 375 380
Ser Pro Trp Ala Glu Trp Thr Gln Cys Ser Val Thr Cys Gly Ser Gly
385 390 395 400
Thr Gln Gln Arg Gly Arg Ser Cys Asp Val Thr Ser Asn Thr Cys Leu
405 410 415
Gly Pro Ser Ile Gln Thr Arg Ala Cys Ser Leu Ser Lys Cys Asp Thr
420 425 430
Arg Ile Arg Gln Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser
435 440 445
Cys Ser Val Thr Cys Gly Val Gly Asn Ile Thr Arg Ile Arg Leu Cys
450 455 460
Asn Ser Pro Val Pro Gln Met Gly Gly Lys Asn Cys Lys Gly Ser Gly
465 470 475 480
Arg Glu Thr Lys Ala Cys Gln Gly Ala Pro Cys Pro Ile Asp Gly Arg
485 490 495
Trp Ser Pro Trp Ser Pro Trp Ser Ala Cys Thr Val Thr Cys Ala Gly
500 505 510
Gly Ile Arg Glu Arg Thr Arg Val Cys Asn Ser Pro Glu Pro Gln Tyr
515 520 525
Gly Gly Lys Ala Cys Val Gly Asp Val Gln Glu Arg Gln Met Cys Asn
530 535 540
Lys Arg Ser Cys Pro Val Asp Gly Cys Leu Ser Asn Pro Cys Phe Pro
545 550 555 560
Gly Ala Gln Cys Ser Ser Phe Pro Asp Gly Ser Trp Ser Cys Gly Ser
565 570 575
Cys Pro Val Gly Phe Leu Gly Asn Gly Thr His Cys Glu Asp Leu Asp
580 585 590
Glu Cys Ala Leu Val Pro Asp Ile Cys Phe Ser Thr Ser Lys Val Pro
595 600 605
Arg Cys Val Asn Thr Gln Pro Gly Phe His Cys Leu Pro Cys Pro Pro
610 615 620
Arg Tyr Arg Gly Asn Gln Pro Val Gly Val Gly Leu Glu Ala Ala Lys
625 630 635 640
Thr Glu Lys Gln Val Cys Glu Pro Glu Asn Pro Cys Lys Asp Lys Thr
645 650 655
His Asn Cys His Lys His Ala Glu Cys Ile Tyr Leu Gly His Phe Ser
660 665 670
Asp Pro Met Tyr Lys Cys Glu Cys Gln Thr Gly Tyr Ala Gly Asp Gly
675 680 685
Leu Ile Cys Gly Glu Asp Ser Asp Leu Asp Gly Trp Pro Asn Leu Asn
690 695 700
Leu Val Cys Ala Thr Asn Ala Thr Tyr His Cys Ile Lys Asp Asn Cys
705 710 715 720
Pro His Leu Pro Asn Ser Gly Gln Glu Asp Phe Asp Lys Asp Gly Ile
725 730 735
Gly Asp Ala Cys Asp Asp Asp Asp Asp Asn Asp Gly Val Thr Asp Glu
740 745 750
Lys Asp Asn Cys Gln Leu Leu Phe Asn Pro Arg Gln Ala Asp Tyr Asp
755 760 765
Lys Asp Glu Val Gly Asp Arg Cys Asp Asn Cys Pro Tyr Val His Asn
770 775 780
Pro Ala Gln Ile Asp Thr Asp Asn Asn Gly Glu Gly Asp Ala Cys Ser
785 790 795 800
Val Asp Ile Asp Gly Asp Asp Val Phe Asn Glu Arg Asp Asn Cys Pro
805 810 815
Tyr Val Tyr Asn Thr Asp Gln Arg Asp Thr Asp Gly Asp Gly Val Gly
820 825 830
Asp His Cys Asp Asn Cys Pro Leu Val His Asn Pro Asp Gln Thr Asp
835 840 845
Val Asp Asn Asp Leu Val Gly Asp Gln Cys Asp Asn Asn Glu Asp Ile
850 855 860
Asp Asp Asp Gly His Gln Asn Asn Gln Asp Asn Cys Pro Tyr Ile Ser
865 870 875 880
Asn Ala Asn Gln Ala Asp His Asp Arg Asp Gly Gln Gly Asp Ala Cys
885 890 895
Asp Pro Asp Asp Asp Asn Asp Gly Val Pro Asp Asp Arg Asp Asn Cys
900 905 910
Arg Leu Val Phe Asn Pro Asp Gln Glu Asp Leu Asp Gly Asp Gly Arg
915 920 925
Gly Asp Ile Cys Lys Asp Asp Phe Asp Asn Asp Asn Ile Pro Asp Ile
930 935 940
Asp Asp Val Cys Pro Glu Asn Asn Ala Ile Ser Glu Thr Asp Phe Arg
945 950 955 960
Asn Phe Gln Met Val Pro Leu Asp Pro Lys Gly Thr Thr Gln Ile Asp
965 970 975
Pro Asn Trp Val Ile Arg His Gln Gly Lys Glu Leu Val Gln Thr Ala
980 985 990
Asn Ser Asp Pro Gly Ile Ala Val Gly Phe Asp Glu Phe Gly Ser Val
995 1000 1005
Asp Phe Ser Gly Thr Phe Tyr Val Asn Thr Asp Arg Asp Asp Asp
1010 1015 1020
Tyr Ala Gly Phe Val Phe Gly Tyr Gln Ser Ser Ser Arg Phe Tyr
1025 1030 1035
Val Val Met Trp Lys Gln Val Thr Gln Thr Tyr Trp Glu Asp Gln
1040 1045 1050
Pro Thr Arg Ala Tyr Gly Tyr Ser Gly Val Ser Leu Lys Val Val
1055 1060 1065
Asn Ser Thr Thr Gly Thr Gly Glu His Leu Arg Asn Ala Leu Trp
1070 1075 1080
His Thr Gly Asn Thr Pro Gly Gln Val Arg Thr Leu Trp His Asp
1085 1090 1095
Pro Arg Asn Ile Gly Trp Lys Asp Tyr Thr Ala Tyr Arg Trp His
1100 1105 1110
Leu Thr His Arg Pro Lys Thr Gly Tyr Ile Arg Val Leu Val His
1115 1120 1125
Glu Gly Lys Gln Val Met Ala Asp Ser Gly Pro Ile Tyr Asp Gln
1130 1135 1140
Thr Tyr Ala Gly Gly Arg Leu Gly Leu Phe Val Phe Ser Gln Glu
1145 1150 1155
Met Val Tyr Phe Ser Asp Leu Lys Tyr Glu Cys Arg Asp Ile
1160 1165 1170
<210> 13
<211> 2313
<212> DNA
<213> Homo sapiens
<220>
<221> fibulin-1 C mRNA
<222> (1)..(2313)
<400> 13
ctcctcccgg gcgggataat tgaacggcgc ggccctggcc cagcgttggc tgccgaggct 60
cggccggagc gtggagcccg cgccgctgcc ccaggaccgc gcccgcgcct ttgtccgccg 120
ccgcccaccg cccgtcgccc gccgcccatg gagcgcgccg cgccgtcgcg ccgggtcccg 180
cttccgctgc tgctgctcgg cggccttgcg ctgctggcgg ccggagtgga cgcggatgtc 240
ctcctggagg cctgctgtgc ggacggacac cggatggcca ctcatcagaa ggactgctcg 300
ctgccatatg ctacggaatc caaagaatgc aggatggtgc aggagcagtg ctgccacagc 360
cagctggagg agctgcactg tgccacgggc atcagcctgg ccaacgagca ggaccgctgt 420
gccacgcccc acggtgacaa cgccagcctg gaggccacat ttgtgaagag gtgctgccat 480
tgctgtctgc tggggagggc ggcccaggcc cagggccaga gctgcgagta cagcctcatg 540
gttggctacc agtgtggaca ggtcttccgg gcatgctgtg tcaagagcca ggagaccgga 600
gatttggatg tcgggggcct ccaagaaacg gataagatca ttgaggttga ggaggaacaa 660
gaggacccat atctgaatga ccgctgccga ggaggcgggc cctgcaagca gcagtgccga 720
gacacgggtg acgaggtggt ctgctcctgc ttcgtgggct accagctgct gtctgatggt 780
gtctcctgtg aagatgtcaa tgaatgcatc acgggcagcc acagctgccg gcttggagaa 840
tcctgcatca acacagtggg ctctttccgc tgccagcggg acagcagctg cgggactggc 900
tatgagctca cagaggacaa tagctgcaaa gatattgacg agtgtgagag tggtattcat 960
aactgcctcc ccgattttat ctgtcagaat actctgggat ccttccgctg ccgacccaag 1020
ctacagtgca agagtggctt tatacaagat gctctaggca actgtattga tatcaatgag 1080
tgtttgagta tcagtgcccc gtgccctatc gggcatacat gcatcaacac agagggctcc 1140
tacacgtgcc agaagaacgt gcccaactgt ggccgtggct accatctcaa cgaggaggga 1200
acgcgctgtg ttgatgtgga cgagtgcgcg ccacctgctg agccctgtgg gaagggacat 1260
cgctgcgtga actctcccgg cagtttccgc tgcgaatgca agacgggtta ctattttgac 1320
ggcatcagca ggatgtgtgt cgatgtcaac gagtgccagc gctaccccgg gcgcctgtgt 1380
ggccacaagt gcgagaacac gctgggctcc tacctctgca gctgttccgt gggcttccgg 1440
ctctctgtgg atggcaggtc atgtgaagac atcaatgagt gcagcagcag cccctgtagc 1500
caggagtgtg ccaacgtcta cggctcctac cagtgttact gccggcgagg ctaccagctc 1560
agcgatgtgg atggagtcac ctgtgaagac atcgacgagt gcgccctgcc caccgggggc 1620
cacatctgct cctaccgctg catcaacatc cctggaagct tccagtgcag ctgcccctcg 1680
tctggctaca ggctggcccc caatggccgc aactgccaag acattgatga gtgtgtgact 1740
ggcatccaca actgctccat caacgagacc tgcttcaaca tccagggcgg cttccgctgc 1800
ctggccttcg agtgccctga gaactaccgc cgctccgcag ccacccgctg tgagcgcttg 1860
ccttgccatg agaatcggga gtgctccaag ctgcctctga gaataaccta ctaccacctc 1920
tctttcccca ccaacatcca agcgcccgcg gtggttttcc gcatgggccc ctccagtgct 1980
gtccccgggg acagcatgca gctggccatc accggcggca atgaggaggg ctttttcacc 2040
acccggaagg tgagccccca cagtggggtg gtggccctca ccaagcctgt ccccgagccc 2100
agggacttgc tcctgaccgt caagatggat ctctctcgcc acggcaccgt cagctccttt 2160
gtggccaagc ttttcatctt tgtgtctgca gagctctgag cactcgcttc gcgtcgcggg 2220
gtctccctcc tgttgctttc ctaaccctgc cctccggggc gttaataaag tcttagcaag 2280
cgtcccacac agtgaaaaaa aaaaaaaaaa aaa 2313
<210> 14
<211> 683
<212> PRT
<213> Homo sapiens
<220>
<221> fibulin 1 C多肽序列
<222> (1)..(683)
<400> 14
Met Glu Arg Ala Ala Pro Ser Arg Arg Val Pro Leu Pro Leu Leu Leu
1 5 10 15
Leu Gly Gly Leu Ala Leu Leu Ala Ala Gly Val Asp Ala Asp Val Leu
20 25 30
Leu Glu Ala Cys Cys Ala Asp Gly His Arg Met Ala Thr His Gln Lys
35 40 45
Asp Cys Ser Leu Pro Tyr Ala Thr Glu Ser Lys Glu Cys Arg Met Val
50 55 60
Gln Glu Gln Cys Cys His Ser Gln Leu Glu Glu Leu His Cys Ala Thr
65 70 75 80
Gly Ile Ser Leu Ala Asn Glu Gln Asp Arg Cys Ala Thr Pro His Gly
85 90 95
Asp Asn Ala Ser Leu Glu Ala Thr Phe Val Lys Arg Cys Cys His Cys
100 105 110
Cys Leu Leu Gly Arg Ala Ala Gln Ala Gln Gly Gln Ser Cys Glu Tyr
115 120 125
Ser Leu Met Val Gly Tyr Gln Cys Gly Gln Val Phe Arg Ala Cys Cys
130 135 140
Val Lys Ser Gln Glu Thr Gly Asp Leu Asp Val Gly Gly Leu Gln Glu
145 150 155 160
Thr Asp Lys Ile Ile Glu Val Glu Glu Glu Gln Glu Asp Pro Tyr Leu
165 170 175
Asn Asp Arg Cys Arg Gly Gly Gly Pro Cys Lys Gln Gln Cys Arg Asp
180 185 190
Thr Gly Asp Glu Val Val Cys Ser Cys Phe Val Gly Tyr Gln Leu Leu
195 200 205
Ser Asp Gly Val Ser Cys Glu Asp Val Asn Glu Cys Ile Thr Gly Ser
210 215 220
His Ser Cys Arg Leu Gly Glu Ser Cys Ile Asn Thr Val Gly Ser Phe
225 230 235 240
Arg Cys Gln Arg Asp Ser Ser Cys Gly Thr Gly Tyr Glu Leu Thr Glu
245 250 255
Asp Asn Ser Cys Lys Asp Ile Asp Glu Cys Glu Ser Gly Ile His Asn
260 265 270
Cys Leu Pro Asp Phe Ile Cys Gln Asn Thr Leu Gly Ser Phe Arg Cys
275 280 285
Arg Pro Lys Leu Gln Cys Lys Ser Gly Phe Ile Gln Asp Ala Leu Gly
290 295 300
Asn Cys Ile Asp Ile Asn Glu Cys Leu Ser Ile Ser Ala Pro Cys Pro
305 310 315 320
Ile Gly His Thr Cys Ile Asn Thr Glu Gly Ser Tyr Thr Cys Gln Lys
325 330 335
Asn Val Pro Asn Cys Gly Arg Gly Tyr His Leu Asn Glu Glu Gly Thr
340 345 350
Arg Cys Val Asp Val Asp Glu Cys Ala Pro Pro Ala Glu Pro Cys Gly
355 360 365
Lys Gly His Arg Cys Val Asn Ser Pro Gly Ser Phe Arg Cys Glu Cys
370 375 380
Lys Thr Gly Tyr Tyr Phe Asp Gly Ile Ser Arg Met Cys Val Asp Val
385 390 395 400
Asn Glu Cys Gln Arg Tyr Pro Gly Arg Leu Cys Gly His Lys Cys Glu
405 410 415
Asn Thr Leu Gly Ser Tyr Leu Cys Ser Cys Ser Val Gly Phe Arg Leu
420 425 430
Ser Val Asp Gly Arg Ser Cys Glu Asp Ile Asn Glu Cys Ser Ser Ser
435 440 445
Pro Cys Ser Gln Glu Cys Ala Asn Val Tyr Gly Ser Tyr Gln Cys Tyr
450 455 460
Cys Arg Arg Gly Tyr Gln Leu Ser Asp Val Asp Gly Val Thr Cys Glu
465 470 475 480
Asp Ile Asp Glu Cys Ala Leu Pro Thr Gly Gly His Ile Cys Ser Tyr
485 490 495
Arg Cys Ile Asn Ile Pro Gly Ser Phe Gln Cys Ser Cys Pro Ser Ser
500 505 510
Gly Tyr Arg Leu Ala Pro Asn Gly Arg Asn Cys Gln Asp Ile Asp Glu
515 520 525
Cys Val Thr Gly Ile His Asn Cys Ser Ile Asn Glu Thr Cys Phe Asn
530 535 540
Ile Gln Gly Gly Phe Arg Cys Leu Ala Phe Glu Cys Pro Glu Asn Tyr
545 550 555 560
Arg Arg Ser Ala Ala Thr Arg Cys Glu Arg Leu Pro Cys His Glu Asn
565 570 575
Arg Glu Cys Ser Lys Leu Pro Leu Arg Ile Thr Tyr Tyr His Leu Ser
580 585 590
Phe Pro Thr Asn Ile Gln Ala Pro Ala Val Val Phe Arg Met Gly Pro
595 600 605
Ser Ser Ala Val Pro Gly Asp Ser Met Gln Leu Ala Ile Thr Gly Gly
610 615 620
Asn Glu Glu Gly Phe Phe Thr Thr Arg Lys Val Ser Pro His Ser Gly
625 630 635 640
Val Val Ala Leu Thr Lys Pro Val Pro Glu Pro Arg Asp Leu Leu Leu
645 650 655
Thr Val Lys Met Asp Leu Ser Arg His Gly Thr Val Ser Ser Phe Val
660 665 670
Ala Lys Leu Phe Ile Phe Val Ser Ala Glu Leu
675 680
<210> 15
<211> 2485
<212> DNA
<213> Homo sapiens
<220>
<221> 膜联蛋白A11 mRNA
<222> (1)..(2485)
<400> 15
gcactgcctc tggcacctgg ggcagccgcg cccgcggagt tttccgcccg gcgctgacgg 60
ctgctgcgcc cgcggctccc cagtgccccg agtgccccgc gggccccgcg agcgggagtg 120
ggacccagcc ctaggcagaa cccaggcgcc gcgcccggga cgcccgcgga gagagccact 180
cccgcccacg tcccatttcg cccctcgcgt ccggagtccc cgtggccaga tctaaccatg 240
agctaccctg gctatccccc gcccccaggt ggctacccac cagctgcacc aggtggtggt 300
ccctggggag gtgctgccta ccctcctccg cccagcatgc cccccatcgg gctggataac 360
gtggccacct atgcggggca gttcaaccag gactatctct cgggaatggc ggccaacatg 420
tctgggacat ttggaggagc caacatgccc aacctgtacc ctggggcccc tggggctggc 480
tacccaccag tgccccctgg cggctttggg cagcccccct ctgcccagca gcctgttcct 540
ccctatggga tgtatccacc cccaggagga aacccaccct ccaggatgcc ctcatatccg 600
ccatacccag gggcccctgt gccgggccag cccatgccac cccccggaca gcagccccca 660
ggggcctacc ctgggcagcc accagtgacc taccctggtc agcctccagt gccactccct 720
gggcagcagc agccagtgcc gagctaccca ggatacccgg ggtctgggac tgtcaccccc 780
gctgtgcccc caacccagtt tggaagccga ggcaccatca ctgatgctcc cggctttgac 840
cccctgcgag atgccgaggt cctgcggaag gccatgaaag gcttcgggac ggatgagcag 900
gccatcattg actgcctggg gagtcgctcc aacaagcagc ggcagcagat cctactttcc 960
ttcaagacgg cttacggcaa ggatttgatc aaagatctga aatctgaact gtcaggaaac 1020
tttgagaaga caatcttggc tctgatgaag accccagtcc tctttgacat ttatgagata 1080
aaggaagcca tcaagggggt tggcactgat gaagcctgcc tgattgagat cctcgcttcc 1140
cgcagcaatg agcacatccg agaattaaac agagcctaca aagcagaatt caaaaagacc 1200
ctggaagagg ccattcgaag cgacacatca gggcacttcc agcggctcct catctctctc 1260
tctcagggaa accgtgatga aagcacaaac gtggacatgt cactcgccca gagagatgcc 1320
caggagctgt atgcggccgg ggagaaccgc ctgggaacag acgagtccaa gttcaatgcg 1380
gttctgtgct cccggagccg ggcccacctg gtagcagttt tcaatgagta ccagagaatg 1440
acaggccggg acattgagaa gagcatctgc cgggagatgt ccggggacct ggaggagggc 1500
atgctggccg tggtgaaatg tctcaagaat accccagcct tctttgcgga gaggctcaac 1560
aaggccatga ggggggcagg aacaaaggac cggaccctga ttcgcatcat ggtgtctcgc 1620
agcgagaccg acctcctgga catcagatca gagtataagc ggatgtacgg caagtcgctg 1680
taccacgaca tctcgggaga tacttcaggg gattaccgga agattctgct gaagatctgt 1740
ggtggcaatg actgaacagt gactggtggc tcacttctgc ccacctgccg gcaacaccag 1800
tgccaggaaa aggccaaaag aatgtctgtt tctaacaaat ccacaaatag ccccgagatt 1860
caccgtccta gagcttaggc ctgtcttcca cccctcctga cccgtatagt gtgccacagg 1920
acctgggtcg gtctagaact ctctcaggat gccttttcta ccccatccct cacagcctct 1980
tgctgctaaa atagatgttt catttttctg actcatgcaa tcattcccct ttgcctgtgg 2040
ctaagacttg gcttcatttc gtcatgtaat tgtatatttt tatttggagg catattttct 2100
tttcttacag tcattgccag acagaggcat acaagtctgt ttgctgcata cacatttctg 2160
gtgagggcga ctgggtgggt gaagcaccgt gtcctcgctg aggagagaaa gggaggcgtg 2220
cctgagaggg tagcctgtgc atctggtgag tgtgtcacga gctttgttac tgccaaactc 2280
actccttttt agaaaaaaca aaaaaaaagg gccagaaagt cattccttcc atcttccttg 2340
cagaaaccac gagaacaaag ccagttccct gtcagtgaca gggcttcttg taatttgtgg 2400
tatgtgcctt aaacctgaat gtctgtagcc aaaacttgtt tccacattaa gagtcagcca 2460
gctctggaat ggtctggaaa tgtca 2485
<210> 16
<211> 505
<212> PRT
<213> Homo sapiens
<220>
<221> 膜联蛋白A11多肽序列
<222> (1)..(505)
<400> 16
Met Ser Tyr Pro Gly Tyr Pro Pro Pro Pro Gly Gly Tyr Pro Pro Ala
1 5 10 15
Ala Pro Gly Gly Gly Pro Trp Gly Gly Ala Ala Tyr Pro Pro Pro Pro
20 25 30
Ser Met Pro Pro Ile Gly Leu Asp Asn Val Ala Thr Tyr Ala Gly Gln
35 40 45
Phe Asn Gln Asp Tyr Leu Ser Gly Met Ala Ala Asn Met Ser Gly Thr
50 55 60
Phe Gly Gly Ala Asn Met Pro Asn Leu Tyr Pro Gly Ala Pro Gly Ala
65 70 75 80
Gly Tyr Pro Pro Val Pro Pro Gly Gly Phe Gly Gln Pro Pro Ser Ala
85 90 95
Gln Gln Pro Val Pro Pro Tyr Gly Met Tyr Pro Pro Pro Gly Gly Asn
100 105 110
Pro Pro Ser Arg Met Pro Ser Tyr Pro Pro Tyr Pro Gly Ala Pro Val
115 120 125
Pro Gly Gln Pro Met Pro Pro Pro Gly Gln Gln Pro Pro Gly Ala Tyr
130 135 140
Pro Gly Gln Pro Pro Val Thr Tyr Pro Gly Gln Pro Pro Val Pro Leu
145 150 155 160
Pro Gly Gln Gln Gln Pro Val Pro Ser Tyr Pro Gly Tyr Pro Gly Ser
165 170 175
Gly Thr Val Thr Pro Ala Val Pro Pro Thr Gln Phe Gly Ser Arg Gly
180 185 190
Thr Ile Thr Asp Ala Pro Gly Phe Asp Pro Leu Arg Asp Ala Glu Val
195 200 205
Leu Arg Lys Ala Met Lys Gly Phe Gly Thr Asp Glu Gln Ala Ile Ile
210 215 220
Asp Cys Leu Gly Ser Arg Ser Asn Lys Gln Arg Gln Gln Ile Leu Leu
225 230 235 240
Ser Phe Lys Thr Ala Tyr Gly Lys Asp Leu Ile Lys Asp Leu Lys Ser
245 250 255
Glu Leu Ser Gly Asn Phe Glu Lys Thr Ile Leu Ala Leu Met Lys Thr
260 265 270
Pro Val Leu Phe Asp Ile Tyr Glu Ile Lys Glu Ala Ile Lys Gly Val
275 280 285
Gly Thr Asp Glu Ala Cys Leu Ile Glu Ile Leu Ala Ser Arg Ser Asn
290 295 300
Glu His Ile Arg Glu Leu Asn Arg Ala Tyr Lys Ala Glu Phe Lys Lys
305 310 315 320
Thr Leu Glu Glu Ala Ile Arg Ser Asp Thr Ser Gly His Phe Gln Arg
325 330 335
Leu Leu Ile Ser Leu Ser Gln Gly Asn Arg Asp Glu Ser Thr Asn Val
340 345 350
Asp Met Ser Leu Ala Gln Arg Asp Ala Gln Glu Leu Tyr Ala Ala Gly
355 360 365
Glu Asn Arg Leu Gly Thr Asp Glu Ser Lys Phe Asn Ala Val Leu Cys
370 375 380
Ser Arg Ser Arg Ala His Leu Val Ala Val Phe Asn Glu Tyr Gln Arg
385 390 395 400
Met Thr Gly Arg Asp Ile Glu Lys Ser Ile Cys Arg Glu Met Ser Gly
405 410 415
Asp Leu Glu Glu Gly Met Leu Ala Val Val Lys Cys Leu Lys Asn Thr
420 425 430
Pro Ala Phe Phe Ala Glu Arg Leu Asn Lys Ala Met Arg Gly Ala Gly
435 440 445
Thr Lys Asp Arg Thr Leu Ile Arg Ile Met Val Ser Arg Ser Glu Thr
450 455 460
Asp Leu Leu Asp Ile Arg Ser Glu Tyr Lys Arg Met Tyr Gly Lys Ser
465 470 475 480
Leu Tyr His Asp Ile Ser Gly Asp Thr Ser Gly Asp Tyr Arg Lys Ile
485 490 495
Leu Leu Lys Ile Cys Gly Gly Asn Asp
500 505
<210> 17
<211> 3309
<212> DNA
<213> Homo sapiens
<220>
<221> 蛋白S mRNA
<222> (1)..(3309)
<400> 17
ctgcaggggg gggggggggg gggggggggg ggggggggcg cagcacggct cagaccgagg 60
cgcacaggct cgcagctccg ggcgcctagc gcccggtccc cgccgcgacg cgccaccgtc 120
cctgccggcg cctccgcgcc ttcgaaatga gggtcctggg tgggcgctgc ggggcgccgc 180
tggcgtgtct cctcctagtg cttcccgtct cagaggcaaa ccttctgtca aagcaacagg 240
cttcacaagt cctggttagg aagcgtcgtg caaattcttt acttgaagaa accaaacagg 300
gtaatcttga aagagaatgc atcgaagaac tgtgcaataa agaagaagcc agggaggtct 360
ttgaaaatga cccggaaacg gattattttt atccaaaata cttagtttgt cttcgctctt 420
ttcaaactgg gttattcact gctgcacgtc agtcaactaa tgcttatcct gacctaagaa 480
gctgtgtcaa tgccattcca gaccagtgta gtcctctgcc atgcaatgaa gatggatata 540
tgagctgcaa agatggaaaa gcttctttta cttgcacttg taaaccaggt tggcaaggag 600
aaaagtgtga atttgacata aatgaatgca aagatccctc aaatataaat ggaggttgca 660
gtcaaatttg tgataataca cctggaagtt accactgttc ctgtaaaaat ggttttgtta 720
tgctttcaaa taagaaagat tgtaaagatg tggatgaatg ctctttgaag ccaagcattt 780
gtggcacagc tgtgtgcaag aacatcccag gagattttga atgtgaatgc cccgaaggct 840
acagatataa tctcaaatca aagtcttgtg aagatataga tgaatgctct gagaacatgt 900
gtgctcagct ttgtgtcaat taccctggag gttacacttg ctattgtgat gggaagaaag 960
gattcaaact tgcccaagat cagaagagtt gtgaggttgt ttcagtgtgc cttcccttga 1020
accttgacac aaagtatgaa ttactttact tggcggagca gtttgcaggg gttgttttat 1080
atttaaaatt tcgtttgcca gaaatcagca gattttcagc agaatttgat ttccggacat 1140
atgattcaga aggcgtgata ctgtacgcag aatctatcga tcactcagcg tggctcctga 1200
ttgcacttcg tggtggaaag attgaagttc agcttaagaa tgaacataca tccaaaatca 1260
caactggagg tgatgttatt aataatggtc tatggaatat ggtgtctgtg gaagaattag 1320
aacatagtat tagcattaaa atagctaaag aagctgtgat ggatataaat aaacctggac 1380
ccctttttaa gccggaaaat ggattgctgg aaaccaaagt atactttgca ggattccctc 1440
ggaaagtgga aagtgaactc attaaaccga ttaaccctcg tctagatgga tgtatacgaa 1500
gctggaattt gatgaagcaa ggagcttctg gaataaagga aattattcaa gaaaaacaaa 1560
ataagcattg cctggttact gtggagaagg gctcctacta tcctggttct ggaattgctc 1620
aatttcacat agattataat aatgtatcca gtgctgaggg ttggcatgta aatgtgacct 1680
tgaatattcg tccatccacg ggcactggtg ttatgcttgc cttggtttct ggtaacaaca 1740
cagtgccctt tgctgtgtcc ttggtggact ccacctctga aaaatcacag gatattctgt 1800
tatctgttga aaatactgta atatatcgga tacaggccct aagtctatgt tccgatcaac 1860
aatctcatct ggaatttaga gtcaacagaa acaatctgga gttgtcgaca ccacttaaaa 1920
tagaaaccat ctcccatgaa gaccttcaaa gacaacttgc cgtcttggac aaagcaatga 1980
aagcaaaagt ggccacatac ctgggtggcc ttccagatgt tccattcagt gccacaccag 2040
tgaatgcctt ttataatggc tgcatggaag tgaatattaa tggtgtacag ttggatctgg 2100
atgaagccat ttctaaacat aatgatatta gagctcactc atgtccatca gtttggaaaa 2160
agacaaagaa ttcttaaggc atcttttctc tgcttataat accttttcct tgtgtgtaat 2220
tatacttatg tttcaataac agctgaaggg ttttatttac aatgtgcagt ctttgattat 2280
tttgtggtcc tttcctggga tttttaaaag gtcctttgtc aaggaaaaaa attctgttgt 2340
gatataaatc acagtaaaga aattcttact tctcttgcta tctaagaata gtgaaaaata 2400
acaattttaa atttgaattt ttttcctaca aatgacagtt tcaatttttg tttgtaaaac 2460
taaattttaa ttttatcatc atgaactagt gtctaaatac ctatgttttt ttcagaaagc 2520
aaggaagtaa actcaaacaa aagtgcgtgt aattaaatac tattaatcat aggcagatac 2580
tattttgttt atgtttttgt ttttttcctg atgaaggcag aagagatggt ggtctattaa 2640
atatgaattg aatggagggt cctaatgcct tatttcaaaa caattcctca gggggaccag 2700
ctttggcttc atctttctct tgtgtggctt cacatttaaa ccagtatctt tattgaatta 2760
gaaaacaagt gggacatatt ttcctgagag cagcacagga atcttcttct tggcagctgc 2820
agtctgtcag gatgagatat cagattaggt tggataggtg gggaaatctg aagtgggtac 2880
attttttaaa ttttgctgtg tgggtcacac aaggtctaca ttacaaaaga cagaattcag 2940
ggatggaaag gagaatgaac aaatgtggga gttcatagtt ttccttgaat ccaactttta 3000
attaccagag taagttgcca aaatgtgatt gttgaagtac aaaaggaact atgaaaacca 3060
gaacaaattt taacaaaagg acaaccacag agggatatag tgaatatcgt atcattgtaa 3120
tcaaagaagt aaggaggtaa gattgccacg tgcctgctgg tactgtgatg catttcaagt 3180
ggcagtttta tcacgtttga atctaccatt catagccaga tgtgtatcag atgtttcact 3240
gacagttttt aacaataaat tcttttcact gtattttata tcacttataa taaatcggtg 3300
tataatttt 3309
<210> 18
<211> 676
<212> PRT
<213> Homo sapiens
<220>
<221> 蛋白S多肽序列
<222> (1)..(676)
<400> 18
Met Arg Val Leu Gly Gly Arg Cys Gly Ala Pro Leu Ala Cys Leu Leu
1 5 10 15
Leu Val Leu Pro Val Ser Glu Ala Asn Leu Leu Ser Lys Gln Gln Ala
20 25 30
Ser Gln Val Leu Val Arg Lys Arg Arg Ala Asn Ser Leu Leu Glu Glu
35 40 45
Thr Lys Gln Gly Asn Leu Glu Arg Glu Cys Ile Glu Glu Leu Cys Asn
50 55 60
Lys Glu Glu Ala Arg Glu Val Phe Glu Asn Asp Pro Glu Thr Asp Tyr
65 70 75 80
Phe Tyr Pro Lys Tyr Leu Val Cys Leu Arg Ser Phe Gln Thr Gly Leu
85 90 95
Phe Thr Ala Ala Arg Gln Ser Thr Asn Ala Tyr Pro Asp Leu Arg Ser
100 105 110
Cys Val Asn Ala Ile Pro Asp Gln Cys Ser Pro Leu Pro Cys Asn Glu
115 120 125
Asp Gly Tyr Met Ser Cys Lys Asp Gly Lys Ala Ser Phe Thr Cys Thr
130 135 140
Cys Lys Pro Gly Trp Gln Gly Glu Lys Cys Glu Phe Asp Ile Asn Glu
145 150 155 160
Cys Lys Asp Pro Ser Asn Ile Asn Gly Gly Cys Ser Gln Ile Cys Asp
165 170 175
Asn Thr Pro Gly Ser Tyr His Cys Ser Cys Lys Asn Gly Phe Val Met
180 185 190
Leu Ser Asn Lys Lys Asp Cys Lys Asp Val Asp Glu Cys Ser Leu Lys
195 200 205
Pro Ser Ile Cys Gly Thr Ala Val Cys Lys Asn Ile Pro Gly Asp Phe
210 215 220
Glu Cys Glu Cys Pro Glu Gly Tyr Arg Tyr Asn Leu Lys Ser Lys Ser
225 230 235 240
Cys Glu Asp Ile Asp Glu Cys Ser Glu Asn Met Cys Ala Gln Leu Cys
245 250 255
Val Asn Tyr Pro Gly Gly Tyr Thr Cys Tyr Cys Asp Gly Lys Lys Gly
260 265 270
Phe Lys Leu Ala Gln Asp Gln Lys Ser Cys Glu Val Val Ser Val Cys
275 280 285
Leu Pro Leu Asn Leu Asp Thr Lys Tyr Glu Leu Leu Tyr Leu Ala Glu
290 295 300
Gln Phe Ala Gly Val Val Leu Tyr Leu Lys Phe Arg Leu Pro Glu Ile
305 310 315 320
Ser Arg Phe Ser Ala Glu Phe Asp Phe Arg Thr Tyr Asp Ser Glu Gly
325 330 335
Val Ile Leu Tyr Ala Glu Ser Ile Asp His Ser Ala Trp Leu Leu Ile
340 345 350
Ala Leu Arg Gly Gly Lys Ile Glu Val Gln Leu Lys Asn Glu His Thr
355 360 365
Ser Lys Ile Thr Thr Gly Gly Asp Val Ile Asn Asn Gly Leu Trp Asn
370 375 380
Met Val Ser Val Glu Glu Leu Glu His Ser Ile Ser Ile Lys Ile Ala
385 390 395 400
Lys Glu Ala Val Met Asp Ile Asn Lys Pro Gly Pro Leu Phe Lys Pro
405 410 415
Glu Asn Gly Leu Leu Glu Thr Lys Val Tyr Phe Ala Gly Phe Pro Arg
420 425 430
Lys Val Glu Ser Glu Leu Ile Lys Pro Ile Asn Pro Arg Leu Asp Gly
435 440 445
Cys Ile Arg Ser Trp Asn Leu Met Lys Gln Gly Ala Ser Gly Ile Lys
450 455 460
Glu Ile Ile Gln Glu Lys Gln Asn Lys His Cys Leu Val Thr Val Glu
465 470 475 480
Lys Gly Ser Tyr Tyr Pro Gly Ser Gly Ile Ala Gln Phe His Ile Asp
485 490 495
Tyr Asn Asn Val Ser Ser Ala Glu Gly Trp His Val Asn Val Thr Leu
500 505 510
Asn Ile Arg Pro Ser Thr Gly Thr Gly Val Met Leu Ala Leu Val Ser
515 520 525
Gly Asn Asn Thr Val Pro Phe Ala Val Ser Leu Val Asp Ser Thr Ser
530 535 540
Glu Lys Ser Gln Asp Ile Leu Leu Ser Val Glu Asn Thr Val Ile Tyr
545 550 555 560
Arg Ile Gln Ala Leu Ser Leu Cys Ser Asp Gln Gln Ser His Leu Glu
565 570 575
Phe Arg Val Asn Arg Asn Asn Leu Glu Leu Ser Thr Pro Leu Lys Ile
580 585 590
Glu Thr Ile Ser His Glu Asp Leu Gln Arg Gln Leu Ala Val Leu Asp
595 600 605
Lys Ala Met Lys Ala Lys Val Ala Thr Tyr Leu Gly Gly Leu Pro Asp
610 615 620
Val Pro Phe Ser Ala Thr Pro Val Asn Ala Phe Tyr Asn Gly Cys Met
625 630 635 640
Glu Val Asn Ile Asn Gly Val Gln Leu Asp Leu Asp Glu Ala Ile Ser
645 650 655
Lys His Asn Asp Ile Arg Ala His Ser Cys Pro Ser Val Trp Lys Lys
660 665 670
Thr Lys Asn Ser
675
<210> 19
<211> 3926
<212> DNA
<213> Homo sapiens
<220>
<221> H因子1(补体)mRNA
<222> (1)..(3926)
<400> 19
aattcttgga agaggagaac tggacgttgt gaacagagtt agctggtaaa tgtcctctta 60
aaagatccaa aaaatgagac ttctagcaaa gattatttgc cttatgttat gggctatttg 120
tgtagcagaa gattgcaatg aacttcctcc aagaagaaat acagaaattc tgacaggttc 180
ctggtctgac caaacatatc cagaaggcac ccaggctatc tataaatgcc gccctggata 240
tagatctctt ggaaatgtaa taatggtatg caggaaggga gaatgggttg ctcttaatcc 300
attaaggaaa tgtcagaaaa ggccctgtgg acatcctgga gatactcctt ttggtacttt 360
tacccttaca ggaggaaatg tgtttgaata tggtgtaaaa gctgtgtata catgtaatga 420
ggggtatcaa ttgctaggtg agattaatta ccgtgaatgt gacacagatg gatggaccaa 480
tgatattcct atatgtgaag ttgtgaagtg tttaccagtg acagcaccag agaatggaaa 540
aattgtcagt agtgcaatgg aaccagatcg ggaataccat tttggacaag cagtacggtt 600
tgtatgtaac tcaggctaca agattgaagg agatgaagaa atgcattgtt cagacgatgg 660
tttttggagt aaagagaaac caaagtgtgt ggaaatttca tgcaaatccc cagatgttat 720
aaatggatct cctatatctc agaagattat ttataaggag aatgaacgat ttcaatataa 780
atgtaacatg ggttatgaat acagtgaaag aggagatgct gtatgcactg aatctggatg 840
gcgtccgttg ccttcatgtg aagaaaaatc atgtgataat ccttatattc caaatggtga 900
ctactcacct ttaaggatta aacacagaac tggagatgaa atcacgtacc agtgtagaaa 960
tggtttttat cctgcaaccc ggggaaatac agccaaatgc acaagtactg gctggatacc 1020
tgctccgaga tgtaccttga aaccttgtga ttatccagac attaaacatg gaggtctata 1080
tcatgagaat atgcgtagac catactttcc agtagctgta ggaaaatatt actcctatta 1140
ctgtgatgaa cattttgaga ctccgtcagg aagttactgg gatcacattc attgcacaca 1200
agatggatgg tcgccagcag taccatgcct cagaaaatgt tattttcctt atttggaaaa 1260
tggatataat caaaatcatg gaagaaagtt tgtacagggt aaatctatag acgttgcctg 1320
ccatcctggc tacgctcttc caaaagcgca gaccacagtt acatgtatgg agaatggctg 1380
gtctcctact cccagatgca tccgtgtcaa aacatgttcc aaatcaagta tagatattga 1440
gaatgggttt atttctgaat ctcagtatac atatgcctta aaagaaaaag cgaaatatca 1500
atgcaaacta ggatatgtaa cagcagatgg tgaaacatca ggatcaatta gatgtgggaa 1560
agatggatgg tcagctcaac ccacgtgcat taaatcttgt gatatcccag tatttatgaa 1620
tgccagaact aaaaatgact tcacatggtt taagctgaat gacacattgg actatgaatg 1680
ccatgatggt tatgaaagca atactggaag caccactggt tccatagtgt gtggttacaa 1740
tggttggtct gatttaccca tatgttatga aagagaatgc gaacttccta aaatagatgt 1800
acacttagtt cctgatcgca agaaagacca gtataaagtt ggagaggtgt tgaaattctc 1860
ctgcaaacca ggatttacaa tagttggacc taattccgtt cagtgctacc actttggatt 1920
gtctcctgac ctcccaatat gtaaagagca agtacaatca tgtggtccac ctcctgaact 1980
cctcaatggg aatgttaagg aaaaaacgaa agaagaatat ggacacagtg aagtggtgga 2040
atattattgc aatcctagat ttctaatgaa gggacctaat aaaattcaat gtgttgatgg 2100
agagtggaca actttaccag tgtgtattgt ggaggagagt acctgtggag atatacctga 2160
acttgaacat ggctgggccc agctttcttc ccctccttat tactatggag attcagtgga 2220
attcaattgc tcagaatcat ttacaatgat tggacacaga tcaattacgt gtattcatgg 2280
agtatggacc caacttcccc agtgtgtggc aatagataaa cttaagaagt gcaaatcatc 2340
aaatttaatt atacttgagg aacatttaaa aaacaagaag gaattcgatc ataattctaa 2400
cataaggtac agatgtagag gaaaagaagg atggatacac acagtctgca taaatggaag 2460
atgggatcca gaagtgaact gctcaatggc acaaatacaa ttatgcccac ctccacctca 2520
gattcccaat tctcacaata tgacaaccac actgaattat cgggatggag aaaaagtatc 2580
tgttctttgc caagaaaatt atctaattca ggaaggagaa gaaattacat gcaaagatgg 2640
aagatggcag tcaataccac tctgtgttga aaaaattcca tgttcacaac cacctcagat 2700
agaacacgga accattaatt catccaggtc ttcacaagaa agttatgcac atgggactaa 2760
attgagttat acttgtgagg gtggtttcag gatatctgaa gaaaatgaaa caacatgcta 2820
catgggaaaa tggagttctc cacctcagtg tgaaggcctt ccttgtaaat ctccacctga 2880
gatttctcat ggtgttgtag ctcacatgtc agacagttat cagtatggag aagaagttac 2940
gtacaaatgt tttgaaggtt ttggaattga tgggcctgca attgcaaaat gcttaggaga 3000
aaaatggtct caccctccat catgcataaa aacagattgt ctcagtttac ctagctttga 3060
aaatgccata cccatgggag agaagaagga tgtgtataag gcgggtgagc aagtgactta 3120
cacttgtgca acatattaca aaatggatgg agccagtaat gtaacatgca ttaatagcag 3180
atggacagga aggccaacat gcagagacac ctcctgtgtg aatccgccca cagtacaaaa 3240
tgcttatata gtgtcgagac agatgagtaa atatccatct ggtgagagag tacgttatca 3300
atgtaggagc ccttatgaaa tgtttgggga tgaagaagtg atgtgtttaa atggaaactg 3360
gacggaacca cctcaatgca aagattctac aggaaaatgt gggccccctc cacctattga 3420
caatggggac attacttcat tcccgttgtc agtatatgct ccagcttcat cagttgagta 3480
ccaatgccag aacttgtatc aacttgaggg taacaagcga ataacatgta gaaatggaca 3540
atggtcagaa ccaccaaaat gcttacatcc gtgtgtaata tcccgagaaa ttatggaaaa 3600
ttataacata gcattaaggt ggacagccaa acagaagctt tattcgagaa caggtgaatc 3660
agttgaattt gtgtgtaaac ggggatatcg tctttcatca cgttctcaca cattgcgaac 3720
aacatgttgg gatgggaaac tggagtatcc aacttgtgca aaaagataga atcaatcata 3780
aagtgcacac ctttattcag aactttagta ttaaatcagt tctcaatttc attttttatg 3840
tattgtttta ctccttttta ttcatacgta aaattttgga ttaatttgtg aaaatgtaat 3900
tataagctga gaccggtggc tctctt 3926
<210> 20
<211> 1231
<212> PRT
<213> Homo sapiens
<220>
<221> H因子1多肽序列
<222> (1)..(1231)
<400> 20
Met Arg Leu Leu Ala Lys Ile Ile Cys Leu Met Leu Trp Ala Ile Cys
1 5 10 15
Val Ala Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile
20 25 30
Leu Thr Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Thr Gln Ala
35 40 45
Ile Tyr Lys Cys Arg Pro Gly Tyr Arg Ser Leu Gly Asn Val Ile Met
50 55 60
Val Cys Arg Lys Gly Glu Trp Val Ala Leu Asn Pro Leu Arg Lys Cys
65 70 75 80
Gln Lys Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Thr Phe
85 90 95
Thr Leu Thr Gly Gly Asn Val Phe Glu Tyr Gly Val Lys Ala Val Tyr
100 105 110
Thr Cys Asn Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asn Tyr Arg Glu
115 120 125
Cys Asp Thr Asp Gly Trp Thr Asn Asp Ile ProIle Cys Glu Val Val
130 135 140
Lys Cys Leu Pro Val Thr Ala Pro Glu Asn Gly Lys Ile Val Ser Ser
145 150 155 160
Ala Met Glu Pro Asp Arg Glu Tyr His Phe Gly Gln Ala Val Arg Phe
165 170 175
Val Cys Asn Ser Gly Tyr Lys Ile Glu Gly Asp Glu Glu Met His Cys
180 185 190
Ser Asp Asp Gly Phe Trp Ser Lys Glu Lys Pro Lys Cys Val Glu Ile
195 200 205
Ser Cys Lys Ser Pro Asp Val Ile Asn Gly Ser Pro Ile Ser Gln Lys
210 215 220
Ile Ile Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Asn Met Gly
225 230 235 240
Tyr Glu Tyr Ser Glu Arg Gly Asp Ala Val Cys Thr Glu Ser Gly Trp
245 250 255
Arg Pro Leu Pro Ser Cys Glu Glu Lys Ser Cys Asp Asn Pro Tyr Ile
260 265 270
Pro Asn Gly Asp Tyr Ser Pro Leu Arg Ile Lys His Arg Thr Gly Asp
275 280 285
Glu Ile Thr Tyr Gln Cys Arg Asn Gly Phe Tyr Pro Ala Thr Arg Gly
290 295 300
Asn Thr Ala Lys Cys Thr Ser Thr Gly Trp Ile Pro Ala Pro Arg Cys
305 310 315 320
Thr Leu Lys Pro Cys Asp Tyr Pro Asp Ile Lys His Gly Gly Leu Tyr
325 330 335
His Glu Asn Met Arg Arg Pro Tyr Phe Pro Val Ala Val Gly Lys Tyr
340 345 350
Tyr Ser Tyr Tyr Cys Asp Glu His Phe Glu Thr Pro Ser Gly Ser Tyr
355 360 365
Trp Asp His Ile His Cys Thr Gln Asp Gly Trp Ser Pro Ala Val Pro
370 375 380
Cys Leu Arg Lys Cys Tyr Phe Pro Tyr Leu Glu Asn Gly Tyr Asn Gln
385 390 395 400
Asn His Gly Arg Lys Phe Val Gln Gly Lys Ser Ile Asp Val Ala Cys
405 410 415
His Pro Gly Tyr Ala Leu Pro Lys Ala Gln Thr Thr Val Thr Cys Met
420 425 430
Glu Asn Gly Trp Ser Pro Thr Pro Arg Cys Ile Arg Val Lys Thr Cys
435 440 445
Ser Lys Ser Ser Ile Asp Ile Glu Asn Gly Phe Ile Ser Glu Ser Gln
450 455 460
Tyr Thr Tyr Ala Leu Lys Glu Lys Ala Lys Tyr Gln Cys Lys Leu Gly
465 470 475 480
Tyr Val Thr Ala Asp Gly Glu Thr Ser Gly Ser Ile Arg Cys Gly Lys
485 490 495
Asp Gly Trp Ser Ala Gln Pro Thr Cys Ile Lys Ser Cys Asp Ile Pro
500 505 510
Val Phe Met Asn Ala Arg Thr Lys Asn Asp Phe Thr Trp Phe Lys Leu
515 520 525
Asn Asp Thr Leu Asp Tyr Glu Cys His Asp Gly Tyr Glu Ser Asn Thr
530 535 540
Gly Ser Thr Thr Gly Ser Ile Val Cys Gly Tyr Asn Gly Trp Ser Asp
545 550 555 560
Leu Pro Ile Cys Tyr Glu Arg Glu Cys Glu Leu Pro Lys Ile Asp Val
565 570 575
His Leu Val Pro Asp Arg Lys Lys Asp Gln Tyr Lys Val Gly Glu Val
580 585 590
Leu Lys Phe Ser Cys Lys Pro Gly Phe Thr Ile Val Gly Pro Asn Ser
595 600 605
Val Gln Cys Tyr His Phe Gly Leu Ser Pro Asp Leu Pro Ile Cys Lys
610 615 620
Glu Gln Val Gln Ser Cys Gly Pro Pro Pro Glu Leu Leu Asn Gly Asn
625 630 635 640
Val Lys Glu Lys Thr Lys Glu Glu Tyr Gly His Ser Glu Val Val Glu
645 650 655
Tyr Tyr Cys Asn Pro Arg Phe Leu Met Lys Gly Pro Asn Lys Ile Gln
660 665 670
Cys Val Asp Gly Glu Trp Thr Thr Leu Pro Val Cys Ile Val Glu Glu
675 680 685
Ser Thr Cys Gly Asp Ile Pro Glu Leu Glu His Gly Trp Ala Gln Leu
690 695 700
Ser Ser Pro Pro Tyr Tyr Tyr Gly Asp Ser Val Glu Phe Asn Cys Ser
705 710 715 720
Glu Ser Phe Thr Met Ile Gly His Arg Ser Ile Thr Cys Ile His Gly
725 730 735
Val Trp Thr Gln Leu Pro Gln Cys Val Ala Ile Asp Lys Leu Lys Lys
740 745 750
Cys Lys Ser Ser Asn Leu Ile Ile Leu Glu Glu His Leu Lys Asn Lys
755 760 765
Lys Glu Phe Asp His Asn Ser Asn Ile Arg Tyr Arg Cys Arg Gly Lys
770 775 780
Glu Gly Trp Ile His Thr Val Cys Ile Asn Gly Arg Trp Asp Pro Glu
785 790 795 800
Val Asn Cys Ser Met Ala Gln Ile Gln Leu Cys Pro Pro Pro Pro Gln
805 810 815
Ile Pro Asn Ser His Asn Met Thr Thr Thr Leu Asn Tyr Arg Asp Gly
820 825 830
Glu Lys Val Ser Val Leu Cys Gln Glu Asn Tyr Leu Ile Gln Glu Gly
835 840 845
Glu Glu Ile Thr Cys Lys Asp Gly Arg Trp Gln Ser Ile Pro Leu Cys
850 855 860
Val Glu Lys Ile Pro Cys Ser Gln Pro Pro Gln Ile Glu His Gly Thr
865 870 875 880
Ile Asn Ser Ser Arg Ser Ser Gln Glu Ser Tyr Ala His Gly Thr Lys
885 890 895
Leu Ser Tyr Thr Cys Glu Gly Gly Phe Arg Ile Ser Glu Glu Asn Glu
900 905 910
Thr Thr Cys Tyr Met Gly Lys Trp Ser Ser Pro Pro Gln Cys Glu Gly
915 920 925
Leu Pro Cys Lys Ser Pro Pro Glu Ile Ser His Gly Val Val Ala His
930 935 940
Met Ser Asp Ser Tyr Gln Tyr Gly Glu Glu Val Thr Tyr Lys Cys Phe
945 950 955 960
Glu Gly Phe Gly Ile Asp Gly Pro Ala Ile Ala Lys Cys Leu Gly Glu
965 970 975
Lys Trp Ser His Pro Pro Ser Cys Ile Lys Thr Asp Cys Leu Ser Leu
980 985 990
Pro Ser Phe Glu Asn Ala Ile Pro Met Gly Glu Lys Lys Asp Val Tyr
995 1000 1005
Lys Ala Gly Glu Gln Val Thr Tyr Thr Cys Ala Thr Tyr Tyr Lys
1010 1015 1020
Met Asp Gly Ala Ser Asn Val Thr Cys Ile Asn Ser Arg Trp Thr
1025 1030 1035
Gly Arg Pro Thr Cys Arg Asp Thr Ser Cys Val Asn Pro Pro Thr
1040 1045 1050
Val Gln Asn Ala Tyr Ile Val Ser Arg Gln Met Ser Lys Tyr Pro
1055 1060 1065
Ser Gly Glu Arg Val Arg Tyr Gln Cys Arg Ser Pro Tyr Glu Met
1070 1075 1080
Phe Gly Asp Glu Glu Val Met Cys Leu Asn Gly Asn Trp Thr Glu
1085 1090 1095
Pro Pro Gln Cys Lys Asp Ser Thr Gly Lys Cys Gly Pro Pro Pro
1100 1105 1110
Pro Ile Asp Asn Gly Asp Ile Thr Ser Phe Pro Leu Ser Val Tyr
1115 1120 1125
Ala Pro Ala Ser Ser Val Glu Tyr Gln Cys Gln Asn Leu Tyr Gln
1130 1135 1140
Leu Glu Gly Asn Lys Arg Ile Thr Cys Arg Asn Gly Gln Trp Ser
1145 1150 1155
Glu Pro Pro Lys Cys Leu His Pro Cys Val Ile Ser Arg Glu Ile
1160 1165 1170
Met Glu Asn Tyr Asn Ile Ala Leu Arg Trp Thr Ala Lys Gln Lys
1175 1180 1185
Leu Tyr Ser Arg Thr Gly Glu Ser Val Glu Phe Val Cys Lys Arg
1190 1195 1200
Gly Tyr Arg Leu Ser Ser Arg Ser His Thr Leu Arg Thr Thr Cys
1205 1210 1215
Trp Asp Gly Lys Leu Glu Tyr Pro Thr Cys Ala Lys Arg
1220 1225 1230
<210> 21
<211> 1984
<212> DNA
<213> Homo sapiens
<220>
<221> 超氧化物歧化酶3 mRNA
<222> (1)..(1984)
<400> 21
ggatccagag atttagattt tttataagct ttcctgccac cgaaacgggt gtttgggacc 60
tcacgaggcc ctgttcattc ttcgtcgctg cgctccccac tctgtactgg atgcatttac 120
tgacgttgtt gtctccgtcc ccagagtatg aacccccaag gtgactcatg cagctgtggg 180
tgcccggcat acagcatggt gactggaatg gatgagcacc caataaacat ttgttgcagg 240
aatgcaggag gacgggcagg ccagcaagca ggctgcctgg tttttcccac atgggctttt 300
ctgggaaaga agagcttcta tttttggaaa gggctgctat gattgagaaa agttcatggc 360
agcaaaaaaa ggacagacgt cgggagggaa acactcctag ttctcccaga caacacattt 420
tttaaaaaga ctccttcatc tctttaataa taacggtaac gacaatgaca atgatgatta 480
cttatgagtg cggctagtgc cagccactgt gttgtcactg ggcgagtaat gatctcattg 540
gatcttcacg gtgggcgtgc ggggctccag ggacagcctg cgttcctggg ctggctgggt 600
gcagctctct tttcaggaga gaaagctctc ttggaggagc tggaaaggtg cccgactcca 660
gccatgctgg cgctactgtg ttcctgcctg ctcctggcag ccggtgcctc ggacgcctgg 720
acgggcgagg actcggcgga gcccaactct gactcggcgg agtggatccg agacatgtac 780
gccaaggtca cggagatctg gcaggaggtc atgcagcggc gggacgacga cggcacgctc 840
cacgccgcct gccaggtgca gccgtcggcc acgctggacg ccgcgcagcc ccgggtgacc 900
ggcgtcgtcc tcttccggca gcttgcgccc cgcgccaagc tcgacgcctt cttcgccctg 960
gagggcttcc cgaccgagcc gaacagctcc agccgcgcca tccacgtgca ccagttcggg 1020
gacctgagcc agggctgcga gtccaccggg ccccactaca acccgctggc cgtgccgcac 1080
ccgcagcacc cgggcgactt cggcaacttc gcggtccgcg acggcagcct ctggaggtac 1140
cgcgccggcc tggccgcctc gctcgcgggc ccgcactcca tcgtgggccg ggccgtggtc 1200
gtccacgctg gcgaggacga cctgggccgc ggcggcaacc aggccagcgt ggagaacggg 1260
aacgcgggcc ggcggctggc ctgctgcgtg gtgggcgtgt gcgggcccgg gctctgggag 1320
cgccaggcgc gggagcactc agagcgcaag aagcggcggc gcgagagcga gtgcaaggcc 1380
gcctgagcgc ggcccccacc cggcggcggc cagggacccc cgaggccccc ctctgccttt 1440
gagcttctcc tctgctccaa cagacacctt ccactctgag gtctcacctt cgcctctgct 1500
gaagtctccc cgcagccctc tccacccaga ggtctcccta taccgagacc caccatcctt 1560
ccatcctgag gaccgcccca accctcggag ccccccactc agtaggtctg aaggcctcca 1620
tttgtaccga aacaccccgc tcacgctgac agcctcctag gctccctgag gtacctttcc 1680
acccagaccc tccttcccca ccccataagc cctgagactc ccgcctttga cctgacgatc 1740
ttcccccttc ccgccttcag gttcctccta ggcgctcaga ggccgctctg gggggttgcc 1800
tcgagtcccc ccacccctcc ccacccacca ccgctcccgc ggcaagccag cccgtgcaac 1860
ggaagccagg ccaactgccc cgcgtcttca gctgtttcgc atccaccgcc accccactga 1920
gagctgctcc tttgggggaa tgtttggcaa cctttgtgtt acagattaaa aattcagcaa 1980
ttca 1984
<210> 22
<211> 240
<212> PRT
<213> Homo sapiens
<220>
<221> 超氧化物歧化酶3多肽序列
<222> (1)..(240)
<400> 22
Met Leu Ala Leu Leu Cys Ser Cys Leu Leu Leu Ala Ala Gly Ala Ser
1 5 10 15
Asp Ala Trp Thr Gly Glu Asp Ser Ala Glu Pro Asn Ser Asp Ser Ala
20 25 30
Glu Trp Ile Arg Asp Met Tyr Ala Lys Val Thr Glu Ile Trp Gln Glu
35 40 45
Val Met Gln Arg Arg Asp Asp Asp Gly Thr Leu His Ala Ala Cys Gln
50 55 60
Val Gln Pro Ser Ala Thr Leu Asp Ala Ala Gln Pro Arg Val Thr Gly
65 70 75 80
Val Val Leu Phe Arg Gln Leu Ala Pro Arg Ala Lys Leu Asp Ala Phe
85 90 95
Phe Ala Leu Glu Gly Phe Pro Thr Glu Pro Asn Ser Ser Ser Arg Ala
100 105 110
Ile His Val His Gln Phe Gly Asp Leu Ser Gln Gly Cys Glu Ser Thr
115 120 125
Gly Pro His Tyr Asn Pro Leu Ala Val Pro His Pro Gln His Pro Gly
130 135 140
Asp Phe Gly Asn Phe Ala Val Arg Asp Gly Ser Leu Trp Arg Tyr Arg
145 150 155 160
Ala Gly Leu Ala Ala Ser Leu Ala Gly Pro His Ser Ile Val Gly Arg
165 170 175
Ala Val Val Val His Ala Gly Glu Asp Asp Leu Gly Arg Gly Gly Asn
180 185 190
Gln Ala Ser Val Glu Asn Gly Asn Ala Gly Arg Arg Leu Ala Cys Cys
195 200 205
Val Val Gly Val Cys Gly Pro Gly Leu Trp Glu Arg Gln Ala Arg Glu
210 215 220
His Ser Glu Arg Lys Lys Arg Arg Arg Glu Ser Glu Cys Lys Ala Ala
225 230 235 240
<210> 23
<211> 1338
<212> DNA
<213> Homo sapiens
<220>
<221> neuronatin mRNA
<222> (1)..(1338)
<400> 23
taggtggcgg gcgggtactt aaggcgcggc caccgcggct gcggcagtgc gcccaacagc 60
ggactccgag accagcggat ctcggcaaac cctctttctc gaccacccac ctaccattct 120
tggaaccatg gcggcagtgg cggcggcctc ggctgaactg ctcatcatcg gctggtacat 180
cttccgcgtg ctgctgcagg tgttcctgga atgctgcatt tactgggtag gattcgcttt 240
tcgaaatcct ccagggacac agcccattgc gagaagtgag gtgttcaggt actccctgca 300
gaagctggca tacacggtgt cgcggaccgg gcggcaggtg ttgggggagc gcaggcagcg 360
agcccccaac tgaggcccca gctcccagcc ctgggcggcc gtatcatcag gtgctcctgt 420
gcatctcggc cagcacggga gccagtgccg cgcaggaatg tggggtcccc tgtgttccct 480
cgccagagga gcacttggca aggtcagtga ggggccagta gacccccgga gaagcagtac 540
cgacaatgac gaagatacca gatcccttcc caaccccttt gcaccggtcc cactaagggg 600
cagggtcgag agaggagggg ggataggggg agcagacccc tgagatctgg gcataggcac 660
cgcattctga tctggacaaa gtcgggacag caccatccca gccccgaagc cagggccatg 720
ccagcaggcc ccaccatgga aatcaaaaca ccgcaccagc cagcagaatg gacattctga 780
catcgccagc cgacgccctg aatcttggtg cagcaccaac cgcgtgcctg tgtggcggga 840
ctggagggca cagttgagga aggagggtgg ttaagaaata cagtggggcc ctctcgctgt 900
cccttgccca gggcacttgc attccagcct cgctgcattt gctctctcga ttcccctttc 960
ctcctcactg cctcccaagc ccaccctact ccaaaataat gtgtcacttg atttggaact 1020
attcaagcag taaaagtaaa tgaatcccac ctttactaaa acactttctc tgaacccccc 1080
ttgcccctca ctgatcttgc ttttccctgg tctcatgcag ttgtggtcaa tattgtggta 1140
atcgctaatt gtactgattg tttaagtgtg cattagttgt gtctccccag ctagattgta 1200
agctcctgga ggacagggac cacctctaca aaaaataaaa aaagtacctc ccctgtctcg 1260
cacagtgtcc caggaccctg cggtgcagta gaggcgcacc aaaaaaaaaa aaaaaaaaaa 1320
aaaaaaaaaa aaaaaaaa 1338
<210> 24
<211> 81
<212> PRT
<213> Homo sapiens
<220>
<221> neuronatin多肽序列
<222> (1)..(81)
<400> 24
Met Ala Ala Val Ala Ala Ala Ser Ala Glu Leu Leu Ile Ile Gly Trp
1 5 10 15
Tyr Ile Phe Arg Val Leu Leu Gln Val Phe Leu Glu Cys Cys Ile Tyr
20 25 30
Trp Val Gly Phe Ala Phe Arg Asn Pro Pro Gly Thr Gln Pro Ile Ala
35 40 45
Arg Ser Glu Val Phe Arg Tyr Ser Leu Gln Lys Leu Ala Tyr Thr Val
50 55 60
Ser Arg Thr Gly Arg Gln Val Leu Gly Glu Arg Arg Gln Arg Ala Pro
65 70 75 80
Asn
<210> 25
<211> 2500
<212> DNA
<213> Homo sapiens
<220>
<221> 滤泡素抑制素-样3糖蛋白mRNA
<222> (1)..(2500)
<400> 25
gttcgccatg cgtcccgggg cgccagggcc actctggcct ctgccctggg gggccctggc 60
ttgggccgtg ggcttcgtga gctccatggg ctcggggaac cccgcgcccg gtggtgtttg 120
ctggctccag cagggccagg aggccacctg cagcctggtg ctccagactg atgtcacccg 180
ggccgagtgc tgtgcctccg gcaacattga caccgcctgg tccaacctca cccacccggg 240
gaacaagatc aacctcctcg gcttcttggg ccttgtccac tgccttccct gcaaagattc 300
gtgcgacggc gtggagtgcg gcccgggcaa ggcgtgccgc atgctggggg gccgcccgcg 360
ctgcgagtgc gcgcccgact gctcggggct cccggcgcgg ctgcaggtct gcggctcaga 420
cggcgccacc taccgcgacg agtgcgagct gcgcgccgcg cgctgccgcg gccacccgga 480
cctgagcgtc atgtaccggg gccgctgccg caagtcctgt gagcacgtgg tgtgcccgcg 540
gccacagtcg tgcgtcgtgg accagacggg cagcgcccac tgcgtggtgt gtcgagcggc 600
gccctgccct gtgccctcca gccccggcca ggagctttgc ggcaacaaca acgtcaccta 660
catctcctcg tgccacatgc gccaggccac ctgcttcctg ggccgctcca tcggcgtgcg 720
ccacgcgggc agctgcgcag gcacccctga ggagccgcca ggtggtgagt ctgcagaaga 780
ggaagagaac ttcgtgtgag cctgcaggac aggcctgggc ctggtgcccg aggcccccca 840
tcatcccctg ttatttattg ccacagcaga gtctaattta tatgccacgg acactcctta 900
gagcccggat tcggaccact tggggatccc agaacctccc tgacgatatc ctggaaggac 960
tgaggaaggg aggcctgggg gccggctggt gggtgggata gacctgcgtt ccggacactg 1020
agcgcctgat ttagggccct tctctaggat gccccagccc ctaccctaag acctattgcc 1080
ggggaggatt ccacacttcc gctcctttgg ggataaacct attaattatt gctactatca 1140
agagggctgg gcattctctg ctggtaattc ctgaagaggc atgactgctt ttctcagccc 1200
caagcctcta gtctgggtgt gtacggaggg tctagcctgg gtgtgtacgg agggtctagc 1260
ctgggtgagt acggagggtc tagcctgggt gagtacggag ggtctagcct gggtgagtac 1320
ggagagtcta gcctgggtgt gtatggagga tctagcctgg gtgagtatgg agggtctagc 1380
ctgggtgagt atggagggtc tagcctgggt gtgtatggag ggtctagcct gggtgagtat 1440
ggagggtcta gcctgggtgt gtatggaggg tctagcctgg gtgagtatgg agggtctagc 1500
ctgggtgtgt acggagggtc tagtctgagt gcgtgtgggg acctcagaac actgtgacct 1560
tagcccagca agccaggccc ttcatgaagg ccaagaaggc tgccaccatt ccctgccagc 1620
ccaagaactc cagcttcccc actgcctctg tgtgcccctt tgcgtcctgt gaaggccatt 1680
gagaaatgcc cagtgtgccc cctgggaaag ggcacggcct gtgctcctga cacgggctgt 1740
gcttggccac agaaccaccc agcgtctccc ctgctgctgt ccacgtcagt tcatgaggca 1800
acgtcgcgtg gtctcagacg tggagcagcc agcggcagct cagagcaggg cactgtgtcc 1860
ggcggagcca agtccactct gggggagctc tggcggggac cacgggccac tgctcaccca 1920
ctggccccga ggggggtgta gacgccaaga ctcacgcatg tgtgacatcc ggagtcctgg 1980
agccgggtgt cccagtggca ccactaggtg cctgctgcct ccacagtggg gttcacaccc 2040
agggctcctt ggtcccccac aacctgcccc ggccaggcct gcagacccag actccagcca 2100
gacctgcctc acccaccaat gcagccgggg ctggcgacac cagccaggtg ctggtcttgg 2160
gccagttctc ccacgacggc tcaccctccc ctccatctgc gttgatgctc agaatcgcct 2220
acctgtgcct gcgtgtaaac cacagcctca gaccagctat ggggagagga caacacggag 2280
gatatccagc ttccccggtc tggggtgagg agtgtgggga gcttgggcat cctcctccag 2340
cctcctccag cccccaggca gtgccttacc tgtggtgccc agaaaagtgc ccctaggttg 2400
gtgggtctac aggagcctca gccaggcagc ccaccccacc ctggggccct gcctcaccaa 2460
ggaaataaag actcaaagaa gccttttttt tttttttttt 2500
<210> 26
<211> 263
<212> PRT
<213> Homo sapiens
<220>
<221> 滤泡素抑制素-样3糖蛋白多肽序列
<222> (1)..(263)
<400> 26
Met Arg Pro Gly Ala Pro Gly Pro Leu Trp Pro Leu Pro Trp Gly Ala
1 5 10 15
Leu Ala Trp Ala Val Gly Phe Val Ser Ser Met Gly Ser Gly Asn Pro
20 25 30
Ala Pro Gly Gly Val Cys Trp Leu Gln Gln Gly Gln Glu Ala Thr Cys
35 40 45
Ser Leu Val Leu Gln Thr Asp Val Thr Arg Ala Glu Cys Cys Ala Ser
50 55 60
Gly Asn Ile Asp Thr Ala Trp Ser Asn Leu Thr His Pro Gly Asn Lys
65 70 75 80
Ile Asn Leu Leu Gly Phe Leu Gly Leu Val His Cys Leu Pro Cys Lys
85 90 95
Asp Ser Cys Asp Gly Val Glu Cys Gly Pro Gly Lys Ala Cys Arg Met
100 105 110
Leu Gly Gly Arg Pro Arg Cys Glu Cys Ala Pro Asp Cys Ser Gly Leu
115 120 125
Pro Ala Arg Leu Gln Val Cys Gly Ser Asp Gly Ala Thr Tyr Arg Asp
130 135 140
Glu Cys Glu Leu Arg Ala Ala Arg Cys Arg Gly His Pro Asp Leu Ser
145 150 155 160
Val Met Tyr Arg Gly Arg Cys Arg Lys Ser Cys Glu His Val Val Cys
165 170 175
Pro Arg Pro Gln Ser Cys Val Val Asp Gln Thr Gly Ser Ala His Cys
180 185 190
Val Val Cys Arg Ala Ala Pro Cys Pro Val Pro Ser Ser Pro Gly Gln
195 200 205
Glu Leu Cys Gly Asn Asn Asn Val Thr Tyr Ile Ser Ser Cys His Met
210 215 220
Arg Gln Ala Thr Cys Phe Leu Gly Arg Ser Ile Gly Val Arg His Ala
225 230 235 240
Gly Ser Cys Ala Gly Thr Pro Glu Glu Pro Pro Gly Gly Glu Ser Ala
245 250 255
Glu Glu Glu Glu Asn Phe Val
260
<210> 27
<211> 3750
<212> DNA
<213> Homo sapiens
<220>
<221> 丝氨酸23蛋白酶mRNA
<222> (1)..(3750)
<400> 27
gcgctgctcg ccagcttgct cgcactcggc tgtgcggcgg ggcaggcatg ggagccgcgc 60
gctctctccc ggcgcccaca cctgtctgag cggcgcagcg agccgcggcc cgggcgggct 120
gctcggcgcg gaacagtgct cggcatggca gggattccag ggctcctctt ccttctcttc 180
tttctgctct gtgctgttgg gcaagtgagc ccttacagtg ccccctggaa acccacttgg 240
cctgcatacc gcctccctgt cgtcttgccc cagtctaccc tcaatttagc caagccagac 300
tttggagccg aagccaaatt agaagtatct tcttcatgtg gaccccagtg tcataaggga 360
actccactgc ccacttacga agaggccaag caatatctgt cttatgaaac gctctatgcc 420
aatggcagcc gcacagagac gcaggtgggc atctacatcc tcagcagtag tggagatggg 480
gcccaacacc gagactcagg gtcttcagga aagtctcgaa ggaagcggca gatttatggc 540
tatgacagca ggttcagcat ttttgggaag gacttcctgc tcaactaccc tttctcaaca 600
tcagtgaagt tatccacggg ctgcaccggc accctggtgg cagagaagca tgtcctcaca 660
gctgcccact gcatacacga tggaaaaacc tatgtgaaag gaacccagaa gcttcgagtg 720
ggcttcctaa agcccaagtt taaagatggt ggtcgagggg ccaacgactc cacttcagcc 780
atgcccgagc agatgaaatt tcagtggatc cgggtgaaac gcacccatgt gcccaagggt 840
tggatcaagg gcaatgccaa tgacatcggc atggattatg attatgccct cctggaactc 900
aaaaagcccc acaagagaaa atttatgaag attggggtga gccctcctgc taagcagctg 960
ccagggggca gaattcactt ctctggttat gacaatgacc gaccaggcaa tttggtgtat 1020
cgcttctgtg acgtcaaaga cgagacctat gacttgctct accagcaatg cgatgcccag 1080
ccaggggcca gcgggtctgg ggtctatgtg aggatgtgga agagacagca gcagaagtgg 1140
gagcgaaaaa ttattggcat tttttcaggg caccagtggg tggacatgaa tggttcccca 1200
caggatttca acgtggctgt cagaatcact cctctcaaat atgcccagat ttgctattgg 1260
attaaaggaa actacctgga ttgtagggag gggtgacaca gtgttccctc ctggcagcaa 1320
ttaagggtct tcatgttctt attttaggag aggccaaatt gttttttgtc attggcgtgc 1380
acacgtgtgt gtgtgtgtgt gtgtgtgtgt aaggtgtctt ataatctttt acctatttct 1440
tacaattgca agatgactgg ctttactatt tgaaaactgg tttgtgtatc atatcatata 1500
tcatttaagc agtttgaagg catacttttg catagaaata aaaaaaatac tgatttgggg 1560
caatgaggaa tatttgacaa ttaagttaat cttcacgttt ttgcaaactt tgatttttat 1620
ttcatctgaa cttgtttcaa agatttatat taaatatttg gcatacaaga gatatgaatt 1680
cttatatgtg tgcatgtgtg ttttcttctg agattcatct tggtggtggg tttttttgtt 1740
tttttaattc agtgcctgat ctttaatgct tccataaggc agtgttccca tttaggaact 1800
ttgacagcat ttgttaggca gaatattttg gatttggagg catttgcatg gtagtctttg 1860
aacagtaaaa tgatgtgttg actatactga tacacatatt aaactatacc ttatagtaaa 1920
ccagtatccc aagctgcttt tagttccaaa aatagtttct tttccaaagg ttgttgctct 1980
actttgtagg aagtctttgc atatggccct cccaacttta aagtcatacc agagtggcca 2040
agagtgttta tcccaaccct tccatttaac aggatttcac tcacatttct ggaactagct 2100
atttttcaga agacaataat cagggcttaa ttagaacagg ctgtatttcc tcccagcaaa 2160
cagttgtggc cacactaaaa acaatcatag cattttaccc ctggattata gcacatctca 2220
tgttttatca tttggatgga gtaatttaaa atgaattaaa ttccagagaa caatggaagc 2280
attgcctggc agatgtcaca acagaataac cacttgtttg gagcctggca cagtcctcca 2340
gcctgatcaa aaattattct gcatagtttt cagtgtgctt tctgggagct atgtacttct 2400
tcaatttgga aacttttctc tctcatttat agtgaaaata cttggaagtt actttaagaa 2460
aaccagtgtg gcctttttcc ctctagcttt aaaagggccg cttttgctgg aatgctctag 2520
gttatagata aacaattagg tataatagca aaaatgaaaa ttggaagaat gcaaaatgga 2580
tcagaatcat gccttccaat aaaggccttt acacatgttt tatcaatatg attatcaaat 2640
cacagcatat acagaaaaga cttggactta ttgtatgttt ttattttatg gctctcggcc 2700
taagcacttc tttctaaatg tatcggagaa aaaatcaaat ggactacaag cacgtgtttg 2760
ctgtgcttgc accccaggta aacctgcatt gtagcaattt gtaaggatat tcagatggag 2820
cactgtcact tagacattct ctgggggatt ttctgcttgt ctttcttgag ctttttggaa 2880
ggataattct gataaggcac tcaagaaacg tacaaccaca gtgctttctt caaatcatat 2940
gagaaatact atgcatagca aggagatgca gagccgccag gaaaattctg agttccagca 3000
caattttctt tggaatctaa caggaatcta gcctgaggaa gaagggaggt ctccatttct 3060
atgtctggta tttgggggtt ttgtttgttt ttgctttagc ttggtgaaaa aaagttcact 3120
gaacaccaag accagaatgg atttttttaa aaaaatagat gttccttttg tgaagcacct 3180
tgattccttg attttgattt tttgcaaagt tagacaatgg cacaaagtca aaatgaaatc 3240
aatgtttagt tcacaagtag atgtaattta ctaaagaatg atacacccat atgctatata 3300
cagcttaact cacagaactg taaaagaaaa ttataaaata attcaacatg tccatctttt 3360
tagtgataat aaaagaaagc atggtattaa actatcatag aagtagacag aaaaagaaaa 3420
aaggactcat ggcattatta atataattag tgctttacat gtgttagtta tacatattag 3480
aagcatattt gcctagtaag gctagtagaa ccacatttcc caaagtgtgc tccttaaaca 3540
ctcatgcctt atgattttct accaaaagta aaaagggttg tattaagtca gaggaagatg 3600
cctctccatt ttccctctct ttatcagagg ttcacatgcc tgtctgcaca ttaaaagctc 3660
tgggaagacc tgttgtaaag ggacaagttg aggttgtaaa atctgcattt aaataaacat 3720
ctttgatcac aaaaaaaaaa aaaaaaaaaa 3750
<210> 28
<211> 383
<212> PRT
<213> Homo sapiens
<220>
<221> 丝氨酸23蛋白酶多肽序列
<222> (1)..(383)
<400> 28
Met Ala Gly Ile Pro Gly Leu Leu Phe Leu Leu Phe Phe Leu Leu Cys
1 5 10 15
Ala Val Gly Gln Val Ser Pro Tyr Ser Ala Pro Trp Lys Pro Thr Trp
20 25 30
Pro Ala Tyr Arg Leu Pro Val Val Leu Pro Gln Ser Thr Leu Asn Leu
35 40 45
Ala Lys Pro Asp Phe Gly Ala Glu Ala Lys Leu Glu Val Ser Ser Ser
50 55 60
Cys Gly Pro Gln Cys His Lys Gly Thr Pro Leu Pro Thr Tyr Glu Glu
65 70 75 80
Ala Lys Gln Tyr Leu Ser Tyr Glu Thr Leu Tyr Ala Asn Gly Ser Arg
85 90 95
Thr Glu Thr Gln Val Gly Ile Tyr Ile Leu Ser Ser Ser Gly Asp Gly
100 105 110
Ala Gln His Arg Asp Ser Gly Ser Ser Gly Lys Ser Arg Arg Lys Arg
115 120 125
Gln Ile Tyr Gly Tyr Asp Ser Arg Phe Ser Ile Phe Gly Lys Asp Phe
130 135 140
Leu Leu Asn Tyr Pro Phe Ser Thr Ser Val Lys Leu Ser Thr Gly Cys
145 150 155 160
Thr Gly Thr Leu Val Ala Glu Lys His Val Leu Thr Ala Ala His Cys
165 170 175
Ile His Asp Gly Lys Thr Tyr Val Lys Gly Thr Gln Lys Leu Arg Val
180 185 190
Gly Phe Leu Lys Pro Lys Phe Lys Asp Gly Gly Arg Gly Ala Asn Asp
195 200 205
Ser Thr Ser Ala Met Pro Glu Gln Met Lys Phe Gln Trp Ile Arg Val
210 215 220
Lys Arg Thr His Val Pro Lys Gly Trp Ile Lys Gly Asn Ala Asn Asp
225 230 235 240
Ile Gly Met Asp Tyr Asp Tyr Ala Leu Leu Glu Leu Lys Lys Pro His
245 250 255
Lys Arg Lys Phe Met Lys Ile Gly Val Ser Pro Pro Ala Lys Gln Leu
260 265 270
Pro Gly Gly Arg Ile His Phe Ser Gly Tyr Asp Asn Asp Arg Pro Gly
275 280 285
Asn Leu Val Tyr Arg Phe Cys Asp Val Lys Asp Glu Thr Tyr Asp Leu
290 295 300
Leu Tyr Gln Gln Cys Asp Ala Gln Pro Gly Ala Ser Gly Ser Gly Val
305 310 315 320
Tyr Val Arg Met Trp Lys Arg Gln Gln Gln Lys Trp Glu Arg Lys Ile
325 330 335
Ile Gly Ile Phe Ser Gly His Gln Trp Val Asp Met Asn Gly Ser Pro
340 345 350
Gln Asp Phe Asn Val Ala Val Arg Ile Thr Pro Leu Lys Tyr Ala Gln
355 360 365
Ile Cys Tyr Trp Ile Lys Gly Asn Tyr Leu Asp Cys Arg Glu Gly
370 375 380
<210> 29
<211> 1362
<212> DNA
<213> Homo sapiens
<220>
<221> 膜联蛋白2 mRNA
<222> (1)..(1362)
<223> 同义词:脂皮质蛋白II
<400> 29
catttgggga cgctctcagc tctcggcgca cggcccagct tccttcaaaa tgtctactgt 60
tcacgaaatc ctgtgcaagc tcagcttgga gggtgatcac tctacacccc caagtgcata 120
tgggtctgtc aaagcctata ctaactttga tgctgagcgg gatgctttga acattgaaac 180
agccatcaag accaaaggtg tggatgaggt caccattgtc aacattttga ccaaccgcag 240
caatgcacag agacaggata ttgccttcgc ctaccagaga aggaccaaaa aggaacttgc 300
atcagcactg aagtcagcct tatctggcca cctggagacg gtgattttgg gcctattgaa 360
gacacctgct cagtatgacg cttctgagct aaaagcttcc atgaaggggc tgggaaccga 420
cgaggactct ctcattgaga tcatctgctc cagaaccaac caggagctgc aggaaattaa 480
cagagtctac aaggaaatgt acaagactga tctggagaag gacattattt cggacacatc 540
tggtgacttc cgcaagctga tggttgccct ggcaaagggt agaagagcag aggatggctc 600
tgtcattgat tatgaactga ttgaccaaga tgctcgggat ctctatgacg ctggagtgaa 660
gaggaaagga actgatgttc ccaagtggat cagcatcatg accgagcgga gcgtgcccca 720
cctccagaaa gtatttgata ggtacaagag ttacagccct tatgacatgt tggaaagcat 780
caggaaagag gttaaaggag acctggaaaa tgctttcctg aacctggttc agtgcattca 840
gaacaagccc ctgtattttg ctgatcggct gtatgactcc atgaagggca aggggacgcg 900
agataaggtc ctgatcagaa tcatggtctc ccgcagtgaa gtggacatgt tgaaaattag 960
gtctgaattc aagagaaagt acggcaagtc cctgtactat tatatccagc aagacactaa 1020
gggcgactac cagaaagcgc tgctgtacct gtgtggtgga gatgactgaa gcccgacacg 1080
gcctgagcgt ccagaaatgg tgctcaccat gcttccagct aacaggtcta gaaaaccagc 1140
ttgcgaataa cagtccccgt ggccatccct gtgagggtga cgttagcatt acccccaacc 1200
tcattttagt tgcctaagca ttgcctggcc ttcctgtcta gtctctcctg taagccaaag 1260
aaatgaacat tccaaggagt tggaagtgaa gtctatgatg tgaaacactt tgcctcctgt 1320
gtactgtgtc ataaacagat gaataaactg aatttgtact tt 1362
<210> 30
<211> 339
<212> PRT
<213> Homo sapiens
<220>
<221> 膜联蛋白2多肽序列
<222> (1)..(339)
<400> 30
Met Ser Thr Val His Glu Ile Leu Cys Lys Leu Ser Leu Glu Gly Asp
1 5 10 15
His Ser Thr Pro Pro Ser Ala Tyr Gly Ser Val Lys Ala Tyr Thr Asn
20 25 30
Phe Asp Ala Glu Arg Asp Ala Leu Asn Ile Glu Thr Ala Ile Lys Thr
35 40 45
Lys Gly Val Asp Glu Val Thr Ile Val Asn Ile Leu Thr Asn Arg Ser
50 55 60
Asn Ala Gln Arg Gln Asp Ile Ala Phe Ala Tyr Gln Arg Arg Thr Lys
65 70 75 80
Lys Glu Leu Ala Ser Ala Leu Lys Ser Ala Leu Ser Gly His Leu Glu
85 90 95
Thr Val Ile Leu Gly Leu Leu Lys Thr Pro Ala Gln Tyr Asp Ala Ser
100 105 110
Glu Leu Lys Ala Ser Met Lys Gly Leu Gly Thr Asp Glu Asp Ser Leu
115 120 125
Ile Glu Ile Ile Cys Ser Arg Thr Asn Gln Glu Leu Gln Glu Ile Asn
130 135 140
Arg Val Tyr Lys Glu Met Tyr Lys Thr Asp Leu Glu Lys Asp Ile Ile
145 150 155 160
Ser Asp Thr Ser Gly Asp Phe Arg Lys Leu Met Val Ala Leu Ala Lys
165 170 175
Gly Arg Arg Ala Glu Asp Gly Ser Val Ile Asp Tyr Glu Leu Ile Asp
180 185 190
Gln Asp Ala Arg Asp Leu Tyr Asp Ala Gly Val Lys Arg Lys Gly Thr
195 200 205
Asp Val Pro Lys Trp Ile Ser Ile Met Thr Glu Arg Ser Val Pro His
210 215 220
Leu Gln Lys Val Phe Asp Arg Tyr Lys Ser Tyr Ser Pro Tyr Asp Met
225 230 235 240
Leu Glu Ser Ile Arg Lys Glu Val Lys Gly Asp Leu Glu Asn Ala Phe
245 250 255
Leu Asn Leu Val Gln Cys Ile Gln Asn Lys Pro Leu Tyr Phe Ala Asp
260 265 270
Arg Leu Tyr Asp Ser Met Lys Gly Lys Gly Thr Arg Asp Lys Val Leu
275 280 285
Ile Arg Ile Met Val Ser Arg Ser Glu Val Asp Met Leu Lys Ile Arg
290 295 300
Ser Glu Phe Lys Arg Lys Tyr Gly Lys Ser Leu Tyr Tyr Tyr Ile Gln
305 310 315 320
Gln Asp Thr Lys Gly Asp Tyr Gln Lys Ala Leu Leu Tyr Leu Cys Gly
325 330 335
Gly Asp Asp
<210> 31
<211> 1946
<212> DNA
<213> Homo sapiens
<220>
<221> LOX mRNA
<222> (1)..(1946)
<400> 31
agacactgcc cgctctccgg gactccgcgc cgctccccgt tgccttccag gactgagaaa 60
ggggaaaggg aagggtgcca cgtccgagca gccgccttga ctggggaagg gtctgaatcc 120
cacccttggc attgcttggt ggagactgag atacccgtgc tccgctcgcc tccttggttg 180
aagatttctc cttccctcac gtgatttgag ccccgttttt attttctgtg agccacgtcc 240
tcctcgagcg gggtcaatct ggcaaaagga gtgatgcgct tcgcctggac cgtgctcctg 300
ctcgggcctt tgcagctctg cgcgctagtg cactgcgccc ctcccgccgc cggccaacag 360
cagcccccgc gcgagccgcc ggcggctccg ggcgcctggc gccagcagat ccaatgggag 420
aacaacgggc aggtgttcag cttgctgagc ctgggctcac agtaccagcc tcagcgccgc 480
cgggacccgg gcgccgccgt ccctggtgca gccaacgcct ccgcccagca gccccgcact 540
ccgatcctgc tgatccgcga caaccgcacc gccgcggcgc gaacgcggac ggccggctca 600
tctggagtca ccgctggccg ccccaggccc accgcccgtc actggttcca agctggctac 660
tcgacatcta gagcccgcga agctggcgcc tcgcgcgcgg agaaccagac agcgccggga 720
gaagttcctg cgctcagtaa cctgcggccg cccagccgcg tggacggcat ggtgggcgac 780
gacccttaca acccctacaa gtactctgac gacaaccctt attacaacta ctacgatact 840
tatgaaaggc ccagacctgg gggcaggtac cggcccggat acggcactgg ctacttccag 900
tacggtctcc cagacctggt ggccgacccc tactacatcc aggcgtccac gtacgtgcag 960
aagatgtcca tgtacaacct gagatgcgcg gcggaggaaa actgtctggc cagtacagca 1020
tacagggcag atgtcagaga ttatgatcac agggtgctgc tcagatttcc ccaaagagtg 1080
aaaaaccaag ggacatcaga tttcttaccc agccgaccaa gatattcctg ggaatggcac 1140
agttgtcatc aacattacca cagtatggat gagtttagcc actatgacct gcttgatgcc 1200
aacacccaga ggagagtggc tgaaggccac aaagcaagtt tctgtcttga agacacatcc 1260
tgtgactatg gctaccacag gcgatttgca tgtactgcac acacacaggg attgagtcct 1320
ggctgttatg atacctatgg tgcagacata gactgccagt ggattgatat tacagatgta 1380
aaacctggaa actatatcct aaaggtcagt gtaaacccca gctacctggt tcctgaatct 1440
gactatacca acaatgttgt gcgctgtgac attcgctaca caggacatca tgcgtatgcc 1500
tcaggctgca caatttcacc gtattagaag gcaaagcaaa actcccaatg gataaatcag 1560
tgcctggtgt tctgaagtgg gaaaaaatag actaacttca gtaggattta tgtattttga 1620
aaaagagaac agaaaacaac aaaagaattt ttgtttggac tgttttcaat aacaaagcac 1680
ataactggat tttgaacgct taagtcatca ttacttggga aatttttaat gtttattatt 1740
tacatcactt tgtgaattaa cacagtgttt caattctgta attacatatt tgactctttc 1800
aaagaaatcc aaatttctca tgttcctttt gaaattgtag tgcaaaatgg tcagtattat 1860
ctaaatgaat gagccaaaat gactttgaac tgaaactttt ctaaagtgct ggaactttag 1920
tgaaacataa taataatggg tttata 1946
<210> 32
<211> 417
<212> PRT
<213> Homo sapiens
<220>
<221> LOX多肽序列
<222> (1)..(417)
<400> 32
Met Arg Phe Ala Trp Thr Val Leu Leu Leu Gly Pro Leu Gln Leu Cys
1 5 10 15
Ala Leu Val His Cys Ala Pro Pro Ala Ala Gly Gln Gln Gln Pro Pro
20 25 30
Arg Glu Pro Pro Ala Ala Pro Gly Ala Trp Arg Gln Gln Ile Gln Trp
35 40 45
Glu Asn Asn Gly Gln Val Phe Ser Leu Leu Ser Leu Gly Ser Gln Tyr
50 55 60
Gln Pro Gln Arg Arg Arg Asp Pro Gly Ala Ala Val Pro Gly Ala Ala
65 70 75 80
Asn Ala Ser Ala Gln Gln Pro Arg Thr Pro Ile Leu Leu Ile Arg Asp
85 90 95
Asn Arg Thr Ala Ala Ala Arg Thr Arg Thr Ala Gly Ser Ser Gly Val
100 105 110
Thr Ala Gly Arg Pro Arg Pro Thr Ala Arg His Trp Phe Gln Ala Gly
115 120 125
Tyr Ser Thr Ser Arg Ala Arg Glu Ala Gly Ala Ser Arg Ala Glu Asn
130 135 140
Gln Thr Ala Pro Gly Glu Val Pro Ala Leu Ser Asn Leu Arg Pro Pro
145 150 155 160
Ser Arg Val Asp Gly Met Val Gly Asp Asp Pro Tyr Asn Pro Tyr Lys
165 170 175
Tyr Ser Asp Asp Asn Pro Tyr Tyr Asn Tyr Tyr Asp Thr Tyr Glu Arg
180 185 190
Pro Arg Pro Gly Gly Arg Tyr Arg Pro Gly Tyr Gly Thr Gly Tyr Phe
195 200 205
Gln Tyr Gly Leu Pro Asp Leu Val Ala Asp Pro Tyr Tyr Ile Gln Ala
210 215 220
Ser Thr Tyr Val Gln Lys Met Ser Met Tyr Asn Leu Arg Cys Ala Ala
225 230 235 240
Glu Glu Asn Cys Leu Ala Ser Thr Ala Tyr Arg Ala Asp Val Arg Asp
245 250 255
Tyr Asp His Arg Val Leu Leu Arg Phe Pro Gln Arg Val Lyg Asn Gln
260 265 270
Gly Thr Ser Asp Phe Leu Pro Ser Arg Pro Arg Tyr Ser Trp Glu Trp
275 280 285
His Ser Cys His Gln His Tyr His Ser Met Asp Glu Phe Ser His Tyr
290 295 300
Asp Leu Leu Asp Ala Asn Thr Gln Arg Arg Val Ala Glu Gly His Lys
305 310 315 320
Ala Ser Phe Cys Leu Glu Asp Thr Ser Cys Asp Tyr Gly Tyr His Arg
325 330 335
Arg Phe Ala Cys Thr Ala His Thr Gln Gly Leu Ser Pro Gly Cys Tyr
340 345 350
Asp Thr Tyr Gly Ala Asp Ile Asp Cys Gln Trp Ile Asp Ile Thr Asp
355 360 365
Val Lys Pro Gly Asn Tyr Ile Leu Lys Val Ser Val Asn Pro Ser Tyr
370 375 380
Leu Val Pro Glu Ser Asp Tyr Thr Asn Asn Val Val Arg Cys Asp Ile
385 390 395 400
Arg Tyr Thr Gly His His Ala Tyr Ala Ser Gly Cys Thr Ile Ser Pro
405 410 415
Tyr
<210> 33
<211> 1600
<212> DNA
<213> Homo sapiens
<220>
<221> ECGF 1 mRNA
<222> (1)..(1600)
<400> 33
gccccgccgc cggcagtgga ccgctgtgcg cgaaccctga accctacggt cccgacccgc 60
gggcgaggcc gggtacctgg gctgggatcc ggagcaagcg ggcgagggca gcgccctaag 120
caggcccgga gcgatggcag ccttgatgac cccgggaacc ggggccccac ccgcgcctgg 180
tgacttctcc ggggaaggga gccagggact tcccgaccct tcgccagagc ccaagcagct 240
cccggagctg atccgcatga agcgagacgg aggccgcctg agcgaagcgg acatcagggg 300
cttcgtggcc gctgtggtga atgggagcgc gcagggcgca cagatcgggg ccatgctgat 360
ggccatccga cttcggggca tggatctgga ggagacctcg gtgctgaccc aggccctggc 420
tcagtcggga cagcagctgg agtggccaga ggcctggcgc cagcagcttg tggacaagca 480
ttccacaggg ggtgtgggtg acaaggtcag cctggtcctc gcacctgccc tggcggcatg 540
tggctgcaag gtgccaatga tcagcggacg tggtctgggg cacacaggag gcaccttgga 600
taagctggag tctattcctg gattcaatgt catccagagc ccagagcaga tgcaagtgct 660
gctggaccag gcgggctgct gtatcgtggg tcagagtgag cagctggttc ctgcggacgg 720
aatcctatat gcagccagag atgtgacagc caccgtggac agcctgccac tcatcacagc 780
ctccattctc agtaagaaac tcgtggaggg gctgtccgct ctggtggtgg acgttaagtt 840
cggaggggcc gccgtcttcc ccaaccagga gcaggcccgg gagctggcaa agacgctggt 900
tggcgtggga gccagcctag ggcttcgggt cgcggcagcg ctgaccgcca tggacaagcc 960
cctgggtcgc tgcgtgggcc acgccctgga ggtggaggag gcgctgctct gcatggacgg 1020
cgcaggcccg ccagacttaa gggacctggt caccacgctc gggggcgccc tgctctggct 1080
cagcggacac gcggggactc aggctcaggg cgctgcccgg gtggccgcgg cgctggacga 1140
cggctcggcc cttggccgct tcgagcggat gctggcggcg cagggcgtgg atcccggtct 1200
ggcccgagcc ctgtgctcgg gaagtcccgc agaacgccgg cagctgctgc ctcgcgcccg 1260
ggagcaggag gagctgctgg cgcccgcaga tggcaccgtg gagctggtcc gggcgctgcc 1320
gctggcgctg gtgctgcacg agctcggggc cgggcgcagc cgcgctgggg agccgctccg 1380
cctgggggtg ggcgcagagc tgctggtcga cgtgggtcag aggctgcgcc gtgggacccc 1440
ctggctccgc gtgcaccggg acggccccgc gctcagcggc ccgcagagcc gcgccctgca 1500
ggaggcgctc gtactctccg accgcgcgcc attcgccgcc ccctcgccct tcgcagagct 1560
cgttctgccg ccgcagcaat aaagctcctt tgccgcgaaa 1600
<210> 34
<211> 482
<212> PRT
<213> Homo sapiens
<220>
<221> ECGF1多肽序列
<222> (1)..(482)
<400> 34
Met Ala Ala Leu Met Thr Pro Gly Thr Gly Ala Pro Pro Ala Pro Gly
1 5 10 15
Asp Phe Ser Gly Glu Gly Ser Gln Gly Leu Pro Asp Pro Ser Pro Glu
20 25 30
Pro Lys Gln Leu Pro Glu Leu Ile Arg Met Lys Arg Asp Gly Gly Arg
35 40 45
Leu Ser Glu Ala Asp Ile Arg Gly Phe Val Ala Ala Val Val Asn Gly
50 55 60
Ser Ala Gln Gly Ala Gln Ile Gly Ala Met Leu Met Ala Ile Arg Leu
65 70 75 80
Arg Gly Met Asp Leu Glu Glu Thr Ser Val Leu Thr Gln Ala Leu Ala
85 90 95
Gln Ser Gly Gln Gln Leu Glu Trp Pro Glu Ala Trp Arg Gln Gln Leu
100 105 110
Val Asp Lys His Ser Thr Gly Gly Val Gly Asp Lys Val Ser Leu Val
115 120 125
Leu Ala Pro Ala Leu Ala Ala Cys Gly Cys Lys Val Pro Met Ile Ser
130 135 140
Gly Arg Gly Leu Gly His Thr Gly Gly Thr Leu Asp Lys Leu Glu Ser
145 150 155 160
Ile Pro Gly Phe Asn Val Ile Gln Ser Pro Glu Gln Met Gln Val Leu
165 170 175
Leu Asp Gln Ala Gly Cys Cys Ile Val Gly Gln Ser Glu Gln Leu Val
180 185 190
Pro Ala Asp Gly Ile Leu Tyr Ala Ala Arg Asp Val Thr Ala Thr Val
195 200 205
Asp Ser Leu Pro Leu Ile Thr Ala Ser Ile Leu Ser Lys Lys Leu Val
210 215 220
Glu Gly Leu Ser Ala Leu Val Val Asp Val Lys Phe Gly Gly Ala Ala
225 230 235 240
Val Phe Pro Asn Gln Glu Gln Ala Arg Glu Leu Ala Lys Thr Leu Val
245 250 255
Gly Val Gly Ala Ser Leu Gly Leu Arg Val Ala Ala Ala Leu Thr Ala
260 265 270
Met Asp Lys Pro Leu Gly Arg Cys Val Gly His Ala Leu Glu Val Glu
275 280 285
Glu Ala Leu Leu Cys Met Asp Gly Ala Gly Pro Pro Asp Leu Arg Asp
290 295 300
Leu Val Thr Thr Leu Gly Gly Ala Leu Leu Trp Leu Ser Gly His Ala
305 310 315 320
Gly Thr Gln Ala Gln Gly Ala Ala Arg Val Ala Ala Ala Leu Asp Asp
325 330 335
Gly Ser Ala Leu Gly Arg Phe Glu Arg Met Leu Ala Ala Gln Gly Val
340 345 350
Asp Pro Gly Leu Ala Arg Ala Leu Cys Ser Gly Ser Pro Ala Glu Arg
355 360 365
Arg Gln Leu Leu Pro Arg Ala Arg Glu Gln Glu Glu Leu Leu Ala Pro
370 375 380
Ala Asp Gly Thr Val Glu Leu Val Arg Ala Leu Pro Leu Ala Leu Val
385 390 395 400
Leu His Glu Leu Gly Ala Gly Arg Ser Arg Ala Gly Glu Pro Leu Arg
405 410 415
Leu Gly Val Gly Ala Glu Leu Leu Val Asp Val Gly Gln Arg Leu Arg
420 425 430
Arg Gly Thr Pro Trp Leu Arg Val His Arg Asp Gly Pro Ala Leu Ser
435 440 445
Gly Pro Gln Ser Arg Ala Leu Gln Glu Ala Leu Val Leu Ser Asp Arg
450 455 460
Ala Pro Phe Ala Ala Pro Ser Pro Phe Ala Glu Leu Val Leu Pro Pro
465 470 475 480
Gln Gln
Claims (26)
1.一种诊断前驱糖尿病,糖尿病或糖尿病易感性的方法,其包含:
获得生物样品;和
检测或测量多肽标记的水平,所述多肽标记包含至少一种选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的多肽的多肽。
2.一种诊断前驱糖尿病,糖尿病或糖尿病易感性的方法,其包含检测或测量生物样品中多肽标记的水平,所述多肽标记包含至少一种选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的多肽的多肽。
3.权利要求1或2中任何一项权利要求的方法,其中所述多肽标记包含至少两种多肽。
4.权利要求1至3中任何一项的方法,其中所述生物样品来源于血清,血浆,和脂肪组织细胞。
5.权利要求1至4中任何一项的方法,其中将在怀疑患前驱糖尿病,糖尿病或糖尿病易感的个体中所述多肽标记的水平与在健康个体中相同多肽标记的表达水平比较。
6.权利要求1至5中任何一项的体外方法,其中所述多肽标记的水平随时间增加或减小是前驱糖尿病,糖尿病或糖尿病易感性的征兆。
7.一种诊断前驱糖尿病,糖尿病或糖尿病易感性的方法,其包含:
获得生物样品;和
检测或测量标记的水平,所述核酸标记包含至少一种选自SEQ ID No.1,3,5,7,9,11,13,15,17,19,21,23,25,27,29,31和33的核酸分子的核酸分子。
8.一种诊断前驱糖尿病,糖尿病或糖尿病易感性的方法,其包含检测或测量生物样品中标记的水平,所述核酸标记包含至少一种选自SEQ IDNo.1,3,5,7,9,11,13,15,17,19,21,23,25,27,29,31和33的核酸分子的核酸分子。
9.权利要求7或8中任何一项的方法,其中所述核酸标记是RNA。
10.权利要求7至9中任何一项的方法,其中将怀疑患前驱糖尿病,糖尿病或糖尿病易感个体中所述核酸标记的表达水平与健康个体中相同核酸标记的表达水平比较。
11.权利要求7至10中任何一项的体外方法,其中所述核酸标记的表达水平随时间增加或减小是前驱糖尿病,糖尿病或糖尿病易感性的征兆。
12.一种鉴定与其表达在糖尿病中受调节的多肽相互作用的化合物的筛选方法,所述多肽选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的多肽,该方法包含:
将所述多肽与一种化合物或多种化合物在允许所述化合物与所述多肽相互作用的条件下接触;和
检测所述化合物或多种化合物与所述多肽之间的相互作用。
13.一种鉴定化合物的筛选方法,所述化合物是在糖尿病中表达受调节的多肽的激动剂或拮抗剂,所述多肽选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的多肽,该方法包含:
将所述多肽与化合物在允许所述化合物与所述多肽相互作用的条件下接触;
测定所述多肽的第一活性水平;
测定在未与所述化合物接触的宿主中表达的所述多肽的第二活性水平;和
使所述第一活性水平与所述第二活性水平定量关联,其中当所述第一活性水平低于所述第二活性水平时,将所述化合物鉴定为所述多肽的激动剂或拮抗剂。
14.一种鉴定化合物的筛选方法,所述化合物是在糖尿病中表达上调的多肽表达的抑制剂,所述多肽选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的多肽,该方法包含:
将表达所述多肽的宿主与化合物接触;
测定所述多肽的第一表达水平或活性;
测定在未与所述化合物接触的宿主中所述多肽的第二表达水平或活性;和
使所述第一表达水平或活性与所述第二表达水平或活性定量关联,其中当所述第一表达水平或活性低于所述第二表达水平或活性时,将所述化合物鉴定为所述多肽的表达的抑制剂。
15.针对蛋白质的抗体,或其抗原结合片段,其用于诊断前驱糖尿病,糖尿病或糖尿病易感性的体外方法中,所述蛋白质选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的蛋白质。
16.一种将哺乳动物中的蛋白质水平与前驱糖尿病,糖尿病或发展糖尿病的易感性的诊断相关联的方法,该方法包含:
选择一种或多种选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的蛋白质的蛋白质;
测定所述哺乳动物中所述一种或多种蛋白质的水平;和
产生指数,Y,其表示糖尿病或对其易感性的存在。
17.按照权利要求16的方法,其另外包含将指数,Y,与已知糖尿病患者和非糖尿病患者的指数比较。
18.按照权利要求16的方法,其另外包含随时间监视所述指数Y以测定糖尿病或对其的易感性的阶段。
19.一种诊断糖尿病和前驱糖尿病的试剂盒,其包含一种或多种权利要求15的抗体,或其抗原结合片段。
20.一种诊断糖尿病和前驱糖尿病的试剂盒,其包含一种或多种编码权利要求1的多肽标记的核酸。
21.一种筛选化合物的试剂盒,所述化合物活化或抑制多肽或刺激或抑制任何一种所述多肽的表达,所述多肽选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的多肽。
22.监视一种或多种蛋白质血清水平以检测前驱糖尿病病状,糖尿病病状或发展糖尿病病状的易感性的方法,该方法包含:
产生所述一种或多种蛋白质的抗体;
检测所述蛋白质的血清水平;和
将所述血清水平与已知糖尿病患者和已知非糖尿病患者的血清水平比较。
23.一种治疗糖尿病和前驱糖尿病的方法,其包含向需要其的患者施用治疗有效量的针对至少一种蛋白质的至少一种抗体或其抗原结合片段,该蛋白质选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的蛋白质。
24.治疗有效量的针对至少一种蛋白质的至少一种抗体或其抗原结合片段在制备用于治疗糖尿病和前驱糖尿病的药物中的应用,该蛋白质选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的蛋白质。
25.治疗有效量的至少一种蛋白质,蛋白质片段或肽在制备用于治疗糖尿病和前驱糖尿病的药物中的应用,所述蛋白质,蛋白质片段或肽选自具有SEQ ID No.2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32和34的蛋白质。
26.以上,特别参考前述实施例所述的方法和试剂盒。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50869903P | 2003-10-03 | 2003-10-03 | |
US60/508,699 | 2003-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1609616A true CN1609616A (zh) | 2005-04-27 |
Family
ID=34421774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100849804A Pending CN1609616A (zh) | 2003-10-03 | 2004-10-08 | 糖尿病的特异性标记 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050074805A1 (zh) |
EP (1) | EP1560025A3 (zh) |
JP (1) | JP4245539B2 (zh) |
CN (1) | CN1609616A (zh) |
CA (1) | CA2480616A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101233410B (zh) * | 2005-06-01 | 2012-05-30 | 拜奥默里克斯股份有限公司 | 用于标记或处理包含目的生物分子特别是核酸的生物样品的方法 |
CN102565416A (zh) * | 2010-12-27 | 2012-07-11 | 中国科学院上海生命科学研究院 | 载脂蛋白a1作为糖尿病标志物的应用 |
CN113092771A (zh) * | 2019-12-23 | 2021-07-09 | 首都医科大学附属北京世纪坛医院 | 尿液α-1B-糖蛋白及其多肽片段在过敏性疾病中的应用 |
CN114026426A (zh) * | 2019-03-28 | 2022-02-08 | 隆德诊断有限公司 | 卵泡抑素在2型糖尿病风险预测中的用途 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1522857A1 (en) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
US20070218519A1 (en) * | 2005-10-11 | 2007-09-20 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
KR100792630B1 (ko) | 2006-07-05 | 2008-01-09 | 고려대학교 산학협력단 | 당뇨병성 신증 진단용 바이오 마커 |
EP2087359A1 (en) * | 2006-10-16 | 2009-08-12 | Bayer Schering Pharma AG | Prss23 as a biomarker, therapeutic and diagnostic target |
WO2011068956A2 (en) * | 2009-12-02 | 2011-06-09 | The General Hospital Corporation | Follistatin-like 3 (fstl3) levels in gestational diabetes |
JP5422799B2 (ja) * | 2010-05-27 | 2014-02-19 | 国立大学法人 東京大学 | 肥満化リスク・糖尿病発症リスクの検出方法 |
EP2544007A1 (en) * | 2011-07-07 | 2013-01-09 | Atlas Antibodies AB | Biomarker of renal impairment |
WO2021064452A1 (en) | 2019-10-03 | 2021-04-08 | Dasman Diabetes Institute | Method for preventing progression to type ii diabetes |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525490A (en) * | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
US5541109A (en) * | 1994-04-19 | 1996-07-30 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Expression cloning of c-src SH3-domain binding proteins |
US5928939A (en) * | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000075163A1 (en) * | 1999-06-03 | 2000-12-14 | Human Genome Sciences, Inc. | Angiogenic proteins and uses thereof |
US20030092890A1 (en) * | 1999-07-28 | 2003-05-15 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AUPQ592100A0 (en) * | 2000-02-29 | 2000-03-23 | Council Of The Queensland Institute Of Medical Research, The | A method of treatment and prophylaxis |
WO2003021262A1 (fr) * | 2001-08-28 | 2003-03-13 | Takeda Chemical Industries, Ltd. | Procede de criblage |
WO2003021263A1 (fr) * | 2001-09-03 | 2003-03-13 | Takeda Chemical Industries, Ltd. | Utilisation d'une proteine de recepteur couple a une proteine g |
EP1467207B1 (en) * | 2002-01-10 | 2008-06-04 | Takeda Pharmaceutical Company Limited | Screening method for a prophylactic and therapeutic substance for a renal disease. |
CA2462133A1 (en) * | 2002-02-20 | 2003-08-28 | Kunitake Abe | Novel polypeptide |
-
2004
- 2004-09-27 EP EP04022939A patent/EP1560025A3/en not_active Withdrawn
- 2004-09-28 US US10/952,459 patent/US20050074805A1/en not_active Abandoned
- 2004-09-30 CA CA002480616A patent/CA2480616A1/en not_active Abandoned
- 2004-10-01 JP JP2004289849A patent/JP4245539B2/ja not_active Expired - Fee Related
- 2004-10-08 CN CNA2004100849804A patent/CN1609616A/zh active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101233410B (zh) * | 2005-06-01 | 2012-05-30 | 拜奥默里克斯股份有限公司 | 用于标记或处理包含目的生物分子特别是核酸的生物样品的方法 |
CN102565416A (zh) * | 2010-12-27 | 2012-07-11 | 中国科学院上海生命科学研究院 | 载脂蛋白a1作为糖尿病标志物的应用 |
CN114026426A (zh) * | 2019-03-28 | 2022-02-08 | 隆德诊断有限公司 | 卵泡抑素在2型糖尿病风险预测中的用途 |
CN113092771A (zh) * | 2019-12-23 | 2021-07-09 | 首都医科大学附属北京世纪坛医院 | 尿液α-1B-糖蛋白及其多肽片段在过敏性疾病中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP4245539B2 (ja) | 2009-03-25 |
US20050074805A1 (en) | 2005-04-07 |
EP1560025A2 (en) | 2005-08-03 |
CA2480616A1 (en) | 2005-04-03 |
JP2005114725A (ja) | 2005-04-28 |
EP1560025A3 (en) | 2011-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1293203C (zh) | 大规模鉴定疾病基因型的方法和6型脊髓小脑共济失调的诊断试验 | |
CN1134704A (zh) | 药物结合蛋白质 | |
CN1527720A (zh) | 利用蛋白组芯片全面分析蛋白活性 | |
CN1732270A (zh) | Actn3基因型筛选运动性能 | |
CN101044247A (zh) | 用于鉴定,评估,预防和治疗子宫颈癌的组合物,试剂盒及方法 | |
CN1609616A (zh) | 糖尿病的特异性标记 | |
CN1839205A (zh) | 用于鉴定、评估、预防和治疗乳腺癌的组合物、试剂盒及方法 | |
CN1117876C (zh) | 刺激促生长素抑制素和胰岛素产生的化合物的筛选方法 | |
CN1930306A (zh) | 发展用于血栓形成倾向识别的方法(mert) | |
CN1890384A (zh) | 与炎性疾病的治疗功效相关的遗传多态性的用途 | |
CN1592625A (zh) | G蛋白偶联受体测定 | |
CN1533435A (zh) | 用于诊断及治疗胰岛素抗性及相关病症之方法和试剂 | |
CN1592793A (zh) | 肝细胞癌-相关基因和多肽,以及检测肝细胞癌的方法 | |
CN1906309A (zh) | 特异于产生多巴胺的神经元的标记物Lmx1a | |
CN1705746A (zh) | 新转移因子及其应用 | |
CN1961073A (zh) | 切割型dance、dance复合体及其使用方法 | |
CN1619312A (zh) | 代谢综合征的特异标记 | |
CN101061239A (zh) | 通过URLC8的tRNA-二氢尿苷合酶活性诊断非小细胞肺癌的方法 | |
CN1433482A (zh) | 高脂血症的治疗或预防剂的检验方法 | |
CN100342030C (zh) | 试验肿瘤细胞对于抗癌药剂敏感性的方法 | |
CN1747968A (zh) | 预测作用于生长激素受体的制剂的治疗反应的方法 | |
CN1761472A (zh) | 细胞表面蛋白质的调节 | |
CN1571842A (zh) | 肽基精氨酸脱亚氨酶6 | |
CN1906306A (zh) | Sars相关冠状病毒的多等位分子检测 | |
CN1229386C (zh) | 具有抑癌功能的新的人蛋白及其编码序列 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20050427 |
|
C20 | Patent right or utility model deemed to be abandoned or is abandoned |